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Abstract
The incidence of autoimmune diseases, many of which lack effective treatments, is rapidly increasing in
the developed world. Mendelian diseases allow the study of autoimmunity in humans, enabling new
insights into the underlying pathology. In this study, I have identified a patient cohort suffering from a
novel recessive Mendelian disease of immune dysregulation characterized by severe lymphopenia,
splenomegaly, thrombocytopenia and liver failure. Whole exome sequencing revealed mutations in
GIMAP5, a small GTPase primarily expressed in T, NK and endothelial cells. The missense mutations in
these patients destabilize the protein in vitro and lead to a near complete loss of protein in patient cells.
Animal models lacking GIMAP5 develop a disease remarkably similar to that observed in the human
patients; however, the molecular role of this gene in the immune system remains obscure. To address
this, I defined the interactome of GIMAP5 via immunoprecipitation and high-throughput mass
spectrometry. This revealed a robust interaction with all seven members of the Ragulator complex which I
went on to confirm via endogenous co-immunoprecipitation and proximity ligation assays. This complex
has recently been described as a key regulator of mTORC1, Erk signaling and lysosome positioning. In
order to study the functional relevance of this interaction I utilized an in vitro CRISPR mediated approach
to knockout Gimap5 in murine primary T cells. I observed a very rapid and robust induction of apoptosis
accompanied by significant increases in ceramide levels following the loss of GIMAP5 which is
consistent with the lymphopenic phenotype. Future studies will relate the increased ceramide to the
Ragulator complex and induction of apoptosis in GIMAP5-deficient T cells and leverage these findings to
develop novel treatments for GIMAP5 deficiency and other autoimmune diseases.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Immunology

First Advisor
Michael J. Lenardo

Second Advisor
Helen C. Su

Keywords
Autoimmunity, Ceramides, GIMAP5, Immunodeficiency, Lymphopenia, Mendelian Diseases

Subject Categories
Allergy and Immunology | Genetics | Immunology and Infectious Disease | Medical Immunology |
Microbiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3469

A MENDELIAN DISEASE OF AUTOIMMUNITY REVEALS GIMAP5 AS A NOVEL MEMBER OF
THE RAGULATOR COMPLEX
Michael A. Leney-Greene
A DISSERTATION
in
Immunology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2019

Supervisor of Dissertation

Co-Supervisor of Dissertation

_____________________

_______________________

Michael J. Lenardo

Helen C. Su

Chief – Molecular Development of the
Immune System Section

Chief – Human Immunological
Diseases Section

Graduate Group Chairperson
_____________________

David M. Allman, Ph.D., Professor of Pathology and Laboratory Medicine

Dissertation Committee
Igor Brodsky, Ph.D., Associate Professor of Pathobiology
Sara Cherry, Ph.D., Professor of Microbiology
Pamela Schwartzberg, M.D., Ph. D., Cell Signaling and Immunity Section Chief
E. John Wherry, Ph. D., Professor of Immunology
1

ABSTRACT
A MENDELIAN DISEASE OF AUTOIMMUNITY REVEALS GIMAP5 AS A NOVEL MEMBER OF
THE RAGULATOR COMPLEX
Michael A. Leney-Greene
Michael J. Lenardo & Helen C. Su

The incidence of autoimmune diseases, many of which lack effective treatments,
is rapidly increasing in the developed world. Mendelian diseases allow the study of
autoimmunity in humans, enabling new insights into the underlying pathology. In this
study, I have identified a patient cohort suffering from a novel recessive Mendelian
disease of immune dysregulation characterized by severe lymphopenia, splenomegaly,
thrombocytopenia and liver failure. Whole exome sequencing revealed mutations in
GIMAP5, a small GTPase primarily expressed in T, NK and endothelial cells. The
missense mutations in these patients destabilize the protein in vitro and lead to a near
complete loss of protein in patient cells. Animal models lacking GIMAP5 develop a
disease remarkably similar to that observed in the human patients; however, the
molecular role of this gene in the immune system remains obscure. To address this, I
defined the interactome of GIMAP5 via immunoprecipitation and high-throughput mass
spectrometry. This revealed a robust interaction with all seven members of the Ragulator
complex which I went on to confirm via endogenous co-immunoprecipitation and
proximity ligation assays. This complex has recently been described as a key regulator of
mTORC1, Erk signaling and lysosome positioning. In order to study the functional
relevance of this interaction I utilized an in vitro CRISPR mediated approach to knockout
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Gimap5 in murine primary T cells. I observed a very rapid and robust induction of
apoptosis accompanied by significant increases in ceramide levels following the loss of
GIMAP5 which is consistent with the lymphopenic phenotype. Future studies will relate
the increased ceramide to the Ragulator complex and induction of apoptosis in GIMAP5deficient T cells and leverage these findings to develop novel treatments for GIMAP5
deficiency and other autoimmune diseases.
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CHAPTER I - Introduction
I.

Summary

Lymphocytes are critical effectors of the immune system whose dysregulation can
lead to immunodeficiency and/or autoimmunity. Proper regulation of lymphocyte number
in addition to function is key for an appropriate immune response. Thus, the rates of
generation of new lymphocytes, proliferation of existing ones as well as death of older
ones tightly controlled. The generation of new lymphocytes generally occurs at a steady
rate, and in the case of T cells, steadily decays with age. On the other hand, proliferation
and death are regulated by a complex system of competition for soluble cytokines,
exposure self-antigens and pro-apoptotic surface receptors. Genetic lesions affecting any
of these processes lead to immunodeficiency and/or immune dysregulation due to
abnormalities of lymphocyte numbers. Many autoimmune diseases have high heritability,
indicating a strong genetic component. Harnessing genetics to study autoimmunity and
lymphocyte regulation has the potential to both improve our understanding of the
etiology of autoimmune disease and also develop novel, more effective therapeutics
targeting previously poorly understood pathways.

II.

Human Genetics and Whole Genome Sequencing

A) The history of DNA sequencing techniques and human genetic variation
DNA sequencing became possible in the 1970s due in part to pioneering work by
Frederick Sanger (Sanger, Nicklen and Coulson, 1977). His method exploited the
sequential addition of chain-terminating dideoxynucleotides to a DNA synthesis reaction
to generate DNA fragments with single nucleotide resolution, allowing the derivation of
1

the DNA sequence. While labor-intensive and expensive, ‘Sanger Sequencing’ remained
the principal method used to sequence DNA for four decades and was used to sequence
the human genome. The initial draft of the sequence of the human genome was published
in 2001 with roughly 90% coverage and at cost of approximately 3 billion USD (Petersen
et al., 2017). This sequence is actually a haploid mosaic of several different human
donors and thus does not always represent the most common alleles and remains
incomplete. However, attempts are made to represent relatively common alleles that are
present in multiple different populations. While automation and increased use of
computers drastically drove down the cost of Sanger sequencing, a major paradigm shift
occurred in the mid 2000s as massively parallel ‘Next-generation’ sequencing was
developed. This method hybridizes many fragments of the DNA sequence of interest to a
glass slide, followed by a DNA polymerization reaction that emits light when a specific
dideoxy-base is incorporated. A camera can then interpret the sequence of DNA from the
sequences of light emission following each cycle of base addition on the glass slide and
thus generate many short sequences, or “reads” of DNA from the fragments (Alekseyev
et al., 2018). These techniques have slashed both the turnaround time and cost of
sequencing a human exome or genome by several orders of magnitude. As of this writing
sequencing a human exome/genome costs in the range of hundreds of dollars per sample
when done for research purposes (Petersen et al., 2017). These developments have
combined to usher in a golden age in human genetics and a surge in research studying the
human genome.
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Following the completion of the human genome project, the focus has shifted to
translating these developments in basic science into clinical benefits. The contribution of
genetic variation to the development of human disease is a spectrum. One end is
composed of Mendelian, or monogenic diseases which are caused by rare mutations
which are highly deleterious with high penetrance. The opposite end of the spectrum is
composed of polygenic, or complex diseases, which are typically conceptualized as being
caused by a combination of many low impact genetic variants in combination with
environmental influences (Kaiser, 2012). Broadly speaking, human genetic variation can
be broken down into Single Nucleotide Variants (SNVs), small Insertions or Deletions
(indels) or larger-scale structural variation. The latter exists on a large spectrum, all the
way up to aneuploidies involving duplications or losses of entire chromosomes. They
also include inversions of large sequences as well as duplication/deletion of large
stretches of DNA termed Copy Number Variations (CNVs). These structural variations
are best interrogated by array-based Comparative Genome Hybridization (array-CGH)
(Feuk et al., 2006). Meanwhile, SNVs and small indels are best interrogated by
WES/WGS.
B) GWAS and the heritability of human disease
Twin studies have long given an estimate of the heritability of a variety of
diseases (Tenesa and Haley, 2013). Human disease runs the spectrum from low to high
heritability, with presumably the remaining incidence occurring due to environmental
influences. Many diseases of the immune system such as Systemic Lupus Erythematosus
(SLE) and Type one diabetes (T1D) exhibit very high heritability – both greater than 60%
3

(Guerra, Vyse and Cunninghame Graham, 2012; Leslie, 2018). Initial hypotheses argued
that alleles with large damaging effect sizes would be strongly selected against and thus
extremely rare in the population and not contributing significantly to the total heritability
of these diseases. Thus, research into the genetic contributions to human disease focused
largely on the mapping of relatively common Single Nucleotide Variants (SNVs) with
small effect sizes. This was called the Common Disease-Common Variant (CD-CV)
model and the underlying hypothesis was that cumulatively, the combination of many
such alleles would predispose individuals to disease when exposed to the appropriate
environmental conditions (Reich and Lander, 2001). The hope was that identification of
these alleles would lead to novel molecular pathways involved in the development and
pathogenesis of these diseases that could then be targeted therapeutically. This led to the
generation of the Hapmap project and a proliferation of Genome Wide Association
Studies (GWAS)(Gibbs et al., 2003).
GWAS rely on genetic recombination during meiosis. This process allows
variants on one chromosome to ‘cross over’ to the other, and thus potentially be inherited
independently of other variants present on the parent chromosome. This process typically
occurs at hotspots throughout the genome, resulting in stretches of DNA or ‘haplotypes’
which are frequently inherited together (Evangelou, 2018). Various groups were then
able to develop panels of SNVs spread across these haplotypes, genotype hundreds to
thousands of individuals either carrying or lacking the phenotype of interest, and
associate various haplotypes with given traits.
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Some initial GWAS generated very promising results – in particular, a study
investigating Macular Degeneration (MD) using a relatively small number of participants
yielded polymorphisms accounting for a very large fraction of the heritability (Klein et
al., 2005). However, the majority of the studies to follow only revealed relatively small
fractions of the heritability for many complex diseases such as (Maher, 2008; Manolio et
al., 2009). Boyle et al. have proposed an alternative framework which they call the
‘omnigenic’ model (Boyle, Li and Pritchard, 2017). This pushes the CD-CV model even
beyond GWAS and hypothesizes that all aspects of cell biology are so intertwined that
complex, polygenic diseases being caused by a small number of genetic variants is naïve.
Rather, a large number of low-effect SNVs mostly in the non-coding regions of the
genome predispose individuals to common diseases and the effect sizes are so small that
even the largest GWAS had insufficient power to detect them.
C) Monogenic Mendelian diseases and the contribution of rare variants to human
disease
More recently, several groups have proposed that a larger fraction than previously
estimated of the heritability of common diseases could in fact be caused by rare, highly
deleterious alleles (Lupski et al., 2011; Casanova, 2015). For example, many patients
suffering from Autism Spectrum Disorders (ASD) have been found to carry rare, (defined
as having a MAF of less than 1%) de novo, deleterious genetic variants (Geschwind and
State, 2015). The number of de novo variants varies as a function of the father’s age,
however, on average one can expect 1-2 de novo coding mutations per individual (Kong
et al., 2012). Recent estimates propose that 20-40% of ASD cases may be caused by de
5

novo SNVs or structural rearrangements (Iossifov et al., 2014). The contribution of rare
genetic variants to other complex diseases remains unclear, however, recent studies have
estimated that each individual carries hundreds of deleterious loss of function SNVs in
their genome (Macarthur et al., 2012).
The massive drop in sequencing costs has led to the realistic use of Whole Exome
and, more recently, Whole Genome Sequencing (WES/WGS) as a diagnostic tool for
Mendelian disease. WES uses a hybridization approach in order to exclusively sequence
the coding regions of the genome (1-2% of the total sequence), while WGS also captures
the non-coding regions by sequencing the entire genomic DNA. It is estimated that 85%
of Mendelian disease-causing mutations are in the coding regions of genes, thus WES
offers a significant cost reduction relative to WGS while still capturing most of the
relevant information (Rabbani et al., 2012; Seleman et al., 2017). However, the
hybridization approach does result in relatively poor sequence quality for some fraction
of genes, an estimated 15% of disease-causing variants will be missed and other
drawbacks to WES likely means that over time if sequencing costs continue to fall WGS
will eventually be favored. One key observation of large scale exome or genome
sequencing is that the number of variants is much larger than was previously thought.
The number of Mendelian diseases identified has vastly increased with the advent
of WES/WGS analysis: as of 2015, 1000 new genes had been associated with Mendelian
traits through WES (Chong et al., 2015). Specifically in the immune system, over 350
inborn errors of immunity have been described and recognized (Cunningham-Rundles et
al., 2017). In some cases, these diseases can exhibit extensive incomplete penetrance
6

whereby related family members may also carry the pathogenic SNV but not exhibit any
clinical manifestations (Bleesing, Nagaraj and Zhang, 2004; Avery et al., 2014; Schubert
et al., 2014). In addition to increasing our understanding of the genetic mechanisms
underlying complex diseases the study of Mendelian diseases has other translational
advantages to offer. Firstly, by sequencing large cohorts of patients one can essentially
replicate high-throughput forward genetic screening that was previously only possible in
model organisms. The vast majority of potential therapeutics fail in the transition from
animal models to the human and screening for important therapeutic targets directly in
humans can bridge the divide (Mak, Evaniew and Ghert, 2014). Secondly, Mendelian
diseases represent a more homogenous cohort of patients for the testing of novel
therapeutics. This can greatly facilitate testing the efficacy of new therapeutics before
offering them to the broader cohort of patients suffering from autoimmune disease.
Lastly, the promise of personalized medicine will be most easily realized initially in
monogenic diseases as the impacts of these alleles are the most straightforward. It is clear
that variations in both complex disease manifestations and responses to therapies are
caused in part by genetic.
Miller syndrome was the first Mendelian disease whose underlying genetic cause
was determined by Whole Exome Sequencing (WES) in 2010 (Ng et al., 2010). In the
intervening years, WES and more recently Whole Genome Sequencing (WGS) have seen
remarkable success in both diagnostic and discovery roles. Early studies reported a
variable success rate of 20-50% in providing a diagnosis to patients, with this variation
very likely to be a function of the initial patient cohort selected for the study (Dixon7

Salazar et al., 2012; Need et al., 2012; Yang et al., 2013; Zhu et al., 2015). As data
accumulates over time the diagnostic success rate of WES/WGS is likely to increase
greatly and it will undoubtedly become a standard tool in the physician’s repertoire.

III. Lymphocyte development, homeostasis and
autoimmunity
A) Autoimmune disease and the contribution of lymphocytes
The concept of autoimmunity stretches back to the idea of ‘horror autotoxicus’ in
which the immune system resists attacking self and this resistance occasionally fails as
proposed by Paul Ehrlich. However, it was not until the middle of the 20th century that
the concept was broadly accepted (Arthur M. Silverstein, 2001). Autoimmune disease is
defined as the loss of self-tolerance whereby an immune response is triggered against
self, or host tissues. The incidence of autoimmune diseases such as SLE and T1D has
markedly increased in developed countries in the modern era and are now collectively a
leading cause of death among young and middle-aged women (Walsh and Rau, 2000;
Lerner, Jeremias and Matthias, 2016). Furthermore, therapies for many diseases are
ineffective and often cause significant side effects. New approaches to understand and
treat autoimmune diseases are urgently needed. Harnessing recently developed genomic
technologies to discover novel pathways and drug targets has led to breakthroughs in
knowledge of genetic diseases of the immune system (Milner and Holland, 2013;
Cunningham-Rundles et al., 2017; Comrie and Lenardo, 2018).
Decades of research in model organisms and more recently in human patients
have demonstrated a critical role for the regulation and homeostasis of lymphocytes in
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avoiding the development of autoimmune disease (Fisher et al., 1995; Avery et al., 2014;
Lo et al., 2015). The immune system is staggeringly complex with a multitude of cell
types in constant equilibrium, and disruption frequently leads to both susceptibility to
specific pathogens as well as dysregulation and consequently autoimmunity.
Lymphocytes are critical effectors of the immune system as evidenced by individuals
with severe defects in lymphocyte development, termed Severe Combined
Immunodeficiency (SCID), invariably face early mortality in the absence of bone marrow
transplants (Linte et al., 2015). Similarly, selective defects in either CD4+, CD8+ or B cell
development/function lead to severe disease with well characterized groups of infections
(Agammaglobulinemia et al., 2000; Zhang et al., 2009; Matthews et al., 2014; Cirillo et
al., 2015). As one of many examples, loss of function mutations in MAGT1 result in a
drastic loss of NKG2D surface expression on CD8+ T cells leading to a selective
susceptibility to Epstein-Barr Virus (EBV) infection and consequently lymphomas (Li et
al., 2011; Chaigne-Delalande et al., 2013; Matthews et al., 2014) Interestingly, many of
these defects actually simultaneously result in both autoimmunity and immunodeficiency.
For instance, loss of the AIRE gene causes Autoimmune PolyendocrinopathyCandidiasis-Ectodermal Dystrophy (APECED), which is characterized by autoimmune
mediated hypoparathyroidism, adrenal insufficiency, susceptibility to Candida infections
(Bosticardo, Peterson and Villa, 2016; Ferre et al., 2016).
B) Lymphocyte development and homeostasis
Conventional  T cells originate in the thymus and are subject to stringent
selective processes based on their T cell receptor specificity. Hematopoietic Stem Cells
9

(HSCs) first differentiate to Common Lymphoid Progenitors (CLPs) which migrate to the
thymus and further differentiate to CD4-CD8- Double Negative (DN) T cells. At this
point, the DN T cells rearrange the Trb locus in a Rag1/2 dependent manner and
successful signaling through the pre-T Cell Receptor (TCR) leads to a burst of
proliferation and progression to the CD4+CD8+ Double Positive (DP) stage (Shah and
Zuniga-Pflucker, 2014). Cells that were unable to productively rearrange the Trb locus
either die by neglect or are shunted towards a different developmental pathway. At this
point, the DP T cells rearrange the Tra locus and again test the nascent TCR against selfligands. Current models posit that cells with excess affinity for self will either die via
negative selection or become regulatory T cells, whereas if the T cell is unable to
recognize self-MHC at all they die by neglect (Krueger, Ziętara and Łyszkiewicz, 2017).
Finally, the mature naïve T cells emigrate from the thymus to the periphery. Defects in
any step of the process described above lead to severe immunodeficiency and at times
autoimmunity.
One critical aspect of lymphocyte biology that is closely regulated is lymphocyte
number. Many studies in both animal and human models have shown that depletion or
chronic low numbers of lymphocytes predispose or outright induces autoimmunity with
the pancreas and thyroid being particularly susceptible (Allen and Braverman, 1996;
Wong and Roth, 2007; Surh and Sprent, 2008; Onoe et al., 2010; Sauer et al., 2012;
Jones et al., 2013). For example, depletion of lymphocytes via the monoclonal antibody
alemtuzumab leads to the development of autoimmunity in one in three patients (Jones et
al., 2013). In the case of T lymphocytes, thymic output greatly decreases with age and
10

thus homeostatic proliferation in the periphery is required to maintain a complete cohort
of T cells (Hale et al., 2006). Defects in both thymopoiesis and peripheral survival have
been shown to cause lymphopenia associated with autoimmunity. This process is
critically dependent on self-peptide/MHC complexes weakly interacting with the TCR as
well as signaling by -chain cytokines (Surh and Sprent, 2008). Similar to B
lymphocytes, conditional knockout of the TCR or proximal TCR signaling molecules in
mature T lymphocytes leads to a drastic decrease in T cell half-life (Labrecque et al.,
2001; Polic et al., 2001; Seddon and Zamoyska, 2002). Furthermore, this TCR/self-MHC
interaction appears to be antigen specific as transferring transgenic T cells with different
specificities won’t compete with each other, while transferring large numbers of a single
transgenic T cell clone reduces their lifespan (Hataye et al., 2006). This data supports a
model with constant competition amongst T cells in the periphery for weakly-interacting
self-antigens. It has been proposed that this is an additional mechanism to ensure a
diverse polyclonal repertoire in the periphery even after thymic selection has occurred.
Soluble cytokines are the other major mechanism by which the organism
regulates the size of the peripheral lymphocyte repertoire. For T lymphocytes the
common -chain family of cytokines are recognized as particularly critical. This is
supported by the fact that mutations in the common  chain receptor, the receptor subunit
specific for IL-7 or downstream signaling molecules lead to SCID (Lin and Leonard,
2018). IL-2, 7, 15 and others all share a the common  chain, IL-2 and IL-15 share a
common  chain coupled with a unique receptor chain specific for each cytokine
(Waickman, Park and Park, 2016). Signaling by IL-7 is required for naïve T cell survival
11

and development, IL-15 is thought to be required primarily by memory T cells and IL-2
is thought to support the expansion of activated T cells as well as regulatory T cells (Surh
and Sprent, 2008). Indeed, blocking IL-7 signaling reduces survival of naïve T cells
whereas overexpression of IL-7 leads to an increase in the size of the naïve T cell pool
and autoimmunity (Tan et al., 2001; Williams et al., 2016) However, much of the data
regarding IL-7 activity and function is indirect as measurement of endogenous levels of
IL-7 in vivo is difficult. It is thought that endogenous IL-7 is captured by the extracellular
matrix of Secondary Lymphoid Organs (SLO), increasing the local concentration as has
been described for other cytokines (Wrenshall and Platt, 1999). Indeed, naïve T cells
from mice lacking SLOs have drastically decreased half-lives, although this result is
complicated by the fact that these T cells may also have decreased interaction with
endogenous TCR ligands (Ruddle and Akirav, 2009). Furthermore, the genetic program
of naïve T cells ensures that homing receptors for SLOs are constantly expressed. This
simultaneously ensures their exposure to IL-7/self-antigens and allows them to monitor
local Antigen Presenting Cells (APCs) for their cognate antigens.
Signaling through the common -chain family of cytokines occurs via the
JAK/Stat pathway. In particular, IL-7 signaling has been shown to regulate the intrinsic
apoptosis pathway because Bcl-2 overexpression can reverse many of the defects in IL-7
deficient mice (Akashi et al., 1997).
C) Lymphocyte survival, apoptosis and necroptosis
Multiple other pathways are critical for controlling the survival/apoptosis of
lymphocytes both at rest and during the course of an immune response. Classically,
12

apoptosis has been broken down into the intrinsic, extrinsic and perforin/granzyme
pathways (Elmore, 2007). Multiple initiating stimuli such as genotoxic or mitochondrial
stress and death receptor signaling can stimulate the intrinsic and extrinsic apoptosis
pathways respectively. The intrinsic pathway is controlled by the balance of pro and antiapoptotic factors on the surface of the mitochondria (Galluzzi et al., 2018).
More recently, necrosis and the related programmed form of cell death termed
necroptosis have been described. These two forms of cell death are much more
inflammatory than apoptosis. Necroptosis is known to be dependent on the kinases
RIPK1/3 downstream of signaling through TNF family receptors (Grootjans, Vanden
Berghe and Vandenabeele, 2017). The kinase activity of both enzymes is thought to be
important, as well as the dimerization of RIPK1 which is both necessary and sufficient to
initiate the process (Christofferson and Yuan, 2010). Necroptosis is entirely independent
of the caspases which are critical for the process of apoptosis. MLKL is a pseudokinase
downstream of RIPK1/3 and is thought to be the sole and critical effector of necroptosis
via the formation of pores in the membrane (Grootjans, Vanden Berghe and
Vandenabeele, 2017). More recently, CAMK2D has also been described as a substrate
for RIPK3 which can induce a pronounced influx of ions leading to cellular swelling and
death (Zhang et al., 2016). Apoptosis and to a lesser extent necroptosis have been well
documented as being critical for the regulation of the lymphocyte compartment (Fisher et
al., 1995; Ch’en et al., 2011).
Sphingolipid metabolism is a metabolic pathway that has long been linked to the
induction of cell death by various ceramide species. Ceramides are sphingolipids
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consisting of a sphingoid base conjugated to an acyl chain of varying lengths via an
amide bond. Ceramides are both precursors for more complex lipid species such as
glycerosphingolipids/sphingomyelins as well as potent signaling molecules in their own
right. Ceramide levels are maintained via both de novo synthesis and degradation of
glycerosphingolipids and sphingomyelins. De novo synthesis of ceramides occurs
through a series of enzymatic reactions primarily in the ER, with further modification to
more complex lipid species occurring in the ER and Golgi. The final step of ceramide
synthesis is catalyzed by one of six Ceramide Synthase (CerS) enzymes (CerS1-6). Each
enzyme has a specificity for producing ceramides with different acyl chain lengths as
well as different tissue distributions. The length of the acyl chain has been shown to have
profound effects on the biological function. Depending on the cell line being studied and
the stimulus used to induce apoptosis, different acyl chain lengths can be either protective
or pro-apoptotic in different contexts (Grösch, Schiffmann and Geisslinger, 2012).
Overall, the underlying biology is complex and remains incompletely understood.
Conversely, ceramide production via recycling of more complex glycerosphingolipids
occurs in the lysosome. Acid Sphingomyelinase (aSMase) cleaves sphingomyelin into
ceramide and choline. Humans carrying mutations in various enzymes involved in the
catabolism of ceramide and sphingomyelins suffer from what are termed Lipid Storage
Disorders (LSDs) which affect multiple organ systems and are frequently characterized
by large cellular lipid deposits visible via conventional light microscopy.
Multiple lines of evidence have pointed towards ceramide levels influencing cell
survival. Firstly, induction of cell death via extracellular receptors such as TNFR and Fas
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or DNA damage can lead to increased ceramide levels (Taha, Mullen and Obeid, 2006).
Specifically, the CerS and SMase enzymes appear to be key regulatory points within the
pathway that can be influenced by diverse upstream mechanisms such as p53/ATM,
caspases, Bcl-2 family members, pro-apoptotic surface receptors and various signaling
kinases. Both the activity and expression of these enzymes have been observed to
increase during certain forms of cell death (Mullen and Obeid, 2012; Kuzmenko and
Klimentyeva, 2016). Secondly, addition of exogenous ceramides to cells can induce
apoptosis in multiple in vitro models. Lastly and most convincingly, inhibition of the
CerS enzymes via Fumonisin B1 (FB1) can also block cell death induced by genotoxic
agents such as daunorubicin (Bose et al., 1995).
D) Lymphopenia and lymphopenia induced proliferation
In a lymphopenic host the remaining T cell pool will undergo Lymphopenia
Induced Proliferation (LIP) in order to attempt to replenish the full complement of
peripheral T cells. LIP was first recognized following experiments showing that the
transfer of splenocytes from a healthy animal into an athymic nude rat eventually
generated a full complement of T cells (Bell et al., 1987). Multiple models of
lymphopenia have different effects on the remaining T cells and likely reflect a complex
system of replenishment with many interacting variables. LIP is thought to occur by two
different mechanisms termed fast and slow LIP. Fast LIP is thought to be driven by T cell
clones specific for antigens from the gut microbiota. It occurs even in the absence of IL-7
but is blocked when cells are transferred to irradiated germ-free mice (Kieper et al., 2005;
Min et al., 2005). As expected from the nomenclature, the proliferation driven by fast LIP
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is orders of magnitude higher than slow LIP. Slow LIP is driven by the increased
availability of self-peptide/MHC and IL-7 in lymphopenic hosts and can be blocked by
preventing IL-7 signaling (Min et al., 2005). Microarray analysis of T cells undergoing
LIP in a lymphopenic host upregulate a similar set of genes (at a smaller magnitude) to T
cells responding to cognate antigen, consistent with a persistent low-level tonic signal as
opposed to a brief high-affinity binding (Goldrath et al., 2004). The relevance of these
two mechanisms is likely dependent on the context. For example, acute lymphopenia
induced by chemotherapeutic agents or irradiation in the context of cancer treatment
could much more resemble the RAG transfer animal model (and thus fast LIP), although
this is complicated by the age and thus the rate of thymic output in the patient. On the
other hand, chronic lymphopenia caused by genetic conditions or infections could more
closely resemble models of Omenn syndrome, and thus slow LIP (Khiong et al., 2007;
Marrella et al., 2007). While LIP does induce T cells with a phenotype associated with
memory cells, these cells have not mounted a true response to cognate antigen (MuraliKrishna and Ahmed, 2000).

IV. GTPase Immune Associated Protein (GIMAP) Family
A) Introduction
The “GTPase of immunity-associated proteins” (GIMAPs; previously “immuneassociated nucleotide-binding” proteins: IANs) are proteins containing an AIG type GTP
binding domain, highly conserved among vertebrates and higher plants and apparently
descended via duplication from a primordial gene (Nitta and Takahama, 2007). In
humans, there are 7 translated GIMAP genes and one pseudogene (GIMAP3) linked on
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chromosome 7q36.1. All the GIMAPs are highly expressed in thymus, spleen and lymph
node tissues, while all except for GIMAP3 and GIMAP9 (neither of which are expressed
in humans) are also highly expressed in the lung (Nitta et al., 2006). On the other hand,
human GIMAP2 appears to have no direct homologue in Mus musculus (Krücken et al.,
2004).
While relatively little work has been done on any GIMAP in the human system,
multiple genetic association studies have linked this locus to human autoimmune
conditions. Different studies have linked polymorphisms in GIMAPs to Behçet’s disease,
asthma, T1D and SLE (Lee, Horie, Graham R Wallace, et al., 2013; Lee, Horie, Graham
R. Wallace, et al., 2013; M. T. Heinonen et al., 2015). This data suggests that GIMAPs
play a similar role in regulation of the immune system and lymphocyte homeostasis in
humans as well as the mouse model. After decades of study the in vivo impacts of
GIMAP deficiency have been well described in multiple models but the molecular
function of this family of proteins is still very poorly understood.
Guanosine Triphosphate hydrolases (GTPases) are a large class of regulatory
switches for internal cellular functions (Gilman, 1987; Wittinghofer and Vetter, 2011).
The classical paradigm for small GTPases utilizes the conformational change induced by
the binding/hydrolysis of GTP to modulate the interacting partners and enable effector
functions. The GTP bound form of the enzyme is typically ‘on’ or able to perform its
biological function while the GDP bound form is ‘off.’ The transition from GDP to GTP
bound forms is catalyzed by a class of proteins called GTPase Exchange Factors (GEFs)
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while the hydrolysis of GTP is induced by GTPase Activating Proteins (GAPs) and the
regulation of these two classes of proteins is critical for appropriate signaling.
Broadly speaking, GIMAPs are thought to be distinct in their regulation from the
classical small GTPases described above and more similar to the less studied GTPase
families such as the septins and paraseptins. Septins are distinct in that GTP binding
induces the formation of large heterogeneous oligomers. The septins are peculiar relative
to the small GTPases in two other ways as well. Firstly, at least in some model
organisms, it is unclear whether GTPase activity is even required for proper function at
baseline (Zent and Wittinghofer, 2014; Abbey et al., 2016). The ability to bind GTP
seems to be sufficien, or, in some cases, is completely dispensable. Secondly, in humans,
septin proteins appear to be highly redundant with knockout of all the septin genes being
necessary in T lymphocytes to reveal a selective cytokinesis defect (Mujal et al., 2015).
Paraseptins include protein channels such as the Translocon on Outer Chloroplast
membrane (Toc) and the Signal Recognition Particle Receptor (SRPR) and along with the
septin family are termed G proteins Activated by nucleotide-dependent Dimerization
(GADs). These proteins are thought to have a relatively lower affinity for GTP relative to
conventional small GTPases, potentially foregoing the need for GEFs and GAPs to
regulate their activity. Rather, homo or heterodimerization itself regulates the GTP
hydrolysis cycle with both members of the complex providing residues required for GTP
hydrolysis (Gasper et al., 2009). GTP binding prompts dimerization, which is thought to
be the active complex capable of carrying out a biological function. One subgroup of
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GADs is the “GTPase of immunity-associated proteins” (GIMAPs) that is primarily
expressed in lymphocytes (Krücken et al., 2004).
B) GIMAP1
Endogenous murine Gimap1 has been shown to localize to the Golgi in the cell
line C1498, although endogenous localization in primary cells has not been tested
(Vivian W Y Wong et al., 2010). GIMAP1 is expressed at all stages of T and B cell
development (Saunders, Louise M C Webb, et al., 2010). Ablation of a floxed Gimap1
allele with either a CD2- or CD79a-restricted Cre in mice leads to severe peripheral
lymphopenia of T and B cells (Saunders, Louise M C Webb, et al., 2010; Webb et al.,
2016). Interestingly, in both cases the numbers of thymocytes and immature/developing
B cells are not significantly different from controls, with the exception of the CD8+ single
positive (CD8+ SP) stage which are roughly 2-3 fold reduced. (Saunders, Louise M C
Webb, et al., 2010; Webb et al., 2016). The lymphocytes which did survive in the
periphery express Gimap1 and thus represent rare clones which failed to delete the gene
completely, suggesting that expression of this gene is critical for survival in the
periphery. While overall numbers are normal, survival of CD4+SP thymocytes is
deficient in vitro despite IL-7 signaling being intact. Overexpression of Bcl-2 is unable to
rescue survival of GIMAP1 deficient B cells in the periphery, suggesting that GIMAP1
does not affect B cell survival via the classical intrinsic apoptosis pathways as has been
suggested for other GIMAPs (Chen et al., 2011a; Webb et al., 2016). Consistent with
such a drastic decrease in survival in the absence of GIMAP1, acute ablation of GIMAP1
via administration of tamoxifen to ERT2-Cre GIMAP1f/f mice led to a severe reduction
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in B cell responses, germinal center formation, plasma cell generation and B cell memory
recall responses to secondary challenges (Webb et al., 2016).
C) GIMAP2
GIMAP2 is absent from the mouse genome, suggesting that it arose later in
evolution (Krücken et al., 2004). Overexpressed, GFP-tagged GIMAP2 has been shown
to localize to the surface of lipid droplets, presumably via insertion of its C-terminal
hydrophobic segments into the surface phospholipid monolayer (Schwefel et al., 2010).
While knockout mice have not been generated and little is known about the role of
GIMAP2 in lymphocytes, the crystal structure of a construct lacking the C-terminal
hydrophobic sequences (GIMAP21-260) was solved and extensive biochemical
characterization has been done. GIMAP21-260 binds GTP and GDP with a Kd of 40 and
630 nM respectively, which is at the low end of normal compared to classical small
GTPases which typically bind guanine nucleotides in the picomolar to low nanomolar
range (Bos, Rehmann and Wittinghofer, 2007). Interestingly, in vitro purified GIMAP2
both self-oligomerizes and heterodimerizes with GIMAP7 in a GTP-dependent fashion
(Schwefel et al., 2010, 2013). The truncated construct does not show significant intrinsic
GTPase activity in vitro, suggesting that some aspect of the C-terminal domain, insertion
into a membrane in vivo, or a GTPase Activating Protein (GAPs) is required. Finally,
mixtures of GIMAP2 and GIMAP7 showed that GIMAP2 possessed GAP activity for
GIMAP7 in vitro in a GTP-dependent manner. Interestingly, GIMAP2 mutants unable to
hydrolyze/bind GTP are less efficient at catalyzing GTP hydrolysis in GIMAP7
(Schwefel et al., 2013). The fact that GIMAP2 is absent from mice raises interesting
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questions about how GIMAP7 may be regulated in different organisms and suggests that
other GAPs must be involved. However, as virtually nothing is known about the
physiological roles of either GIMAP2 or GIMAP7 in vivo, it is difficult to evaluate the
relevance of this GAP activity or the GTPase activity of these proteins more generally.
D) GIMAP3
Relatively little is known about GIMAP3, most likely due to its being a
pseudogene in humans (Krücken et al., 2004). One study claimed that GIMAP5-deficient
mice have a very mild phenotype that was greatly exacerbated in GIMAP3/GIMAP5
double knockouts, suggesting that these genes were synergistic (Yano et al., 2014).
However, two other independently generated GIMAP5-deficient mouse lines showed
severe lymphopenia even in the presence of GIMAP3, suggesting that GIMAP5 has a
critical, non-redundant role in lymphocyte homeostasis and survival (Ryan D. Schulteis
et al., 2008; Aksoylar et al., 2012). This discrepancy could be due to genetic background
or environmental factors specific to different animal facilities. Furthermore, the absence
of GIMAP3 in humans argues against it synergizing with GIMAP5. Another genomewide linkage study between BALB/c and CAST/Ei mouse strains suggested that
GIMAP3 is responsible for differences in mitochondrial DNA segregation in
hematopoietic tissues (Jokinen et al., 2010). However, this argument was weakened by
the fact that ectopic expression of GIMAP3 had no effect on this phenotype and no lossof-function model was explored.
Nitta et al. also investigated the impact of gain/loss-of-function of GIMAP3 in
Fetal Thymus Organ Cultures (FTOCs). Here, the authors showed no effect of GIMAP3
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overexpression but a significant reduction in CD4+SP cells following knockdown with
shRNA-expressing retroviruses (Nitta et al., 2006). Furthermore, in a 293T
overexpression system, the authors showed an interaction with Bcl-2, Bcl-xl, Bax, Bak,
Bad and BimEL, suggesting GIMAP3’s involvement in the intrinsic apoptosis pathway.
E) GIMAP4 (mIAN1)
Overexpressed GIMAP4 in HeLa cells is spread throughout the cytosol (Schnell
et al., 2006). Staining for GIMAP4 in primary stimulated T cells is more punctate,
although it does not seem to significantly co-localize with vesicular markers such as
Rab27, LAMP1 or EEA-1 (Mirkka T. Heinonen et al., 2015). It is unclear whether the
difference in localization between the HeLa and primary T cells is a function of the cell
type or the activation status of the T cells. Interestingly, while unstimulated T cells from
the knockout mice show slightly higher cell death following serum starvation, both
lymphocyte development and numbers in the periphery are identical to controls (Schnell
et al., 2006). Consistent with this, authors showed an interaction with Bax in a 293T
overexpression system (Nitta et al., 2006). Depletion of GIMAP4 via electroporation of
siRNAs in primary human CD4+ T cells showed no difference in viability or proliferation
but a mild decrease in Interferon-gamma (IFN) secretion (Mirkka T. Heinonen et al.,
2015). Given the normal T cell development and absence of peripheral lymphopenia in
GIMAP4-deficient mice, GIMAP4 could possibly be redundant in the mouse model, the
phenotype could be masked by the genetic background or the gene may be involved in
some currently unknown pathway distinct from the other GIMAPs. While the crystal
structure has not been solved, Cambot et al. purified GST-GIMAP4 and showed that it
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can bind both GTP and GDP with relatively low affinities (Kd of 0.47 and 6 M
respectively) (Cambot et al., 2002).
F) GIMAP5
GIMAP5 is the best studied protein in the GIMAP family. It was first recognized
as a critical regulator of lymphocyte survival and homeostasis in the Biobreeding rat
model of T1D as well as Lymphocytic Thyroiditis (LT) (BioBreeding rat – Diabetes
Prone abbreviated as BBDP). This model spontaneously develops antibodies specific for
multiple pancreatic proteins and mirrors many aspects of the human disease (Allen and
Braverman, 1996). Two groups independently mapped the gene responsible for the
pronounced lymphopenia in the BBDP rat strain to a small locus on chromosome 4 and
discovered a homozygous frameshift mutation in GIMAP5 (Hornum, Rmer and
Markholst, 2002; MacMurray et al., 2002). While other loci were also required for the
development of T1D, wild-type GIMAP5 could rescue the phenotype demonstrating that
it was necessary but not sufficient. Work using T cells from the BBDP rat showed
defective calcium flux, Endoplasmic Reticulum (ER) and mitochondrial function.
However, these studies were likely significantly affected by the lymphopenic
environment and did not validate these phenotypes with bone marrow chimeras or in
vitro knockout strategies (Pandarpurkar et al., 2003; Keita et al., 2007; Ilangumaran et
al., 2009; Pino et al., 2009; Chen et al., 2013). Another group suggested that GIMAP5
regulated NF-kB activity and showed that this was maintained in bone marrow chimeras,
controlling for the lymphopenic environment (Kupfer et al., 2007). Overall, while the
lymphopenic/diabetic phenotype in vivo is very reproducible, a clear in vitro phenotype
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that can either be rescued by wild type GIMAP5 or induced in wild type cells via loss-offunction approaches is lacking. Furthermore, there is controversy as to the function of
GIMAP5 likely due to many groups observing phenotypes secondary to LIP.
Interestingly, crossing the loss-of-function GIMAP5 allele from the BioBreeding to the
PVG background did not lead to DM but rather an eosinophilic colitis suggesting that
genetic background has a significant impact on the GIMAP5 deficiency phenotype
(Cousins et al., 2006).
The subcellular localization of GIMAP5 has been controversial in the literature,
with initial overexpression studies of GFP-fused GIMAP5 co-localizing with markers of
the ER, Golgi, centrosome, nuclear membrane, Multi-Vesicular Body (MVB) and
mitochondria (Sandal et al., 2003; Nitta et al., 2006; Dalberg, Markholst and Hornum,
2007; Pino et al., 2009). More recent studies using a monoclonal antibody measuring
endogenous GIMAP5 in Jurkats or overexpression systems using lower amounts of
plasmid showed significant colocalization with LAMP1 (Vivian W Y Wong et al., 2010;
Serrano et al., 2017). These more recent studies have cast doubt on previous work
suggesting that GIMAP5 regulates the intrinsic apoptosis pathway via direct interaction
with Bcl-2 family members at the mitochondrion.
Multiple studies have shown GIMAP5 to be primarily expressed in lymphocytes
(Dahéron et al., 2001; Stamm et al., 2002; Vivian W Y Wong et al., 2010). Northern
blots have also shown expression in non-lymphoid human tissues such as liver and lungs
but it is unclear whether this is due to resident lymphocytes or some other cell type
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(Krücken et al., 2004). To date, the crystal structure, affinity for GTP/GDP, potential
GEFs/GAPs and in vitro GTP hydrolysis rates remain unknown.
Three groups independently generated GIMAP5-deficient mice – two groups
generating complete knockouts via conventional gene targeting, while a third group
reported an N-ethyl-N-nitrosourea(ENU)-induced missense mutation (p.G38C mutation,
referred to hereafter as GIMAP5sph/sph) that severely destabilizes the protein and likely
results in a complete loss-of-function (Ryan D. Schulteis et al., 2008; Barnes et al.,
2010a; Yano et al., 2014). While two groups reported a phenotype very similar to
GIMAP1-deficient mice with peripheral lymphopenia but relatively normal
thymopoiesis, the third reported that GIMAP3 also had to be knocked out in order to
observe lymphopenia (Yano et al., 2014). The reason for this discrepancy is unclear but
could be related to facility specific environmental factors or minor genetic differences in
the parental mouse strains used to generate the knockouts. In the two congruent studies,
GIMAP5-deficient mice die between 12 and 20 weeks of age and suffer from profound
progressive lymphopenia, anemia, liver failure, extramedullary hematopoiesis and colitis
(Ryan D Schulteis et al., 2008a; Barnes et al., 2010a). There is virtually a complete
absence of iNKT cells, CD8+ T cells and a significant reduction in CD4+ T cells, NK
cells, granulocytes and B cells. Absolute numbers of myeloid lineages are largely
unaffected although experiments testing their function have not been reported to date.
Naïve T cells are drastically decreased, likely due to LIP, and while the absolute number
of FoxP3+ regulatory T cells is decreased the relative fraction of the CD4+ T cell pool is
normal (Barnes et al., 2010a; Aksoylar et al., 2012). Furthermore, TCR/B Cell Receptor
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(BCR)-dependent proliferation of lymphocytes is severely deficient. This could be
secondary to the lymphopenic environment, although the authors later showed that
inhibition of GSK3 by lithium chloride or 6-bromoindirubin-3’-oxime (BIO) could
rescue proliferation (Patterson et al., 2018). This phenotype may be secondary to
lymphopenia because the severity of the proliferative defect increases with age along
with the lymphopenia, possibly due to or exacerbated by decreased thymic output and a
progressive transition of the T cells from a naïve to an exhausted memory state (Aksoylar
et al., 2012). Survival of GIMAP5-deficient mice can be rescued by antibiotic treatment,
depletion of CD4+ T cells or intravenous transfer of wild type splenocytes/FoxP3+
regulatory T cells (Barnes et al., 2010a). One GIMAP5-deficient human patient has been
recently described in the literature (Patterson et al., 2018). The patients phenotype is
consistent with that observed in the mouse, including lymphopenia, splenomegaly and a
susceptibility to infections. Proliferation of the patients peripheral T cells was defective
relative to one control and could be rescued with lithium chloride treatment. Barnes et al.
showed that on a C57BL/6J background GIMAP5sph/sph mice develop severe colitis
(Barnes et al., 2010a). This gut pathology could be consistent with fast LIP leading to gut
inflammation in the lymphopenic environment of the GIMAP5sph/sph mouse.
Many different hypotheses have been put forward with regard to the mechanism
behind the phenotype observed in vivo in GIMAP5-deficient mice. Chen et al. proposed
that GIMAP5 is required for Hematopoietic Stem Cell (HSC) survival due to direct
interactions between GIMAP5 and HSC70, Mcl-1 and Bcl-xl (Chen et al., 2011a).
Defective HSC function is supported by competitive engraftment models wherein wild
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type cells dominate the bone marrow. These findings can account for the anemia and B
cell defects, but considering that thymopoiesis is largely normal in GIMAP5 deficiency it
is unlikely that the peripheral T cell lymphopenia is due to HSC defects. Furthermore,
this model ignores the finding that GIMAP5 is largely absent from the mitochondria and
primarily localizes to the surface of lysosomes and other vesicular compartments
(although it is worth noting this study was in T cell lines and not HSCs), making direct
interactions with members of the intrinsic apoptosis pathway unlikely (Vivian W Y
Wong et al., 2010). A different group has proposed that GIMAP5 controls FOXO1
levels. FOXO1 is known to regulate the transcription of genes critical for naïve T cell
survival in the periphery through an unclear mechanism (Kerdiles et al., 2009; Aksoylar
et al., 2012). This same group also showed that GIMAP5 is a negative regulator of
GSK3 and that both the in vitro and in vivo T cell defects of GIMAP5 deficiency can be
rescued either by inhibitors or genetic ablation of GSK3 activity (Patterson et al., 2018).
Increased GSK3 activity in the absence of GIMAP5 was shown to lead to increased
DNA damage and consequently apoptosis. This finding would be consistent with another
group that showed overexpression of GIMAP5 in Jurkat cells could protect against
okadaic acid and -radiation induced apoptosis, suggesting that GIMAP5 protects against
apoptosis. Chen et al. proposed that GIMAP5 is both a negative regulator of Akt and also
required for appropriate IL-7 signaling, although neither of these publications accounted
for the lymphopenia with either a rescue or acute depletion of GIMAP5 in wild type cells
(Chen et al., 2015, 2016)
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Multiple groups have published conflicting results regarding overexpression or
knockdown of GIMAP5 in vitro. One study showed an increase in apoptosis in Jurkat and
primary human T cells following transient overexpression of GFP-tagged GIMAP5, but
no effect of RNAi knocking down GIMAP5 (Dalberg, Markholst and Hornum, 2007).
However, this publication did not show the efficiency of the knockdown and the
overexpressed tagged form of GFP-GIMAP5 localized throughout the cytosol rather than
in vesicular puncta, raising the possibility of artifactual results. Another group showed
increased apoptosis following siRNA knockdown of GIMAP5 in Jurkat cells, although
again validation of the knockdown at the protein level was lacking (Pandarpurkar et al.,
2003). Another group showed an anti-apoptotic function for GIMAP5 in T-ALL lines
(Chadwick et al., 2010). Despite decades of research and dozens of publications, multiple
studies have reached different conclusions regarding the function of GIMAP5 and a clear
consensus on its molecular function has yet to emerge.
G) GIMAP6
Conditional GIMAP6 knockout mice have a milder but similar phenotype to the
GIMAP1/GIMAP5-deficient lines with B and T cell lymphopenia but no liver disease or
colitis reported. It is worth noting that the mice were generated using a CD2 specific Cre,
restricting the absence of GIMAP6 to B and T lymphocytes which could be responsible
for some of these differences (Pascall et al., 2013, 2018). Interestingly, lymphocytes from
these GIMAP6-deficient mice were shown to have defects in autophagy. At baseline in
the absence of bafilomycin treatment GIMAP6-deficient mice have an accumulation of
LC3-II, suggesting that there may be a defect in autophagosome processing or
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degradation. There is no published data concerning autophagy in the context of any other
GIMAP deficiency which would be interesting given the similarity in phenotypes
between mice deficient for different GIMAP family members.
GFP tagged GIMAP6 overexpression studies in 293T cells have shown
localization dispersed throughout the cytoplasm, although upon starvation it was
recruited to autophagosomes. In a separate study the same group demonstrated that
GIMAP6 interacts with GABARAPL2, an Atg8 homologue, in overexpression systems
(Pascall et al., 2013). Contrary to what is observed with most G proteins which interact
with effectors through the switch regions in the GTPase domain, the interaction between
GIMAP6 and GABARAPL2 was mapped to the C-terminal domain of GIMAP6. The
authors also showed that endogenous GIMAP6 was recruited to autophagic vesicles
following starvation in both Jurkat and Human Vascular Endothelial (HUVEC) cells
(Pascall et al., 2013).
Another group showed that knockdown of GIMAP6 in Jurkat cells via siRNA led
to a mild increase in apoptosis at baseline as well as greater sensitivity to apoptotic
stimuli such as FasL, okadaic acid and hydrogen peroxide. Furthermore, knockdown led
to increased activation kinetics and an increase in GIMAP6 levels in an NF-B
dependent manner (Ho and Tsai, 2017).
H) GIMAP7
From a functional point of view, GIMAP7 has been very poorly studied but the
crystal structure has been solved. GIMAP7 has been shown to localize to the surface of
lipid droplets, similarly to GIMAP2. Indeed, these two proteins have been shown to
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heterodimerize in vitro, and furthermore GIMAP2 is thought to act as a GAP for
GIMAP7 (Schwefel et al., 2013).
I) GIMAP8
GIMAP8 is unique in the GIMAP family and GTPases in general in that it carries
three GTP binding and hydrolysis domains. When a C-terminally His tagged GIMAP8
was overexpressed in Chinese Hamster Ovary (CHO)-K1 cells it localized broadly
throughout the cytoplasm, ER, Golgi and mitochondria (Krücken et al., 2005). This
strategy may be prone to artifacts as the membrane targeting domains of GIMAP proteins
are typically C-terminally located and thus most studies have used N-terminal tags.
While structurally GIMAP8 is unique it is unclear whether or not it has a nonredundant role in the immune system. Webb et al. generated GIMAP8-deficient mice and
saw no major differences in the peripheral T and B cell compartments (Webb et al.,
2014). There were minor increases in apoptosis following irradiation or dexamethasone
treatment in T cells from GIMAP8-deficient mice, supporting an anti-apoptotic role for
this gene. However, T dependent immune responses were normal again leaving it unclear
how this gene functions in the murine immune system (Webb et al., 2014).
J) Summary
While a role in the intrinsic apoptosis pathway is attractive due to the
lymphopenia phenotype of multiple GIMAP deficient mice and various groups have
shown interactions with proteins regulating the intrinsic apoptosis pathway in 293T
overexpression systems, the evidence for this hypothesis is weak. Specifically, GIMAPs
are broadly distributed throughout the cell and none of them have been shown to localize
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to the mitochondria in primary cells. As a result, it is difficult to imagine how these
proteins are interacting with members of the intrinsic apoptosis pathway in vivo. Thus,
these results may be artifacts of overexpression systems or co-immunoprecipitation
approaches which mix proteins from different cellular compartments during cell lysis.
While multiple GIMAP knockout mice share similar phenotypes (GIMAP1,
GIMAP5 and to a lesser extent GIMAP6), the subcellular localization of these proteins
differ from one another. This raises the possibility that at least some members of this
family of proteins have non-redundant roles in a common pathway. Furthermore, the
restricted expression pattern prompts me to speculate that this pathway may be specific to
lymphocytes or at least play some unique role in lymphocytes distinct from other tissues.
However, to date most proposed explanations for possible biochemical roles of GIMAPs
have only been explored in cells isolated from GIMAP1/GIMAP5-deficient hosts which
have significant systemic immune perturbations, raising a caveat to conclusions based on
these findings. Very little work has shown either a rescue of the proposed phenotype or
an in vitro phenocopy via genetic loss-of-function approaches. The closest to meeting this
standard is a study from Patterson et al. showing that both the in vitro and in vivo
phenotypes can be rescued via inhibition of GSK3 (Patterson et al., 2018). However, the
precise molecular mechanism of GIMAP5 in this case as well as the downstream function
of GSK3 in activated T cells remains unclear. Overall, after decades of study the in vivo
impacts of GIMAP deficiency have been well described in multiple models but the
molecular function of this family of proteins is still very poorly understood.
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V.

The Influence of Cellular Metabolism on the T cell
Response

A) Cell culture media and metabolism
The metabolic status of lymphocytes has recently been recognized as critical for both
quiescence/homeostasis and also maintaining an appropriate number of cells in the
periphery. Recent publications have highlighted the influence of lipids, glucose, and
amino acid metabolism on both the magnitude and characteristics of the T cell response
(Pearce et al., 2009; van der Windt and Pearce, 2012; Sinclair et al., 2013; O’Sullivan et
al., 2014; Hosios et al., 2016; Buck et al., 2017; Jacobs et al., 2018). This realization has
influenced and enhanced my understanding of T cell activation in both in vivo and in
vitro model systems.
Formulations of common cell culture media such as RPMI-1640 were developed
in the middle of the 20th century and have undergone remarkably little change. The
compositions of these media were designed to optimize growth of early cancerous cell
lines such as the immortalized murine fibroblast line ‘Strain L’ (Yao and Asayama,
2017). Despite this renewed focus on the effects of metabolic needs on T cell activation
and proliferation very little effort to date has been made to develop culture conditions that
more closely resemble the in vivo milieu that which T lymphocytes experience. More
recently, development of medias such as x-Vivo 15 allow for the culture of T
lymphocytes in serum-free conditions which can be critical for clinical applications
(Medvec et al., 2018). However, one approach that has been less explored in the literature
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is a culture media designed to mimic the in vivo environment rather than optimize the
growth of tumor cell lines.
Recently, several groups have added various additional supplements to RPMI
with the aim of either improving growth in cell culture or better modeling the in vivo
environment (Favaro et al., 2012; Birsoy et al., 2014; Schug et al., 2015; Pan et al.,
2016). Most comprehensive was a study from Cantor et al. in which the authors measured
levels of various metabolites in human plasma and formulated Human Plasma-Like
Media (HPLM) containing a cocktail of small metabolites that are absent from RPMI and
other standard culture media. They may be present in non-physiological levels in Fetal
Bovine Serum (FBS) which is the most widely used medium supplement (Cantor et al.,
2017). In addition to this, the levels of amino acids, glucose and various ions were also
calibrated to physiological values for humans in HPLM.
B) Lymphocyte activation and metabolic demands
Quiescent, unstimulated T cells have drastically different metabolic programs
relative to activated T cell blasts. Similarly, naïve and memory T cells also have different
metabolic requirements. Quiescent T cells are mainly in interphase/G1 and only undergo
a very slow homeostatic proliferation to maintain total cell numbers. Broadly speaking,
these cells have a catabolic metabolism whereby they mostly degrade nutrients
completely via oxidative phosphorylation in order to obtain the maximal amount of
energy. On the other hand, stimulated T cells preferentially use anaerobic glycolysis to
promote anabolism and accumulate the biomass and macromolecules required for growth
and cell division (Heiden et al., 2009). Massive changes occur in the cell to accommodate
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this: for example, the main glucose transporter of the cell GLUT1 is highly upregulated
following TCR stimulation (Jacobs et al., 2018). Furthermore, the same study showed
that overexpression of GLUT1 was sufficient to skew the T cell pool away from a naïve
phenotype and towards a CD44hi effector phenotype. In in vitro assays of
memory/effector T cell skewing, increased glycolysis is inversely correlated with
memory formation while inhibition skews the cells towards a memory fate (Sukumar et
al., 2013). Memory T lymphocytes also have a greater requirement for glycerol and fatty
acid metabolism as the upregulation of glycerol transporters is necessary for memory T
cell formation (Cui et al., 2015).
C) mTORC1 signaling in T lymphocytes
Multiple sensors of the metabolic status of the cell have an influence on T cell
activation, proliferation and the requisite switch to a glycolytic metabolism. One of the
most studied sensors is the mechanistic Target Of Rapamycin Complex 1 (mTORC1), a
critical nexus for sensing multiple metabolic and signaling inputs and inducing
proliferation, cell growth, global protein translation and T cell differentiation. This
complex consists of the mTOR kinase, Raptor, MLST8, PRAS40 and DEPTOR proteins.
The mTORC1 signaling pathway couples growth and proliferation to nutrient availability
and can be dysregulated in a plethora of diseases (Altomare and Gitto, 2015). The
mTORC1 is regulated by two sets of small GTPases upstream – the Rag GTPases and
Rheb (Groenewoud and Zwartkruis, 2013; Bar-Peled and Sabatini, 2014). These in turn
are thought to be governed by nutrient availability and growth factor signaling
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respectively. Downstream, the mTOR kinase phosphorylates a variety of targets involved
in protein translation, cell metabolism and proliferation.
The mTORC1 has been shown to play a critical role in the regulation and
homeostasis of T lymphocytes. It has been recognized that TCR stimulation activates
pathways stimulating protein translation even before the mTOR kinase had been
discovered (Calvo, Bierer and Vik, 1992). Genetic ablation of one of the main negative
regulators of mTORC1 activity, Tsc1, has no major effect on thymocyte development
(although thymocytes are larger consistent with increased mTORC1 activity) but does
lead to a loss of naïve cells and decrease in lymphocyte numbers in the periphery (Wu et
al., 2011). T lymphocytes from these mice also exhibit increased proliferation in vivo
although it is unclear whether this is due to LIP or a primary effect of the ablation of
Tsc1. Curiously, T lymphocytes from these mice also exhibit increased apoptosis
although the mechanism behind this remains unclear. A separate study with similar
findings showed that the defect could be partially rescued by overexpression of a Bcl-2
transgene suggesting that the intrinsic apoptosis pathway may be affected (Yang et al.,
2011). Puzzlingly, human patients carrying germline autosomal dominant negative
mutations in TSC1/2 do not suffer from lymphopenia and their T cells activate and
proliferate normally with no evidence of increased mTORC1 activity (Pilipow et al.,
2014). There is some evidence that cell survival may be affected in these cells similarly
to the mice. Conversely, at least in B cells, loss of Raptor (and consequently mTORC1
signaling) also led to defective survival of these cells (Iwata et al., 2016). It is worth
noting that a complete loss of function of mTORC1 leads to effects on many other
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pathways such as an increase in mTORC2 signaling which could compensate for some
functions (Xie and Proud, 2013). This could explain the finding that in some contexts
both loss and gain of function mutations in the mTORC1 pathway lead to defective
survival. It could also be that appropriate metabolic regulation is required for cell survival
and perturbations in either direction reduce cell fitness.
mTORC1 activity also plays a major role in the response to cognate antigen as
well as memory formation following a successful immune response. Araki et al.
demonstrated that rapamycin treatment during acute infection with LCMV has no major
impact on the magnitude of the initial response (although this finding was dose
dependent) but generated a much larger pool of memory T cells (Araki et al., 2009). They
also confirmed these findings via genetic approaches as well. Previous studies have
shown that mTORC1 and glycolysis are required for development of effector functions
during the T cell response, which may demonstrate a potential drawback of this strategy
to augment memory responses (Chang et al., 2013; Millet et al., 2017). GAPDH is
sensitive to glycolytic flux and can directly bind regulatory elements in the 3’
Untranslated Region (UTR) of IFN and TNF, releasing translational inhibition when
glycolytic flux is high. These findings likely account for some previous findings
suggesting that mTORC1 inhibition affects T cell effector function. mTORC1 signaling
regulates T helper differentiation in addition to memory formation and the induction of
effector functions. Genetic depletion of Raptor and Rictor, unique components of
mTORC1 and mTORC2 respectively, had inverse effects on Th1, Th17 and Th2
differentiation. Ablation of Raptor and consequently mTORC1 signaling prevented the
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generation of Th1 and Th17 cells, whereas loss of Rictor and mTORC2 signaling blocked
the formation of Th2s (Delgoffe et al., 2011).
Upon TCR stimulation, secondary growth signals such as CD28 ligation or IL-2
promote the metabolic switch to glycolysis via activation of multiple signaling pathways.
The Phosphoinositide 3-kinase (PI3K)/Akt and LKB1/AMPK signaling axes have been
shown to be particularly important in the TCR mediated metabolic switch (van der Windt
and Pearce, 2012). Activation of PI3K leads to the generation of phosphatidylinositol3,4,5-triphosphate (PIP3) by phosphorylation of phosphatidylinositol-4,5-bisphosphate
(PIP2). PIP3 recruits both Akt and its activator, PDK1, to the plasma membrane via PIP3
binding Pleckstrin Homology (PH) domains. Furthermore, it induces a conformational
change in Akt exposing the critical threonine 308 residue for phosphorylation by PDK1
(Mora et al., 2004). Activated Akt can then go on to phosphorylate the Tuberous
Sclerosis Complex proteins 1/2 (TSC1/2) which are critical negative regulators of
mTORC1. The TSC complex acts as a GAP for the small GTPase Rheb on the surface of
the lysosome. In the absence of TSC GAP activity Rheb can become GTP loaded and
mediate the phosphorylation of mTOR in mTORC1 which is required for its kinase
activity.
In parallel, a second signaling axis is required for appropriate activation of
mTORC1. It has long been known that amino acid availability can impact mTOR
activity, however, only recently have the molecular underpinnings been elucidated.
Initially it was thought that this was mediated by the TSC1/2/Rheb axis as well; however,
the discovery that Tsc2-/- Murine Embryonic Fibroblasts (MEFs) are still sensitive to
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amino acid starvation pointed towards an alternative pathway (Smith et al., 2005). A
combination of genetic and molecular functional approaches led to the discovery of the
Rag GTPases, Ragulator complex and lysosomal V-ATPase as the molecular components
of this alternative signaling pathway (Kim et al., 2008; Sancak et al., 2008). The
Ragulator complex consists of 5 scaffolding proteins: Late endosomal/lysosomal
Adaptor, MAPK and mTOR activator 1 (LAMTOR1) through LAMTOR5. Some of
these proteins and the general mechanism of regulation are conserved all the way back to
yeast. The crystal structure of these in complex demonstrates a hydrophobic tail of
LAMTOR1 anchoring the complex to the lysosomal membrane (Yonehara et al., 2017).
LAMTOR1, 2 and 3 have also previously been recognized as scaffolds for Mek/Erk in
the MAPK signaling pathway indicating that the Ragulator complex has other functions
beyond its role in the mTORC1 signaling pathway (Nada et al., 2009). The Ragulator
complex serves as a scaffold for a heterodimer of another set of small GTPases – RagA
or RagB heterodimerized with either RagC or RagD. A series of elegant studies
demonstrated that the GTP/GDP loading state of this heterodimer mediated the
recruitment of mTORC1 to the surface of the lysosome. The active heterodimer has
RagA/RagB in the GTP bound state and RagC/RagD in the GDP bound state (Bar-peled
et al., 2012). The Ragulator complex works in conjunction with the lysosomal V-ATPase
as a GEF for RagA/RagB to stimulate a switch to the active form of the complex. This
complex can then interact with Raptor, recruiting mTORC1 to the surface of the
lysosome to phosphorylate downstream substrates such as p70-S6K, 4EBP1 and Ulk1.
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Upstream of the Ragulator complex are the sestrin and GATOR complexes which
are able to directly sense amino acid levels in the cell. GATOR1 and GATOR2 form a
complex and GATOR1 is able to interact with the Rag GTPases. Loss of function studies
were initially confusing as ablation of GATOR1 led to constitutively active mTORC1
and insensitivity to amino acid starvation whereas loss of GATOR2 led to deficient
mTORC1 signaling. Epistasis experiments later demonstrated that GATOR2 acts
upstream as a negative regulator of GATOR1, which in turn acts as GAP for RagA/B
(Bar-peled et al., 2013). Sestrin2 acts as a further regulator of this pathway upstream of
GATOR2. Sestrin2 binds to GATOR2 and acts as a negative regulator of mTORC1;
however, in the presence of sufficient levels of leucine it dissociates from GATOR2 thus
allowing for the inhibition of GATOR1. Sestrin2 directly binds leucine and presumably
acts as a sensor for levels for this specific amino acid in the cell (Wolfson et al., 2015).
D) Autophagy in lymphocyte metabolism
Another critical metabolic pathway controlling lymphocyte metabolism is
macroautophagy (hereafter referred to as autophagy). Autophagy is an ancient and highly
conserved intracellular pathway for degrading macromolecules, organelles and even
invading pathogens in lysosomal compartments. Autophagy has been shown to be critical
for lymphocyte fitness. Multiple studies have shown that TCR stimulation drastically
increases levels of autophagic flux (Li et al., 2006; Hubbard et al., 2010). In other cell
types, inhibition of mTORC1 has long been recognized to induce autophagy. Current
models posit that the mTORC1 senses starvation conditions and the absence of mTORC1
signaling induces autophagy. The molecular mechanism has recently been described with
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AMPK and mTORC1 directly phosphorylating Ulk1 with opposing effects (Egan et al.,
2011). T cell specific ablation of autophagy genes Atg5, Atg7 and Rab7 led to relatively
minor effects on thymopoiesis but major defects in peripheral T cell fitness and
proliferation following stimulation (Pua et al., 2007; Roy et al., 2013; Lin et al., 2014).
Curiously, both autophagic flux and mTORC1 signaling are greatly increased during
TCR stimulation despite the fact that these two pathways are typically inversely
regulated. Furthermore, rapamycin treatment of activated T lymphocytes has little effect
on autophagic flux contrary to many other cell lines that have been used to study
autophagy (Botbol, Patel and Macian, 2015). While the molecular underpinnings of these
effects remain unclear, there is some evidence that Jnk signaling may drive autophagy
initiation in recently activated T lymphocytes (Li et al., 2006).
The phenotypes of Rab7 deficient T lymphocytes and GIMAP1/GIMAP5deficient T cells is remarkably similar (Ryan D Schulteis et al., 2008a; Saunders, Louise
M C Webb, et al., 2010; Roy et al., 2013). Both have largely regular thymopoiesis with
peripheral lymphopenia, increased apoptosis of peripheral T lymphocytes, a more drastic
defect in CD8+ T cells and defective T cell proliferation in vitro. Several studies have
demonstrated abnormalities in mitophagy (the envelopment of mitochondria in
autophagosomes and their subsequent degradation) and consequently mitochondrial
numbers. This in turn leads to altered levels of genes involved in the intrinsic apoptosis
pathway as well as increased levels of reactive oxygen species T lymphocytes with
genetic defects in autophagy (Pua et al., 2009; Watanabe et al., 2014).
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The classical pathway involves the formation of double membraned
autophagosomes containing the cargo in question and then subsequent delivery to
lysosomes for degradation (Mizushima, Yoshimori and Ohsumi, 2011). This process is
initiated by a complex of UNC-51-like Kinases 1 and 2 (Ulk1 and Ulk2) activating
another complex of PI3KC3, Vps34, Vps15, Atg14 and Beclin1 which can then initiate
the formation of the autophagosome membrane via lipidation of LC3 with
phosphatidylethanolamine to LC3-II (Liang et al., 1999; Eisuke Itakura,*† Chieko
Kishi,* Kinji Inoue, 2010). A cascade of other Atg proteins then mediate the elongation
of this membrane and trafficking of the mature autophagosome to the lysosome for
processing and degradation. A family of small GTPases, the Rab proteins, are also critical
for appropriate trafficking of the autophagosomes (Ao, Zou and Wu, 2014). Measurement
of autophagic activity in the cell is typically expressed as a flux – baseline levels of LC3II are measured and compared to cells treated with bafilomycin to inhibit LC3-II
degradation. Overall, while these studies establish that autophagy is required for proper T
cell function and survival, the mechanism of cell death and biochemical role of
autophagy in T cell activation remain enigmatic.
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CHAPTER 2: A Novel Mendelian Disease of
Autoimmunity Caused by Mutations in GIMAP5

________________________________________________________________________
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I.

Summary
Whole exome sequencing offers the promise of diagnosis to many patients as well

as an avenue for discovering novel genes involved in the regulation of the immune
system and allowing their study in the human model. Here, I describe for the first time a
novel autosomal recessive Mendelian disease of autoimmunity caused by mutations in
the small GTPase GIMAP5. Characterization of a cohort of patients carrying mutations in
GIMAP5 allowed me to describe for the first time the broad clinical and immunological
impacts of the loss of this gene in humans. Virtually every patient suffered from
lymphopenia, thrombocytopenia, mild anemia, bronchiectasis, varying degrees of liver
disease, hepatosplenomegaly and lymphadenopathy. Extensive immunological
phenotyping and functional studies in patient T cells revealed major disruptions in the
balance between naïve and memory T cells, although, surprisingly, no in vitro evidence
of defective survival or proliferation in contrast to the murine model. I then undertook
high-throughput RNA-Seq in an siRNA knockdown model as well as BioID2 labeling
studies to define the interactome. The former revealed surprisingly little impact of
GIMAP5 knockdown on the transcriptome while the latter identified three main
complexes in close proximity to GIMAP5 in the cell: the Ragulator complex, the T cell
receptor complex and various complexes involved in cellular trafficking. I went on to
confirm interactions between GIMAP5 and the Ragulator complex via two independent
methods. These data define for the first time the human presentation of GIMAP5
deficiency as well as multiple new interacting partners.
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II.

Results

Clinical phenotype of a cohort of patients suffering from a novel Mendelian disease of
autoimmunity
We identified 9 affected individuals from 4 pedigrees suffering from a similar
autoimmune disease (Figure 2.1A). Clinical problems common to the patients were
fatigue related to anemia, bleeding, splenomegaly, lymphadenopathy and compromised
breathing due to bronchiectasis which was presumably secondary to recurrent respiratory
infections. Clinical testing revealed severe lymphopenia and thrombocytopenia that were
consistent and in some cases progressive over time (Figure 2.1B, Table 1). Nearly every
measurement of the GIMAP5-deficient patients showed values lower than the 5th
percentile (bottom dotted line). CT scans of the lungs of P1.4 and others revealed ground
glass opacities and bronchial wall thickening typical of bronchiectasis (Figure 2.1C –
white arrows). This clinical finding could represent either a congenital role for GIMAP5
in airway formation or, more likely occurred secondarily to recurrent lung infections. At
the time of the scan the patient was also suffering from an acute fungal infection in his
lungs (Figure 2.1C – red arrows). Three affected individuals from pedigree 1 are
deceased - two of infections and liver failure and one of hypoxemic respiratory failure
due to pulmonary embolus. A bone marrow biopsy was performed on one patient (P1.5)
and revealed findings suggestive of myelodysplasia with increased, atypical
megakaryocytes, increased erythroid progenitors, granulocytic hypoplasia and normal
fractions of lymphocyte lineages. Liver biopsies were taken from P1.4 who had elevated
levels of circulating liver enzymes as well as abnormal CT scan findings. A biopsy
44

showed a mild lymphocytic infiltrate (black arrow) as well as increased CD34+ staining
in the endothelial cells consistent with a diagnosis of Nodular Regenerative Hyperplasia
(NRH) (Figure 2.1D). Detailed clinical information for each of the patients is available in
Table 1.

Table 1: Clinical phenotype of GIMAP5-deficient patients
Age at Presentation (yo)
Current age (yo)

Clinical Presentation

P1-1
13
22

P1-2
11
20

Ecchymosis

Hemoptysis

P2-2
na
27

Negative
No

P2-3
15
Died at 22

Recognized
Abdominal and during screening
Fatigue, epistaxis
back pain
of family
members

Turkish
p.I47T/I47T

Ethnicity
Genotype, GIMAP5
IMMUNODEFICIENCY & AUTOIMMUNITY
Coombs Test
Auto-antibodies
Blood Cell counts
Hemoglobin
(NR: 12-17.5)
WBCs
(NR: 4500-11000)
Neutrophils
(NR: 1900-8000)
Lymphocytes (NR:900-5200)
Platelets
(NR: 130-400 x10e3/μL)
Lymphocyte subsets (%)

P2-1
17
29

P2-4
2
Died at 17

P2-5
35
Died at 44

P3-1
8
16

Recurrent
Infections

Fatigue

Psoriasis

Turkish
p.L223F/L223F

Negative
No

Negative
No

NA
NA

✓
No

9.8

11.1

NA

NA

P4.1
4
6

European
p.L204P/ p.N221S

Turkish
p.P109L
Negative
Negative

Negative
✓

Negative
No

Negative
✓

5.3

9

7.5

10.2

10.5

NA

NA

NA

NA

2960

12.3

13.6

3600

3500

2200

2500

2100

3100

110

300

700

230

1950

800

540

1100

800

380

830

300

790

720

74

123

25

164

69

35

9

44

81

CD3+
CD3+CD4+
CD3+CD8+
CD19+

NA
NA
NA
NA

NA
NA
NA
NA

69% (55-83)
39% (28-57)
28% (10-39)
19% (6-19)

62% (55-83)
13% (28-57)
48% (10-39)
20% (6-19)

67% (52-78)
23% (25-48)
44% (9-35)
22% (8-24)

81% (56-84)
48% (31-52)
30% (18-35)
9% (6-23)

68%
45%
18%
26%

CD3-CD16+/CD56+

NA

6% (7-31)

7% (6-27)

5% (3-22)

6%

380 (588-1573)****

928 (7001600)

NA

5% (7-31)

76%
37%
30%
9%

(55-83)
(28-57)
(10-39)
(6-19)

7%(7-31)

75%
48%
28%
7%

(55-83)
(28-57)
(10-39)
(6-19)

5% (7-31)

Immunoglobulins
IgG (NR: 700-1600mg/dL)

IgM (NR: 40-230mg/dL)

IgA (NR: 70-400mg/dL)

Thoracic CT Findings

1520

59.5

190

Not done

1700 ()

90.4

3360

1340

360

1720

(913-1894)

(913-1894)

(764-2134)

(913-1894)

215

156

178

118

246

874

(88-322)

(88-322)

(88-322)

(69-387)

(88-322)

(57-237)

246

596

176

39

260

18

(135-378)

(135-378)

(135-378)

(70-303)

(135-378)

(46-287)

Bronchiectasis

Bronchiectasis

Bronchiectasis

Left lung
consolidation

Bronchiectasis

Ground glass
nodular pulm.
infiltrates

310
Chronic
fibrotic
changes in
the lingula

1610
(913-1894)

10.5 (40230)
63.5 (70400)

Normal

Numbers in boldface represent values outside the normal range. Lowest values for each
patient are given; NR: Normal Range. **** This value is post Rituxan treatment.
Prepared by M.L.G., A.O. and S.V.
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A) Four pedigrees suffering from GIMAP5 deficiency are shown.
B) Plots showing ALC and platelet counts in GIMAP5-deficient patients over time.
(continued on next page).
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C) Chest CT scans with evidence of bronchiectasis (white arrows) and acute
infection (red arrows).
Figure 2.1A,C,D were prepared by M.L.G. and S.V., 2.1B by M.L.G. and A.O.,

WES reveals autosomal recessive mutations in GIMAP5
Given the inheritance patterns, I hypothesized that affected individuals in my
cohort suffered from an autosomal recessive Mendelian disease. Genomic DNA was
isolated from both affected and unaffected individuals in each pedigree for WES. In my
initial bioinformatics analysis I considered protein-altering variants with minor allele
frequency <0.1% in dbSNP, NHLBI, 1000 Genomes, Exome Aggregation Consortium
(ExAC) and Yale exome databases. This approach revealed recessive mutations in
GIMAP5 that were predicted to be highly deleterious to protein function in every affected
individual, but these alleles were either heterozygous or absent in over 20 unaffected
relatives who were sequenced. Three of the four pedigrees (Pedigrees 1, 2 and 4) had
multiple generations of consanguinity and thus carried homozygous mutations while the
fourth had no reported consanguinity and carried compound heterozygous mutations.
Affected individuals from pedigree 1 were homozygous for a mutation encoding a
p.L223F (c.667C>T) while P3.1 carried compound heterozygous mutations causing
p.L204P (c.610T>C) and p.N221S (c.662A>G) (Figures 2.2A). Affected individuals in
pedigree 2 carried a homozygous mutation causing a I47T (c.140T>C) substitution and
the proband in pedigree 4 harbored a homozygous mutation encoding p.P109L
(c.326C>G) (Figures 2.2A, B).
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The I47T and L223F mutations were unique and had never before been seen
according to multiple genomics databases (Figure 2.2B). The P109L and N221S
mutations were extremely rare, with allele frequencies of 3.98 x 10-6 and 1.19 x 10-5
respectively. While the L204P mutation was more common (0.2% of the population), it
was paired with the rarer N221S. Another study published a patient carrying homozygous
L204P alleles with similar clinical features to the patient cohort described here, although
whether patients homozygous for the L204P have complete penetrance remains to be
seen (Patterson et al., 2018). I confirmed the status of all of these mutations in every
affected individual (barring P1.2 who died before I could acquire a sample) via Sanger
Sequencing (Figure 2.2B).
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A) Chart listing the GIMAP5 mutations and allele frequencies carried by affected
individuals in the pedigrees in (A)
B) Sanger sequencing confirmation of the mutations carried by each surviving
affected individual.
Figure 2.2A prepared by M.L.G. and S.V., Figure 2.2B by M.L.G.

Parametric linkage analysis using the WES data from the parents was also
performed using affected individuals and two unaffected siblings in pedigree 1. Pedigree
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3 yielded a LOD score of 1.8, pedigree 4 yielded a LOD score of 1.2 and pedigree 1
yielded a LOD score of at least 6.2, providing a highly significant combined LOD score
of 9.2 (data not shown). Overall, the genetics data alone provide a strong argument that
mutations in GIMAP5 are responsible for the phenotype of the patients and furthermore
that the disease is 100% penetrant with a modest variation in expressivity.
GIMAP5 residue conservation and expression pattern in human tissues
The amino acid residues of GIMAP5 that were altered in the patient cohort are
normally highly conserved in primates, more distantly related mammals and also other
GIMAP family members. I47 and P109 are absolutely conserved, likely due to their close
proximity to the active site of the GTPase domain (Figure 2.3A). The other mutated
residues were generally conserved across different members of the human GIMAP family
(Figure 2.3A). More distantly related organisms such as fruit flies and zebrafish did not
have direct homologues to GIMAP5. Nevertheless, the strong conservation of these
residues and the extremely low minor allele frequency of the alleles observed in the
patient cohort suggest that the mutated residues are normally critical for GIMAP5
function.
Some mutations (I47T, P109L, L204P) were present in the GTPase domain and
close to the active site of the enzyme, while others were very distal and localized in a helix outside the GTPase domain (N221S, L223F) (Figure 2.3A). This led me to
speculate that the GTPase dynamics or subcellular localization of the protein would be
affected. Surprisingly, all mutations had profoundly destabilizing effects on GIMAP5
with T cells from the patients showing drastically reduced levels of GIMAP5 protein
50

(Figure 2.3B). Furthermore, given the homology of the different GIMAP family members
and possibility that they act in the same pathway I hypothesized they may be upregulated
in the absence of GIMAP5 in an attempt to compensate. However, in three patients from
three different pedigrees, I did not observe significant or reproducible differences in the
levels of any other GIMAP family member (Figure 2.3B).
As most studies of GIMAP5 have been performed in mice, I investigated the
expression pattern of GIMAP5 in human cells. Using a publicly available database of
microarray data from 78 different human tissues, significant GIMAP5 expression was
observed in CD4+ and CD8+ T cells (Figure 2.3C). Less substantial expression was also
observed in NK cells, monocytes, lungs and heart tissue although in the latter two cases it
is unclear if resident immune cells were responsible or if other cell types in these tissues
actually express GIMAP5. Interestingly, virtually no expression was observed in CD19+
B cells which is in contrast to what is observed in mice and puzzling given the B cell
lymphopenia of the patients (Vivian W.Y. Wong et al., 2010). I confirmed this result by
isolating B cells, monocytes, NK cells and T cells and running western blots for GIMAP5
(Figure 2.3D). As expected, robust bands were observed in T and NK cells, very low
expression in monocytes and no detectable GIMAP5 in B cells. I also ran a western blot
with lysates from a wide variety of other human tissues. Interestingly, I saw significant
GIMAP5 expression in a wide variety of tissues such as the liver, lungs, stomach,
intestines, ovary and prostate (Figure 2.3E). Unfortunately, similar to the microarray data,
it is impossible to determine whether this staining is due to resident lymphocytes or, for
example, hepatocytes or alveolar cells. Apparent expression of GIMAP5 in the liver and
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lung is particularly provocative due to the liver disease and bronchiectasis observed in
multiple GIMAP5-deficient patients. I hypothesized that detection in these tissues may be
due to GIMAP5 expression in endothelial cells which has been reported in some online
databases (Schaum et al., 2018). To test this I blotted protein lysates from Human
Umbilical Vein Endothelial Cells (HUVECs) for GIMAP5. No GIMAP5 expression was
detected relative to the titrated lysate from primary human cycling T cell blasts, despite
loading 24 times as much total protein in the HUVEC lane (Figure 2.3F). Thus, if
GIMAP5 protein is truly expressed in endothelial cells it must be at extremely low levels
or is only induced under specific conditions.
Also of interest was my observation that human GIMAP5 migrates as a prominent
doublet between 30 and 35 kilodaltons (Figures 2.3B, D, E). I observed that both bands
were decreased upon electroporation of siRNA or Cas9-RNP complexes specific for
GIMAP5 and were resistant to treatment with phosphatases, Endoglycosidase H and
PNGase F (Figure 2.8C, Figure 3.1D, data not shown). This was also observed in Rat, but
not murine, Gimap5 (Vivian W Y Wong et al., 2010). Furthermore, overexpression of
human or mouse GIMAP5 results in a single band suggesting a genetic origin rather than
a post-translational modification, although there are only two known exons with coding
sequence which would rule out alternative splicing mechanisms. The precise nature of
these two bands remains unclear.
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A) Sequence alignments indicating the location and conservation of each of the
GIMAP5 mutations carried by patients identified in Figure 2.1. Top alignments
show conservation between species while bottom shows conservation amongst the
GIMAP family members expressed in humans.
B) Western blots measuring GIMAP family protein levels in patients representing
each of the pedigrees described in figure 2.1.
C) Ranked order plot of microarray data showing GIMAP5 expression in various
human tissues. Shown are the 17 highest expressing tissues from a larger dataset
of 72 tissues (Su et al., 2004).
D) Western blot validating GIMAP5 expression in indicated human cell types.
E) Western blot probing for GIMAP5 expression in a wide variety of human tissues.
F) Western blot measuring GIMAP5 expression in HUVECs.
Figure 2.3A prepared by M.L.G. and S.V., Figure 2.3B, C, E and F by M.L.G and 2.3D
by A.M.
Data in B, D and F are representative of 2-3 independent repeats.

Immune cell phenotyping of patients suffering from GIMAP5 deficiency
Deep phenotyping of the patient immune cell populations from isolated Peripheral
Blood Mononuclear Cells (PBMCs) was carried out using Cytometry by Time-Of-Flight
(CyTOF) with the goal of gaining some insight into the etiology of the disease caused by
GIMAP5 (Leipold and Maecker, 2015). A panel of 38 different surface markers was
analyzed via the SPADE software to obtain a global view of the immune dysregulation
(Qiu et al., 2011). While major differences in the surface phenotype of  T cells were
observed, most other immune cell populations were largely unaffected (Figure 2.4A, left
panel). Little to no effect was observed on NK cells, γδ T cells, monocytes or dendritic
cell populations. The patients showed a decrease in naïve and central memory T cell
subsets and a corresponding increase in effector memory subsets (Figure 2.4A, left
panel). Another major difference was a pronounced increase of CD57 expression on
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virtually all CD8+ and  T cell subsets (Figure 2.4A, right panel). CD57 is a marker of
replicative senescence and T cell dysfunction, making this finding consistent with LIP.

A) CyTOF mass cytometry data of 38 phenotyping markers collected on peripheral
blood mononuclear cells (PBMCs) from affected individuals or healthy controls
for which higher order data was analyzed and visualized via SPADE. The left
panel shows a phenotyping tree with subsets overrepresented in the patient in red
and subsets underrepresented in blue. The right panel shows the same tree with
coloration showing increased/decreased CD57 expression in the patient.
B) Measurement of naïve T cell fractions (CCR7+CD45RA+) via conventional flow
cytometry in healthy donor or GIMAP5-deficient PBMCs. (continued on next
page)
55

C) Measurement of CD57 expression on T cells isolated from human GIMAP5deficient patients or healthy donors via flow cytometry.
D) Measurement of telomere length in GIMAP5-deficient patients via flow-FISH.
Figure 2.4A prepared by M.L.G., A.F., A.G., M.L., Figure 2.4B,C,D prepared by M.L.G.
Individual points plotted in (B) and (C) represent the mean of individual patients and
pooled normal controls averaged across 1-5 independent measurements. Statistical
significance was calculated by Student’s t-test **p<0.01, ****p<0.0001.

I confirmed the drastic loss of naïve cells and corresponding increase in senescent
effector memory cells in both CD4+ and CD8+ T cell populations in these patients via
conventional flow cytometric analysis. More specifically, I observed a marked decrease
in CD45RA+CCR7+ naïve phenotype CD4+ and CD8+ T cells with a corresponding
increase in CD45RA-CCR7- effector memory T cells with little change in the
CD45RA+CCR7- central memory T cells (Figure 2.4B). Consistent with the CyTOF data
I observed a marked expansion of CD57+ T cells in the patients suggesting their cells had
undergone multiple rounds of proliferation and became replicatively senescent (Figure
2.4C). Finally, telomere lengths of T cells from two patients were within the 1st
percentile for their age consistent with the idea of replicative senescence (Figure 2.4D).
Overall, this phenotype is consistent with LIP caused by the chronic lymphopenia
observed in the absence of functional GIMAP5. The depletion of naïve T cells and small
remainder of senescent T cells can contribute to the immunodeficiency and autoimmunity
observed in these patients, particularly considering the very limited expression pattern of
GIMAP5 in humans.
T cells from GIMAP5-deficient patients activate and proliferate normally
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I next performed a battery of functional tests on GIMAP5-deficient patient T
cells. Murine T cells deficient for Gimap5 show profound defects in survival, activation
(calcium flux) and proliferation leading me to hypothesize that these phenotypes would
be present in patient cells as well (Ryan D Schulteis et al., 2008a; Ilangumaran et al.,
2009; Barnes et al., 2010a). I have been able to confirm the survival and proliferation
phenotypes in T cells isolated from GIMAP5sph/sph mice. It is worth pointing out that to
date no in vitro rescue or acute knockdown/depletion strategy for GIMAP5 has shown
that this is a primary cell intrinsic phenotype and not secondary to the lymphopenia or
other abnormalities in the GIMAP5sph/sph mice, with the exception of one study showing
lithium chloride treatment rescued T cell proliferation (Patterson et al., 2018). Many
different experiments looking at activation of T cells from GIMAP5-deficient patients
showed no defects in CD69 or CD25 expression following 24 or 72 hours of activation
respectively (Figure 2.5A). I next expanded GIMAP5-deficient T cell blasts in IL-2 and
acutely restimulated them to measure calcium flux. I observed no defects in calcium flux
in these cells relative to controls, contrary to previous studies in rodent models of
GIMAP5 deficiency (Figure 2.5B). Even more puzzlingly, acute activation of T cells
isolated from GIMAP5-deficient patients revealed no apparent defect in either survival or
proliferation in GIMAP5-deficient T cells from multiple patients (Figure 2.5C). While I
did observe variability from individual to individual, there was no significant difference
in GIMAP5-deficient T cells relative to healthy controls. Finally, I also exposed
expanded GIMAP5 deficient human T cell blasts to a variety of apoptotic stimuli such as
anti-Fas crosslinking antibody, Restimulation Induced Cell Death (RICD) and cytokine
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withdrawal. RICD refers to the phenomenon whereby activated T cells restimulated
through the T cell receptor will undergo cell death. None of these treatments showed any
increased susceptibility of patient T cells to apoptosis (Figure 2.5D). This result is also
contrary to the model put forth by multiple groups claiming that GIMAP5 regulates the
intrinsic survival pathway of T lymphocytes via direct interactions with Bcl-2 family
members (Chen et al., 2011a).
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A) Paired plots and flow cytometry histograms showing expression of early
activation markers CD25 (day 3) and CD69 (day 1) following stimulation of T
cells from GIMAP5-deficient patients or healthy donors.
B) Calcium flux plots in expanded T cell blasts from either GIMAP5-deficient
patient T cells or healthy donors.
C) Plots showing either the percent divided or proliferation index (left panel) or
sample plots of celltrace violet dilution (right panel) in stimulated T cells from
either GIMAP5-deficient patient cells or healthy donors.
D) Plots showing viability of T cell blasts from either GIMAP5-deficient patients or
healthy donors. Cells were treated with either anti-Fas crosslinking antibody (left
panel), cytokine withdrawal (center panel) or TCR restimulation (right panel).
Figure 2.5A, B, C, D prepared by M.L.G.

Defective survival and proliferation of murine GIMAP5sph/sph T cells can be rescued via
overexpression of GIMAP5
To date, nearly all studies into the phenotype of GIMAP5 deficiency have used
genetic in vivo knockout rodent models with loss of GIMAP5 either in all tissues or
specifically in CD2 expressing tissues (Ryan D Schulteis et al., 2008b; Barnes et al.,
2010a; Aksoylar et al., 2012; Patterson et al., 2018). However, none of the phenotypes
described (defective survival, calcium flux, autophagy or hyperactive mTORC1 activity)
could be recapitulated in GIMAP5-deficient patient cells or GIMAP5 knockout Jurkat
lines. This strongly suggested to me that these phenotypes could be T cell extrinsic and
caused by the inflammatory/lymphopenic environment of the Sphinx mouse. However, it
was puzzling that most of my expression data in humans pointed to GIMAP5 and the
GIMAP family more broadly being mostly lymphoid restricted.
To test this, I undertook two separate strategies. I first established a retroviral
expression system to rescue the defects present in the sphinx mice. I cloned either
GIMAP5WT, GIMAP5L223F (analogous to a mutation present in human patients),
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GIMAP5A240X (mutant lacking C-terminal hydrophobic domains), GIMAP5S41N (unable
to bind nucleotide) or GIMAP5R122D (constitutively active mutant, unable to hydrolyze
GTP (Schwefel et al., 2013)) into the pMSGV1 vector with a C-terminal T2A-GFP
sequence to identify successfully transduced cells. I also generated a ‘GIMAP1-GIMAP5
switch’ construct which swapped the C-terminal hydrophobic domains of GIMAP5 with
that of GIMAP1. This should target this construct to the Golgi complex rather than the
lysosome. I then generated retrovirus, tittered it in NIH-3T3 cells which lack endogenous
GIMAP5 and verified expression of the various alleles (Figure 2.6A). Despite similar
transduction efficiencies, the p.L223F, p.S41N and G1-5 switch alleles had significantly
less protein, while the p.A240X allele had virtually none. This would suggest that
inability to bind nucleotide or localize to the lysosome lead to degradation of GIMAP5.
The constitutively active p.R122D protein was expressed at a similar level to the
GIMAP5WT condition.
I next activated enriched CD4+ T cells from Sphinx mice and transduced with the
indicated retroviruses at 24 hours post-activation. As expected, untransduced T cells from
Sphinx mice were unable to expand significantly. However, I achieved impressive
expansion of the culture when transducing with the GIMAP5WT retrovirus, but none of
the other retroviruses (Figure 2.6B). However, all of the constructs were able to infect the
T cells as evidenced by 50-80% of the cells becoming GFP+ by day 3 post activation
(Figure 2.6B). While the WT was slightly higher already at day 3 post activation, I
hypothesize that this difference is likely due to these cells already having a survival
advantage over their untransduced counterparts. As further evidence that expression of
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the GIMAP5WT protein is rescuing the survival of these cells, the culture transduced with
this retrovirus rapidly becomes nearly 100% GFP+ while presumably the untransduced
GFP- cells die or are unable to proliferate. On the other hand, cultures transduced with the
S41N or L223F constructs undergo little change between day 3 and day 12, suggesting
that these cells have no survival advantage. Interestingly, the R122D+ cells are gradually
selected for in the culture over time, but do not accumulate and rescue the cell numbers
(Figure 2.6B). Overall, these data provide very robust evidence that the survival defect of
GIMAP5-deficient murine cells is T cell intrinsic and furthermore capable of being
rescued with expression of GIMAP5. Furthermore, it also provides the first evidence to
my knowledge that regulation of the GTP-hydrolysis of GIMAP5 is required for proper
functioning of the protein.
We also transduced T cells from GIMAP5WT littermates with the same viruses.
Interestingly, while I observed no difference in cell counts or in the fraction of GFP-T2AGIMAP5+ cells between GIMAP5WT and most of the other alleles, I did observe a
reproducible decrease in fitness in host cells transduced with GIMAP5R122D. While there
were identical fractions of cells expressing GIMAP5 at 48 hours post-transduction, the
fraction of GFP+ cells in the GIMAP5R122D cultures rapidly decreased by nearly half
between 48 and 96 hours following exposure to the retrovirus (Fig. 2.6C). This highlights
that proper regulation of GTP hydrolysis is required for GIMAP5 function and also that
GIMAP5R122D is likely constitutively active and dominant over the endogenous wild type
GIMAP5.
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A) Flow cytometry histograms (left panel) and western blots (right) measuring GFPT2A-GIMAP5 expression in NIH-3T3 cells transduced with the indicated
retroviruses.
B) Cell counts (left panel) and fraction of GFP-T2A-GIMAP5+ cells in stimulated
GIMAP5sph/sph T cells transduced with the same retroviruses as in (A).
C) Sample flow plots and fraction of GFP-T2A-GIMAP5+ cells in stimulated
GIMAP5WT/WT T cells transduced with the same retroviruses as in (A).
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Figure 2.6A, B, C prepared by M.L.G.
Data shown is representative of 2 (A) or 3-4 independent experiments (B,C).

Murine T cell GIMAP5 CRISPR-RNP model recapitulates the phenotype of
GIMAP5sph/sph T cells and reveals a link between GIMAP5 and ceramide metabolism
While the rescue experiment did convince me that decreased survival of murine T
cells lacking GIMAP5 is a cell intrinsic effect, I also wished to generate an acute loss-offunction model in vitro both to cement these findings and provide a convenient model for
further functional experiments. To date, no group has published an acute loss of function
model to study the role of GIMAP5 and thus previous studies have all been done on T
cells generated in a lymphopenic environment. I turned to the recently developed
CRISPR-RNP model in order to acutely and permanently eliminate GIMAP5 (Seki and
Rutz, 2018). I generated gRNAs in vitro by mixing custom CRISPR RNAs (crRNA) with
trans-activating crRNAs (tracrRNA) complexed to a fluorescent tag. These gRNAs
specific for either GIMAP5 or Thy1 were then bound to purified Cas9 enzyme in vitro
and electroporated into activated and cycling WT murine T cells.
We observed a remarkably high electroporation and knockout efficiency. Over
90% of the T cells were positive for the tracrRNA fluophore and virtually all of these
cells lost surface expression of Thy1.1 within 48 hours (Figure 2.7A). Cells
electroporated with the GIMAP5 crRNAs were equivalently positive for the gRNA
fluophore but as expected did not lose Thy1.1 expression. I also observed the gRNA
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fluophore being rapidly diluted as the cells were actively cycling. Western blotting
confirmed a loss of GIMAP5 relative to the Thy1.1 control cultures.
Following electroporation, I tracked viability in the two cultures daily. In every
experiment the T cells electroporated with GIMAP5 crRNAs rapidly began dying
between 48 and 72 hours post electroporation while the Thy1.1 cells recovered and
proliferated (Figure 2.7B). This directly and acutely recapitulated the phenotype of the
Sphinx T cells in a well-controlled manner, both verifying the finding that this
phenomenon is directly caused by GIMAP5 in a T cell intrinsic manner and providing me
with a cleaner model for untangling the biological processes affected by GIMAP5.
In order to begin to understand the biochemical role of GIMAP5 I extracted either
lipids or cytoplasmic metabolites for high-throughput analysis via mass spectrometry. I
ran five biological replicates comparing cells electroporated with gRNAs specific for
GIMAP5 or Thy1 as a negative control. In the lipidomics analysis I observed a
significant overrepresentations of multiple ceramide species with long fatty acid chains
(Figure 2.7C). Ceramides have long been known to be pro-apoptotic as well as generated
during cell death (Bose et al., 1995). Thus, this could potentially represent the biological
mechanism by which loss of GIMAP5 leads to cell death.
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A) Flow cytometry plots showing CRISPR-RNP electroporation efficiency
(tracrRNA) and Thy1.1 expression over time.
B) Viability of stimulated murine T cells over time following electroporation of
CRISPR-RNPs specific for GIMAP5. Cells were stimulated for 7-10 days prior to
electroporation/day 0. (continued on next page)
C) Plots comparing the Log2 Fold Change (GIMAP5-/-/control) versus the p value of
various metabolites in GIMAP5/Thy1 CRISPR-RNP electroporated murine T
cells, with the most significant/affected species highlighted.
Figure 2.7A, B prepared by M.L.G., Figure 2.7C prepared by M.L.G. and J.E.H.
(continued on next page)
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Data shown in (A-B) are representative of over 7 experiments with *p<0.05, **p<0.01,
****p<0.0001. Data in C represent the averages of samples collected from 5 distinct
electroporations and extractions.

III. Discussion
These results represent the first description of a substantial cohort of patients
suffering from GIMAP5 deficiency. Overall, the clinical and immunological phenotype
were similar to that previously described in rodent models (Ryan D Schulteis et al.,
2008b; Barnes et al., 2010b). Surprisingly, the functional manifestations in patient T cells
were different from what has previously been described in the literature. Indeed, I was
unable to discern any consistent defect in GIMAP5-deficient patient T cells in contrast to
previous murine studies or a previous study with a single patient carrying mutations in
GIMAP5 (Barnes et al., 2010a; Aksoylar et al., 2012; Patterson et al., 2018). Thus, I
sought to cast a wider net by defining the transcriptome of human T cells depleted of
GIMAP5 via siRNA knockdown. These data again were negative, showing virtually no
differences between T cells depleted for GIMAP5 or electroporated with a non-specific
siRNA. Previous data has argued for a role for GIMAP5 in regulating FOXO family
transcription factors, leading me to expect transcriptional differences (Aksoylar et al.,
2012). Overall, these data point towards a major difference in GIMAP5 function between
mouse and man in spite of very similar phenotypes at the organism level. This
underscores the value of studying the human model as the majority of GIMAP5 research
has focused on the T cell survival and proliferation defect, while its absence in the human
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model would argue that this is not the cause of the disease or our experimental conditions
do not reflect the in vivo conditions in humans.
There are significant technical hurdles that could compromise the conclusions
mentioned above. Specifically, the GIMAP5-deficient patients and the siRNA
knockdown model have residual GIMAP5 protein. The former suffers from missense
mutations rather than premature truncations, while the latter is limited both in terms of
efficiency (we have measured a ~3-4 fold reduction in protein levels at peak knockdown)
as well as duration. The knockdown efficiency shown in Figure 2.8C is at time zero of
the RNA-Seq experiment, and thus it is likely that after 12-24 hours of TCR stimulation
significant amounts of new GIMAP5 protein were produced. Previous data has shown in
the murine model that T cell activation both in vitro and in vivo is required to induce the
survival defect in GIMAP5-deficient cells (Patterson et al., 2018). Thus, it is possible that
in the siRNA knockdown model either the residual GIMAP5 protein is sufficient or
following stimulation protein levels have already recovered.
Technical considerations aside, there are multiple possible explanations for the
mouse-human difference in GIMAP5-deficient T cell phenotypes. Firstly, and what I
believe is least likely, it is possible that another GIMAP family member is able to
compensate for the loss of GIMAP5. In particular GIMAP2 is absent in mice, although it
is possible that another GIMAP family member diverged sufficiently between mice and
humans to acquire new functions (Krücken et al., 2004). In order for this to be true
GIMAP2 or another family member would have to be able to compensate for the loss of
GIMAP5 in vitro but not in vivo as the GIMAP5-deficient humans are still severely
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lymphopenic. Furthermore, I did not observe upregulation of GIMAP2 or any other
GIMAP family member in T cells isolated from my GIMAP5-deficient patients. A
second possibility is that the survival and proliferation phenotype previously reported in
GIMAP5-deficient murine T cells are either T cell extrinsic or caused by the
lymphopenic/inflammatory environment. The former at least is very unlikely as depletion
of CD4+ T cells in GIMAP5sph/sph mice rescues survival of the animals (Barnes et al.,
2010a; Patterson et al., 2018). The latter is more difficult to rule out and would require
investigation of the survival/proliferation phenotype either in a mixed bone marrow
chimera or by acutely depleting GIMAP5 ex vivo from murine T cells as I have done
above in human cells. To date, neither of these experiments have been done to formally
demonstrate that the survival phenotype is T cell intrinsic and directly caused by a loss of
GIMAP5. A third possibility is that GIMAP5 deficiency causes the same defect in both
mice and humans, while the specific metabolic alterations lead to much more pronounced
survival defects in the murine cells in vitro. In this model, the defect in the human
GIMAP5-deficient cells is extremely subtle/not captured by the data I present in the
previous section or perhaps only present in vivo.
GIMAPs are members of the paraseptin family of GTPases. The regulation and
function of GTPase activity in these proteins is much less understood than conventional
small GTPases whose activity is regulated by GEFs and GAPs. Rather, their GTPase
activity is thought to be regulated by homo/heterodimerization (Ghosh et al., 2006;
Sirajuddin et al., 2009). Within the GIMAP family only GIMAP2 and GIMAP7 have
been shown to have GTPase activity, with GIMAP7 thought to stimulate the GTPase
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activity of GIMAP2 (Schwefel et al., 2013). These authors also generated variants which
were either unable to hydrolyze GTP and thus constitutively active or unable to bind
nucleotide. I generated analogous mutations in GIMAP5 and observed that the analogous
mutant that was unable to bind nucleotide was extremely unstable relative to wild type
protein, however the constitutively active form was expressed normally. However,
neither was able to significantly rescue Sphinx cells from cell death. This provides the
first evidence that both binding of nucleotide and appropriate regulation of GTP
hydrolysis are required for GIMAP5 function. However, I did not directly demonstrate
that the R122D mutant was unable to hydrolyze GTP due to the lack of an assay for
endogenous GTPase activity. In support of this being a constitutively active mutant I did
observe that overexpression of GIMAP5R122D was toxic to wild type T cells.
Overexpression of the same construct in NIH-3T3 cells had no effect, showing that the
protein was broadly cytotoxic.
To conclude, I have comprehensively described the functional and clinical
characteristics of GIMAP5 deficiency in humans. These studies underscored the
importance of studying humans as well as I observed significant differences in the impact
of loss of GIMAP5 on human T cells. However, major questions regarding the basic
phenotype of loss of GIMAP5 in human and murine T cells remain. Further studies using
acute loss-of-function models of GIMAP5 to differentiate between the possibilities
outlined above are required to further shed light on the biochemical function of GIMAP5.
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CHAPTER 3 – Functional studies of GIMAP5
deficiency

________________________________________________________________________
Authors: Michael Leney-Greene, Ann Park, Xijin Xu, Juan Ravell, Lixin Zheng Helen C.
Su and Michael J. Lenardo. Michael Leney-Greene designed research, conducted
experiments, performed analysis and wrote this section. Ann Park conducted endogenous
Co-Immunoprecipitations. Lixin Zheng, Michael Leney-Greene and Xijin Xu performed
BioID2 experiments. Juan Ravell and Michael Leney-Greene performed PLA
experiments. Helen C. Su and Michael J. Lenardo helped design experiments and write
the paper.
71

I.

Summary
The biochemical role of GIMAP5 remains unclear despite decades of study and

multiple conflicting mechanisms having been proposed. Furthermore, virtually all of
these studies have been conducted using T cells isolated from Gimap5-deficient mice
which could yield many conclusions based on phenotypes secondary to the LIP and the
inflammatory in vivo environment. To address these issues, I undertook high-throughput
RNA-Seq in an siRNA knockdown model as well as BioID2 labeling studies to define the
interactome. The former revealed surprisingly little impact of GIMAP5 knockdown on
the transcriptome while the latter identified three main complexes in close proximity to
GIMAP5 in the cell: the Ragulator complex, the T cell receptor complex and various
complexes involved in cellular trafficking. I went on to confirm interactions between
GIMAP5 and the Ragulator complex via two independent methods. These new
interacting partners suggested that GIMAP5 may play a role in MAPK/mTORC1
signaling from the surface of the lysosome.
In this section I performed further functional studies using siRNA/CRISPR
strategies to acutely deplete GIMAP5 in murine and human T cells and test possible
functional implications of the interaction with the Ragulator complex. While I was able to
show clinical benefit in both mice and humans treated with mTORC1 inhibitors, multiple
models of GIMAP5 deficiency showed no direct effect of acute GIMAP5 depletion on
mTORC1 signaling or proliferation. Thus, the benefit conferred on the GIMAP5deficient patients was most likely due to secondary immunosuppressive effects. I also
describe for the first time defects in autophagy in murine T cells deficient for GIMAP5,
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although I again was unable to reproduce this in human cells suggesting that this was
secondary to the in vivo environment of the Sphinx mouse or a mouse-human difference.
Lastly, as GIMAP5 is a lysosomal protein and the Ragulator has previously been reported
to regulate lysosomal dynamics, we tested lysosome number in GIMAP5-deficient
human T cells (Pu et al., 2015; Pu, Keren-Kaplan and Bonifacino, 2017a). Overall, I
conclude that there are clear mouse-human differences in the in vitro manifestation of the
underlying phenotype in T cells, and furthermore, that in human cells GIMAP5 most
likely does not regulate mTORC1. Thus, the functional importance of the interaction with
the Ragulator complex remains unclear.

II.

Results

BioID2 reveals three major clusters of proteins in close proximity to GIMAP5 in human
T cells
As previous work on GIMAP5 has focused primarily on the in vivo phenotype of
GIMAP5-deficient mice and the molecular role of this gene remains unclear, I sought to
investigate which pathways GIMAP5 may be involved in via a series of high-throughput
approaches. In particular, knowledge of the GIMAP5 interactome and identification of
true interacting partners could shed light upon its biochemical role within the cell.
BioID2 is a recently developed method which involves overexpressing a fusion protein of
the bacterial biotin ligase BirA to the gene of interest (bait) (Kim et al., 2016). The bait
fusion protein is able to biotinylate prey proteins within a 10-25nm radius depending on
the size of the linker of the fusion protein. Biotinylated proximal partners can then be
captured via streptavidin and identified by mass spectrometry (Figure 3.1A).
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With this goal in mind constructs containing GIMAP5 N-terminally tagged with
the BirA enzyme or the BirA enzyme alone were cloned and used to generate stably
expressing Jurkat cell lines. A Jurkat cell line whose endogenous GIMAP5 locus had
been disrupted via CRISPR in order to ensure that 100% of the GIMAP5 expressed in
these cells was tagged was used. The full results of the enriched genes are shown in Table
2, with the enrichment being calculated as the ratio of intensities for a given protein in
cell lines expressing BirA-GIMAP5 versus BirA alone. The list of enriched genes was
also plotted comparing overall intensity, enrichment in the GIMAP5 cells compared to
negative controls, and the enrichment p-value added as a heatmap (Figure 3.1A). Some of
the most significantly enriched proteins, including GIMAP5, members of the Ragulator
complex (LAMTOR1-5) and several CD3 subunits are labeled.
Table 2: Most significantly enriched proximal proteins by BioID2
Gene names mean log2 ratio Peptides Unique peptides
AF1Q;MLLT11
TMEM237
TMEM138
CD3E
CD3D
LAMTOR5
IGF2R
GIMAP5
TPD52L2
LAMTOR3
SNAPIN
STIM1
LOH12CR1
RRAGC
LNPEP
ITGAL
ITGB1
CD2
LAMTOR4
TMPO
TPD52
LAMTOR2
TFRC
SYBL1;VAMP7
LAMTOR1
SNAP23
YKT6
CD4
BLOC1S2

5.35
4.38
4.12
3.69
3.55
3.43
3.35
3.31
3.01
2.96
2.94
2.79
2.72
2.67
2.66
2.59
2.54
2.53
2.53
2.50
2.44
2.30
2.27
2.21
2.19
2.18
2.18
2.18
2.10

4
11
3
8
7
3
94
24
13
4
3
26
6
9
30
31
13
6
2
20
9
4
25
6
6
4
7
7
4

-Log10 T-test p-value

4
11
3
8
7
3
2
20
13
4
3
26
6
4
30
31
13
6
2
8
2
4
1
6
6
4
7
7
4

1.72
2.00
4.81
2.75
1.55
2.62
1.74
2.44
2.54
2.54
1.08
2.41
0.99
2.80
3.37
1.26
1.75
2.14
1.54
2.05
4.45
1.42
1.79
1.42
2.11
1.39
1.11
1.64
1.64

Protein names
Protein AF1q
Transmembrane protein 237
Transmembrane protein 138
T-cell surface glycoprotein CD3 epsilon chain
T-cell surface glycoprotein CD3 delta chain
Ragulator complex protein LAMTOR5
Cation-independent mannose-6-phosphate receptor
GTPase IMAP family member 5
Tumor protein D54
Ragulator complex protein LAMTOR3
SNARE-associated protein Snapin
Stromal interaction molecule 1
Loss of heterozygosity 12 chromosomal region 1 protein
Ras-related GTP-binding protein C
Leucyl-cystinyl aminopeptidase
Integrin alpha-L
Integrin beta-1
T-cell surface antigen CD2
LAMTOR4
Thymopoietin
Tumor protein D52
Ragulator complex protein LAMTOR2
Transferrin receptor protein 1
Vesicle-associated membrane protein 7
Ragulator complex protein LAMTOR1
Synaptosomal-associated protein 23
Synaptobrevin homolog YKT6
T-cell surface glycoprotein CD4
Biogenesis of lysosome-related organelles complex 1 subunit 2

In order to better visualize the data, I used the list of significantly enriched
proteins to generate a protein-protein interaction network using STRING (Figure 3.1B)
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(Szklarczyk et al., 2015). Strikingly, across three separate experiments I observed very
high enrichment scores for every single member of the Ragulator complex as well as the
Rag GTPases. While the precise member of the Ragulator complex that is directly
binding to GIMAP5 (if any) remains unclear, this is nevertheless strong evidence that
GIMAP5 is in close proximity to the complex. Interestingly, another cluster of candidate
interacting proteins were members of the TCR complex. This may represent TCR
proteins that have been internalized from the immune synapse and brought to the
lysosome for degradation or may reflect GIMAP5 trafficking to be proximal to the cell
surface. It is reminiscent of a complex on the surface of the lysosome recently described
by Phelan et al. which comprises of the BCR, Ragulator complex and MyD88 (Phelan et
al., 2018a). The exact nature of this interaction is puzzling however considering that the
biotin ligase end of the GIMAP5-BirA fusion protein should be cytosolic, while many of
the biotinylated proteins identified only have small tails on the cytoplasmic side of the
membrane.
To further confirm my results, I also carried out low-throughput verification by
western blot of some candidate interacting genes. I did not label with SILAC media but
otherwise followed the same lysis and biotin-streptavidin capture protocol. I confirmed
that the BirA-GIMAP5 fusion protein was able to preferentially biotinylate LAMTOR3,
RagC and TCR relative to the BirA enzyme alone (Figure 3.1C). There was significant
background signal from the enzyme alone, presumably from spurious non-specific
labeling as it is likely that the enzyme disperses throughout the cytosol in the absence of
any targeting sequence. It is also likely that the SILAC/mass-spectrometry approach is
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more sensitive than the western blot and better able to demonstrate the enhanced
biotinylation with the GIMAP5 construct. Overall these findings represent strong
evidence that GIMAP5 is interacting with members of the Ragulator complex and may
hint at a larger supercomplex including the TCR as well as various endocytic trafficking
components.

A) Heatmap plotting the relative enrichment of a given protein in Jurkat cells
expressing BioID2-GIMAP5 fusion protein relative to Jurkats expressing BioID2
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alone, versus the Log2(intensity) of the mass spectrometry signal. The heatmap
signal represents the associated p value.
B) STRING diagram showing a putative interactome of BioID2-GIMAP5 subdivided
into three broad clusters.
C) Western blots for lysates of Jurkat cells expressing either BioID2 alone or
BioID2-GIMAP5 followed by streptavidin capture. Blots for the indicated
proteins were carried out in either the streptavidin capture or input.
Figure 3.1A prepared by L.Z. and X.X., Figure 3.1B by M.L.G. and L.Z., Figure 3.1C by
M.L.G.
Data in (A-B) represent three pooled experiments. Data in (C) are representative of three
independent experiments.

PLA and conventional Co-IPs confirm that GIMAP5 interacts with the Ragulator
complex
I sought to confirm the data generated by the high-throughput BioID2 approach
via conventional co-IPs. With this in mind, virtually all the different members of the
Ragulator complex immunoprecipitated from human T cell lysates and blotted for
GIMAP5. In line with the data from the high throughput approach, I observed robust
association of GIMAP5 with LAMTOR1, LAMTOR4, RagA and RagC (Figure 3.2A).
As expected from the literature, all of these proteins immunoprecipitated as a unit
confirming that they act as a large complex in T lymphocytes similarly to findings from
other cell types. Both bands from the GIMAP5 doublet interacted with the Ragulator
complex equivalently. In addition to the isotype rabbit IgG used as a negative control,
LAMP1 was also blotted for to be certain my immunoprecipitation strategy was not
isolating the entire lysosome. There was no observed immunoprecipitation of LAMP1
across multiple repeats (Figure 3.2A).
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Figure 3.2
PLA and conventional co-immunoprecipitations confirm that GIMAP5 interacts with the
Ragulator complex
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A) Western blots of Co-immunoprecipitations for the indicated proteins from T cell
blasts of healthy donors.
B) PLA in T cell blasts from either healthy donors or a GIMAP5-deficient patient.
Figure 3.2A prepared by A.P., Figure 3.3B prepared by M.L.G. and J.R.
Data shown in (A-B) are representative of three independent experiments.
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As further validation that GIMAP5 is truly interacting with the Ragulator
complex, I utilized Proximity Ligation Assay (PLA) using complexed antibodies specific
for GIMAP5, members of the Ragulator/mTORC1, or LAMP1 as a negative control on
the surface of the lysosome (Figure 3.2B). This technique allowed me to rule out spurious
interactions caused by dissolving all the cell membranes and mixing proteins that
normally are not adjacent to each other as occurs during conventional coimmunoprecipitations. I used both flow cytometry and confocal microscopy to confirm
my results, showing robust PLA signals in T cell blasts from both normal controls and
GIMAP5-deficient patients when using antibodies specific for TCR and TCR as a
positive control. On the other hand, as a negative control, using PLA antibodies for
GIMAP5 and LAMP1 (which was absent from my BioID2 and conventional coimmunoprecipitation data) showed no positive signal in T cells from healthy donors or a
GIMAP5-deficient patient (Figure 3.2C). On the other hand, I observed robust signals
between GIMAP5 and either LAMTOR4, RagC and mTOR. This confirms that GIMAP5
is in very close proximity to these proteins in vivo, on the order of 10nm or closer.
siRNA mediated knockdown of GIMAP5 in human T lymphocytes has little effect on the
transcriptome
While the BioID2 and FLAG-immunoprecipitation studies were meant to define
the interactome of GIMAP5, I sought to complement these with RNA-Seq studies
following GIMAP5 depletion in order to discover pathways regulated by this protein. I
hypothesized that loss of GIMAP5 would generate a unique transcriptional signature
following disruption of the metabolism of the cell.
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I isolated T cells from three healthy donors and electroporated them with siRNAs
specific for GIMAP5. Following depletion of the protein (Figure 3.3C), cells were
stimulated for 0, 4, 12 and 24 hours with anti-CD2/3/28 magnetic beads and RNA was
isolated for sequencing. I then analyzed the data via Principal Component Analysis
(PCA) and plotted the two largest principal components, accounting for 60% and 23% of
the variability respectively (Figure 3.3A). PC1 seemed to account for most of the
variability caused by stimulation, with the unstimulated samples separating from the 4, 12
and 24 hour samples along the x-axis. PC2 accounted for the variation caused during the
TCR stimulation time course, with the 4, 12 and 24 hour samples clustering separately
primarily on the y-axis. Contrary to my hypothesis, I observed no clear transcriptional
signature caused by depletion of GIMAP5 in primary human T cells at any time point or
condition. These samples clustered remarkably close to each other given that each was
isolated from a different individual.
I plotted the most significantly affected genes in the GIMAP5 knockdown
condition relative to the siCtrl (Figure 3.3B). A number of genes were highly
significantly changed, although the magnitude was small with most showing less than a
twofold change in expression. I chose the most reproducible and highest differentially
regulated gene, WD Repeat domain 12 (WDR12), to verify the results. I saw roughly a
twofold reduction in WDR12 levels following depletion of GIMAP5 from T cells of three
independent donors which was consistent with my high-throughput RNA-Seq data
(Figure 3.3D).
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A) Principle component analysis of RNA-Sequencing data from healthy donor T
depleted of GIMAP5 via siRNAs. Cells were stimulated for the indicated times.
B) Table indicating the most differentially regulated genes at each timepoint as well
as the associated adjusted p value.
C) Western blots validating the knockdown efficiency from the same batches of cells
used for analysis in (A-B).
D) Validation of the most differentially regulated gene identified in each condition of
(C) via qPCR using samples independent from (A-C)
Figure 3.3A,B prepared by M.L.G. and Y.Z., Figure 3.3C, D prepared by M.L.G.
Data plotted in A-C represent three independent experiments. Data plotted in D are the
means of three independent experiments.

Autophagy is dysregulated in GIMAP5-deficient murine but not human T cells
Multiple lines of evidence led me to suspect that GIMAP5 may play a role in
autophagy and metabolism in T lymphocytes. Firstly, the phenotype of GIMAP5deficient mice is very similar to the phenotype of T cells in which critical autophagy
genes have been conditionally deleted (Pua et al., 2007; Roy et al., 2013). Both suffer
from lymphopenia which is more pronounced in the CD8+ T cell fraction, a decreased
fraction of naïve T cells and exhibit defective T cell proliferation in response to antigen
(Roy et al., 2013). Secondly, both interaction studies (BioID2 and overexpression) I
carried out suggested that GIMAP5 interacted with proteins involved in regulating
autophagy, such as multiple Rab trafficking proteins as well as the Ragulator complex.
Thus, I sought to evaluate the autophagic flux in GIMAP5-deficient mice and humans.
When analyzing T cells directly ex vivo from GIMAP5sph/sph mice, I consistently
observed a highly significant increase in levels of LC3-II staining by flow cytometry
(Figure 3.4A). Even in the absence of bafilomycin the GIMAP5sph/sph cells had high
82

levels of staining for LC3-II. These findings could be due to either a block in the
trafficking/degradation of autophagosomes or increased activity through this pathway. In
order to differentiate between the two, I treated the cells with bafilomycin to prevent
acidification of the lysosomes and artificially block degradation of the autophagosomes,
allowing LC3-II to accumulate. While I still observed increased LC3-II staining in the
GIMAP5-deficient cells with bafilomycin treatment, the calculated autophagic flux in the
GIMAP5sph/sph T cells was significantly lower, pointing towards a block in the pathway
rather than an increase in the rate of autophagy initiation (Figure 3.4A right panel).
This led me to hypothesize that GIMAP5 may be involved in the fusion or
trafficking of autophagosomes to the lysosome in unstimulated T cells. Unfortunately, the
proliferation defect is so severe in T cells isolated from GIMAP5sph/sph mice that I was
unable to evaluate autophagic flux in cycling Gimap5-deficient murine T cell blasts, and,
to date I have not investigated this phenomenon in acute depletion models of murine
Gimap5. In mouse models with T cells deficient for Atg5, Atg7 or Rab7 it has been
shown that mitochondria accumulate due to defective mitophagy (Roy et al., 2013).
However, it is worth noting that the Rab7 knockouts had decreased mitotracker staining
and increased TOMM20 staining relative to controls, potentially due to the
autophagosome membrane being impermeable to the mitotracker dye. T cells from
Sphinx mice more closely resembled the Rab7-/- mice than the Atg5-/- cells, again
supporting a role for GIMAP5 in autophagosome trafficking and/or fusion with the
lysosome rather than autophagosome initiation (Figure 3.4B).
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Figure 3.4
Autophagy is dysregulated in Gimap5-deficient murine, but not human, T cells
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A) Murine CD4+ T cells isolated from littermate controls or GIMAP5sph/sph murine lymph
nodes and spleen were stained for LC3-II directly ex vivo, and autophagic flux was
calculated as described in the methods section.
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B) Cells as in (A) were stained and analyzed for Mitotracker.
C) Autophagic flux was measured in resting or activated human T cells from healthy
controls or GIMAP5 patients.
D) GIMAP5 was knocked out of human T cells isolated from healthy donors and
autophagic flux was measured.
Figure 3.4A, B, C, D prepared by M.L.G.
Data shown in (A) represents pooled data from three individual experiments with each
point representing a mouse, ****p<0.0001 by Student’s t test. Data in (C) represents
pooled data from 2-4 experiments with each point representing an individual. Data in (B)
and (C) are representative of 2-3 experiments.

I sought to test the same phenomenon in GIMAP5-deficient patient T cells to
verify that this function was conserved in human cells deficient for GIMAP5 as well. To
my surprise, I observed only a very mild defect in autophagy in unstimulated T cells
isolated from GIMAP5-deficient patients which did not reach statistical significance
(Figure 3.4C – top panel). At baseline in resting human T cells, the flux through the
autophagy pathway was minimal. I reasoned that increasing flux through the system via
TCR stimulation may reveal any defects in the system, especially if the loss of GIMAP5
leads to defective autophagosome trafficking or fusion with the lysosome. However, the
flux from cycling patient T cell blasts was identical to that in normal controls (Figure
3.4C – bottom panel).
We hypothesized that this discrepancy between the human patients and mice
deficient for Gimap5 may be due to residual GIMAP5 protein as all of the patients carry
missense mutations. While Gimap5sph/sph mice also carry a missense mutation in Gimap5,
it has been shown that protein levels are extremely low and they strongly phenocopy
Gimap5 null mice (Barnes et al., 2010a). Furthermore, the human patients have very few
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naïve cells and are not age/sex matched to my normal controls leading me to believe that
some of these factors may be preventing the detection of an autophagy defect in the
patient cells. To address these possibilities, I isolated T lymphocytes from healthy human
donors and electroporated the cells with Cas9/gRNA Ribonucleoproteins (RNPs) specific
for GIMAP5 or CXCR4 as a negative control. This approach presumably would induce
frameshift mutations at the GIMAP5 locus and yield human T cells truly devoid of
GIMAP5 protein. I was able to track cells which acquired the complex via tracrRNA
labeled with the Atto 550 dye and typically observed an electroporation rate of greater
than 90% of the viable cells. Impressively, as soon as 24 hours post-electroporation I
observed >95% of the tracrRNA+ cells electroporated with Cas9 RNPs specific for
CXCR4 expressed virtually no protein on their surface (Figure 3.4D, left panel). As the
GIMAP5 Cas9 RNPs gave similar electroporation efficiencies, I was confident that I was
generating true GIMAP5 knockout cells. In order to ensure that all GIMAP5 protein was
eliminated and also increase the autophagic flux, I stimulated the electroporated cells and
cycled them in IL-2 for several days before measuring GIMAP5 levels via western blot. I
observed a massive reduction in GIMAP5 levels, with the residual protein likely being
present due to cells that were able to successfully repair the GIMAP5 locus or failed to be
electroporated (Figure 3.4D, middle panel). However, even in these cells completely
lacking GIMAP5, I did not observe significant defects in levels of LC3-II either with or
without bafilomycin (Figure 3.4D right panel). The two most likely explanations for these
data are that the defect in autophagy observed in the GIMAP5sph/sph murine T cells is a
secondary effect caused by the LIP/inflammatory environment or there is a major mouse86

human difference in the biochemical role of GIMAP5. Furthermore, in order for the latter
possibility to be true, this would have to mean that the clinical phenotype (which is very
similar in mice and humans) is unrelated to the defect in autophagy and thus diminishes
its importance.
Inhibition of mTORC1 provides clinical benefit in both murine and human GIMAP5
deficiency
The GIMAP5-deficient Sphinx mice share many characteristics with mice carrying
alleles leading to hyperactive mTORC1 in addition to mice with defects in autophagy. For
example, mice deficient for TSC1 (a negative regulator of mTORC1) also suffer from
peripheral lymphopenia with normal thymopoiesis, increased apoptosis, defective
proliferation of T lymphocytes and a loss of peripheral naïve T cells (Yang et al., 2011).
Similarly, human patients with mutations in the PI3K subunit p110 have a clinical
phenotype that significantly overlaps with the GIMAP5-deficient patients (Lucas et al.,
2014). Furthermore, previous work has shown that T cells isolated from GIMAP5sph/sph
mice had increased mTORC1 activity at baseline as measured by the phosphorylation
levels of pS6 at serines 235 and 236 (Chen et al., 2015). This led me to hypothesize that
GIMAP5 may be a T cell specific negative regulator of mTORC1 via interactions with the
Ragulator complex.
We confirmed previous findings regarding increased levels of pS6 as well as
increased cell size in peripheral T cells from GIMAP5sph/sph mice via flow (Figure 3.5A).
Before testing this hypothesis in human cells, I sought to test whether inhibition of
mTORC1 via rapamycin treatment could yield clinical benefits in the murine model in
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order to potentially translate these findings to the clinic. Thus, I injected mice daily with
rapamycin intraperitoneally before measuring mTORC1 and physiological readouts. As
expected, I was able to show that in vivo treatment of Gimap5sph/sph mice with rapamycin
could significantly reduce both pS6 and cell size (forward scatter) to levels comparable to
wild type controls (Figure 3.5A). The loss of naïve T lymphocytes is a major clinical
finding in both the GIMAP5-deficient patients and Gimap5sph/sph mice which I suspect
contributes to the pathology of the disease. As differentiation to effector phenotypes has
been shown to be driven by mTORC1 during the immune response (Araki et al., 2009) and
inhibition of mTORC1 provides significant clinical benefit in other autoimmune diseases
(Bruce, Rane and Schuh, 2014; Karen L. Bride, Tiffaney Vincent, Kim Smith-Whitley,
Michele P. Lambert, 2, 3 Jack J. Bleesing, Alix E. Seif, Catherine S. Manno, James Casper,
Stephan A. Grupp, 2015; Dimitrova et al., 2017) I hypothesized that the loss of naïve T
lymphocytes may be ameliorated via rapamycin treatment. I observed that in vivo treatment
with rapamycin significantly increased the fraction of naïve T cells present in both the
spleen and the blood (Figure 3.5B, data not shown) consistent with this phenotype being
driven by hyperactive mTORC1.
The Ragulator complex is also known to be an anchor for and regulator of both
Mek and Erk (Colaço and Jäättelä, 2017). I also investigated other signaling pathways in
cells isolated from GIMAP5-deficient mice and observed an enormous increase in activity
in the Erk pathway (Figure 3.5C). This demonstrates that the hyperactive signaling present
in the Sphinx mice is not restricted to the mTORC1 pathway and is likely more generalized.
This could complicate my attempts to pin down the precise signaling pathway being
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affected and I expect clearer data from an in vitro acute loss-of-function model using
CRISPR or siRNAs.

A) GIMAP5sph/sph mice or littermate controls were treated with rapamycin as described in
the methods section and then readouts of mTORC1 activity (size, pS6235/236) were
measured in T cells via flow cytometry.
B) Mice were treated with rapamycin as in (A) and then the fraction of naïve cells in the
spleen was measured.
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C) Levels of phospho-Erk (Thr-202/Tyr-204) were measured in protein extracts isolated
from either GIMAP5sph/sph mice or littermate controls.
D) Abdominal CT scans of a GIMAP5-deficient patient pre/post sirolimus treatment for
2 years. Three dimensional reconstruction was used to measure the volume of 5
lymph nodes. (continued on next page)
Figure 3.5A, B, C prepared by M.L.G and K.R.
Data shown in A-B is representative of three experiments, with significance calculated by
ANOVA *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Data in C is representative of
3 separate experiments, while statistical significance was done via Student’s t test in D.

Nevertheless, due to the improvements observed in my Gimap5sph/sph mice
following rapamycin treatment I hypothesized that GIMAP5-deficient human patients
might similarly benefit. P3.1 was treated with sirolimus (an inhibitor of mTORC1)
beginning in November of 2013 and continuing up to the present and I observed a
remarkable reduction in spleen/lymph node size (Figure 3.5D). In this same time period
his severe psoriasis was similarly resolved. Taken together, these data suggest that
mTORC1 inhibitors may be a valuable clinical intervention in treating human patients
deficient for GIMAP5. The data also supports a model that GIMAP5 is a T cell specific
negative regulator of mTORC1.
mTORC1 activity is normal in various GIMAP5-deficient human models
Previous work has shown that silencing of GIMAP5 via siRNA in Jurkat cells
reduced the viability of these cells and increased their susceptibility to apoptosis, again
reminiscent of mice with hyperactive mTORC1 signaling (Pandarpurkar et al., 2003;
Yang et al., 2011). I hypothesized that this increase in death may be due to a
dysregulation of cellular metabolism caused by increased mTORC1 activity in the
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absence of GIMAP5. In order to test this hypothesis, I transiently transfected Jurkat cells
with plasmids expressing both the Cas9 enzyme and guide RNAs (gRNAs) specific for
the GIMAP5 locus. I then single cell-cloned Jurkat cell lines deficient for GIMAP5. I
used 5 knockout and 3 control lines to test a multitude of mTORC1 downstream targets
(p4EBP1, pS6, pUlk1, pS6K) as well as upstream regulators (pTSC2) as negative
controls under basal culture conditions. While I confirmed that these cells were
completely lacking GIMAP5, I did not observe any significant difference in any readout
downstream of mTORC1 in more than five different experiments (Figure 3.6A). While I
did observe significant differences from one clone to the next (even in the control lines) I
have since repeated this experiment in non-clonal populations of Jurkats completely
deficient for GIMAP5 and again obtained negative results (data not shown). mTORC1
activity has previously been shown to increase cell size. However, when cell size was
measured via flow cytometry I observed the four Jurkat clones deficient for GIMAP5
trended towards being smaller than the three wild type lines (Figure 3.6A – right panel). I
also repeated the measurement of levels of pS6240 in the Jurkat lines via flow cytometry
to confirm the results of my western blots. I confirmed that this site was exquisitely
dependent on mTORC1 activity as rapamycin treatment completely abrogated the signal
(grey trace). However, again I observed no significant difference in mTORC1 activity at
baseline (Figure 3.6A). However, in most of the readouts tested there was significant
variability from clone to clone suggesting that I may have obtained more reliable data
from bulk populations of cells.
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Figure 3.6
mTORC1 activity is normal in various GIMAP5-deficient human models
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A) GIMAP5-deficient or wild type single cell Jurkat clones were generated via CRISPR
and then a variety of mTORC1 readouts were measured via western blot (left panel).
Cell size and pS6240 were also measured via flow cytometry.
B) T cell blasts from GIMAP5-deficient human patients were expanded in IL-2, rested,
restimulated with TCR crosslinking for the indicated time and then mTORC1 activity
was measured.
C) T cells from bulk PBMCs were stimulated and cell counts over time were measured.
The average doubling time of the culture beginning on day 2 was calculated.
Figure 3.6A, B, C prepared by M.L.G.
Data shown in (A) and (B) are representative of 4-6 experiments. Data in (C) shows 4
experiments, each consisting of 1-2 GIMAP5-deficient patients and at least 3 normal
controls.

We reasoned that Jurkat cells may be a poor model to study mTORC1 activation
with due to the fact that this cell line has constitutive signaling through this pathway.
Thus, I next evaluated a large selection of downstream mTORC1 targets in T cell blasts
expanded from GIMAP5-deficient patient T cells. Cells were rested in serum free media
for two hours to decrease the basal level of mTORC1 signaling and then restimulated via
soluble anti-CD3 and cross-linking F(ab’)2 fragment. Again, in a number of different
experiments, I observed no difference in a number of different mTORC1 readouts at
multiple timepoints (Figure 3.6B).
One main downstream biological function of mTORC1 signaling is cell
proliferation and thus I predicted that patient cells would behave differently from
controls. Furthermore, murine models of GIMAP5 deficiency show drastically decreased
proliferation relative to controls (Barnes et al., 2010a). To test this hypothesis, I activated
T cells from GIMAP5-deficient patients in vitro, added IL-2 after three days and
measured cell counts over time from this point forwards. Although I observed significant
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variability from experiment to experiment likely related to the way the blood was handled
during shipment and processing, once the GIMAP5-deficient patient T cells had been
activated they were able to proliferate at the same rate as control cells (Figure 3.6C). I
consistently observed an initial decrease in cell counts early in the activation cycle,
however this was most likely an artifact caused by using PBMCs from lymphopenic
individuals as starting material. While they were normalized for total cell counts, the
lymphopenic patients had fewer T cells initially thus leading to the initial decrease. These
data are in stark contrast to what has been published regarding murine T cells deficient
for GIMAP5 which have striking proliferation defects. It is however consistent with the
data shown in Figure 2.5 where I observed no major defects in Celltrace Violet dilution in
GIMAP5-deficient patient cells acutely following stimulation.
Acute depletion of GIMAP5 in human T cells via siRNA has no impact on mTORC1
activity or proliferation
Increased mTORC1 activity has been observed in the peripheral T cells of
GIMAP5sph/sph mice and there is a similarity between the clinical phenotype of GIMAP5deficient patients and other diseases caused by enhanced mTORC1 activity. Moreover, I
have observed improvement in disease course following treatment of both GIMAP5sph/sph
mice and humans with mTORC1 inhibitors. Therefore, I hypothesized that GIMAP5 may
be a negative regulator of mTORC1. This hypothesis was also supported by the robust
interaction between GIMAP5 and members of the Ragulator complex which is known to
be required for the recruitment of mTORC1 to the surface of the lysosome (Sancak et al.,
2008). However, many of these findings could have been secondary findings due to
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lymphopenia or other disruptions of T cell homeostasis in vivo in GIMAP5-deficient
mice/humans. Furthermore, my initial experiments using cells from the human patients
and Jurkat cells deficient for GIMAP5 failed to reveal a consistent difference in
mTORC1 signaling. This led me to develop in vitro methods to deplete GIMAP5 and
study mTORC1 signaling in an internally controlled setting.
We electroporated either unstimulated primary human T cells or activated T cell
blasts with siRNAs specific for either GIMAP5 or scrambled controls. It would appear
the half-life of GIMAP5 is relatively long as significant depletion of GIMAP5 in human
T cell blasts was not observed until 72 hours post electroporation and was most consistent
at 96 hours post electroporation (Figure 3.7A). However, even after depletion of
GIMAP5 in cycling T cell blasts no difference in levels of phospho-S6 (pS6) were
observed. It is worth noting that even at the peak of GIMAP5 depletion residual levels of
GIMAP5 remained which could complicate my analysis.
As mTORC1 is a critical regulator of proliferation and cell size, and furthermore,
GIMAP5sph/sph murine T cells exhibit a drastic block in proliferation, I hypothesized that
if these defects were not secondary to lymphopenia or other systemic factors siRNA
knockdown of GIMAP5 should affect these cellular processes. To test this I
electroporated GIMAP5 siRNA into unstimulated human T cells, waited 96 hours then
stimulated them and measured proliferation, upregulation of cell cycle genes via qPCR
and cell size. Cell cycle genes CDC25A and MCM10 were both upregulated 40-200 fold
following T cell stimulation, however no significant difference was observed between T
cells electroporated with scrambled siRNA or siRNA specific for GIMAP5 (Figure 3.7B,
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top panel). Similarly, at three days post stimulation no defect was observed in T cell
proliferation as measured by Celltrace violet dilution (Figure 3.7B, middle panel). It is
worth pointing out that the transient knockdown was likely only efficient at the time of
stimulation and GIMAP5 was likely re-expressed at some point during proliferation.
Previous studies have shown that increased mTORC1 activity leads to an increase in cell
size (Montagne et al., 1999). Thus, I measured cell size by flow cytometry following
siRNA depletion of GIMAP5 both before and after TCR stimulation. While stimulation
greatly increased cell size as expected, no difference in cell size was observed in either
condition in the absence of GIMAP5 (Figure 3.7B bottom panel).
While I did not observe any broad effects on cell function following GIMAP5
knockdown, I reasoned that there may be differences in acute mTORC1 signaling
following TCR stimulation. Thus, I depleted GIMAP5 in either cycling T cell blasts
(Figure 3.7C – top panel) or unstimulated T cells (Figure 3.7C – bottom panel) from
healthy human controls. I then stimulated the cells with soluble CD3 crosslinked with
F(ab’)2 fragments for the indicated time periods. While depletion of GIMAP5 was
robust, I observed no difference in a number of direct and indirect mTORC1 targets
(Ulk1, S6K, S6, 4EBP1) at multiple timepoints (Figure 3.7D). Finally, I hypothesized
that GIMAP5 may be involved in the regulation of mTORC1 by amino acid sensing
rather than TCR stimulation as it interacts with the Ragulator complex. As the Ragulator
complex mediates the recruitment of mTORC1 to the surface of the lysosome in the
presence of amino acids, I starved cycling GIMAP5 depleted T cell blasts of amino acids
for 60 minutes and then returned them to cRPMI for 30 minutes. This strategy has
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previously revealed defects in mTORC1 signaling in other cell types lacking components
of the Ragulator complex (Bar-peled et al., 2012). While I did observe a decrease in
mTORC1 readouts following starvation and recovery after incubation with cRPMI, again
there was no difference in mTORC1 signaling in the absence of GIMAP5.
Overall, I failed to replicate any phenotypes observed in the murine model of
GIMAP5 deficiency with my siRNA/Cas9-RNP GIMAP5 depletion strategies, and more
broadly, in GIMAP5-deficient patient cells or GIMAP5-deficient Jurkat lines (see Figure
3.6). These results could be due to a number of technical or biological causes. Primarily,
both the siRNA knockdown model and GIMAP5-deficient patient cells have residual
GIMAP5, while Jurkat cells have constitutive activity through the mTORC1 signaling
pathway. It could also be that prolonged depletion of GIMAP5 is required to see some
effect or some other factor is present in vivo that is lacking in vitro.
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Figure 3.7
Acute depletion of GIMAP5 in human T cells via siRNA has no impact on mTORC1
activity or proliferation
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A) GIMAP5 was measured in unstimulated human T cells electroporated with the
indicated siRNAs at the indicated time points.
B) Measurements of genes required for cell cycle (top panel), proliferation (middle
panel) or cell size (bottom panel) are shown from human T cells depleted of
GIMAP5 via siRNA.
C) Western blots of various mTORC1 readouts following TCR stimulation of
activated T cell blasts electroporated with either scrambled or GIMAP5 specific
siRNA.
D) Western blots of various mTORC1 readouts following TCR stimulation of
previously unstimulated human T cells electroporated with either scrambled or
GIMAP5 specific siRNA.
E) Western blots of various mTORC1 readouts following amino acid starvation and
addback to T cells electroporated with either scrambled or GIMAP5 specific
siRNA.
Figure 3.7A, B, C, D, E prepared by M.L.G.
Data shown is representative of 2 (A), 3 (B, D) or 6 (C) experiments.

Lysosome number is normal in GIMAP5-deficient human T cells
The potential role of GIMAP5 in regulating lysosome number and function has
not previously been tested. This may have been overlooked due to previous studies
claiming that GIMAP5 localizes to the mitochondria or ER (Dalberg, Markholst and
Hornum, 2007; Keita et al., 2007). Furthermore, I have shown that GIMAP5 interacts
with the Ragulator complex on the surface of the lysosome/late endosome. This complex
has previously been shown to regulate lysosome numbers and dynamics in other cell
types (Colaço and Jäättelä, 2017; Pu, Keren-Kaplan and Bonifacino, 2017b).
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Figure 3.8
Lysosome number is normal in GIMAP5-deficient human T cells
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A) Quantitation of lysosome number via confocal microscopy in either untreated or
amino acid starved GIMAP5-deficient patient cells or healthy donors (left panel).
Sample microscopy images are shown in the right panel.
Figure 3.8A prepared by M.L.G.
Data is representative of two individual experiments using 3 GIMAP5-deficient patients
and 4-5 healthy donors each.

Thus, I sought to quantify lysosomes in proliferating T cells from patients. I
stained patient T cell blasts for LAMTOR4 to detect lysosomes as well as DAPI to
delineate individual cells and then imaged them via confocal microscopy. I also included
cells which had been starved of amino acids which is known to induce autophagy and
inhibit mTORC1 (Rabanal-Ruiz, Otten and Korolchuk, 2017). I observed no differences
between cells isolated from GIMAP5-deficient patients relative to controls despite testing
three individuals representing two independent pedigrees and five unrelated healthy
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controls (Figure 3.8A). The variability in average lysosome number per cell was
relatively low given sex, age and genetic background were not controlled in this assay
and suggests that this is a strictly regulated parameter in T lymphocytes. However, it
would appear that GIMAP5 does not regulate lysosome number in human T cells.

III. Discussion
I have undertaken extensive interaction and transcriptomic studies of GIMAP5.
The RNA-Seq data analyzing the impact of GIMAP5 knockdown by siRNA in human T
cells was not particularly fruitful, with the vast majority of differences between the
samples being explained by T cell activation/proliferation. Comparison of human cells
depleted of GIMAP5 versus those electroporated with control siRNAs showed virtually
no differences, indicating that either technical issues (i.e. residual protein, culture
conditions) were responsible or GIMAP5 does not affect the transcriptome in human T
cells.
Regarding the interaction studies, most previous publications have described
direct interactions between GIMAP5 and Bcl-2 family members (Chen et al., 2011b).
More recently studies of endogenous GIMAP5 have demonstrated a strict lysosomal
localization suggesting that the previous interaction data may have been an artifact of
overexpression systems (Vivian W.Y. Wong et al., 2010). Encouragingly, the majority of
the protein complexes identified by the BioID2 study were either known to be
lysosomally localized (the Ragulator complex) or known to traffic to/from lysosomes
(TCR complex, endosomal trafficking members). Furthermore, this association was
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confirmed via two independent techniques including endogenous coimmunoprecipitations that GIMAP5.
While I am confident that I have truly identified GIMAP5 associated proteins in
this study, a major open question is what the functional relevance of these interactions is.
The Ragulator complex is known to regulate the activity of mTORC1 in response to the
presence of amino acids as well as acting as a scaffold for MAPK signaling (Colaço and
Jäättelä, 2017). Strikingly, previous work has shown increased Akt and mTORC1 activity
in GIMAP5sph/sph T cells, suggesting that GIMAP5 may act as a negative regulator of this
complex. The association of the TCR complex is also very reminiscent of a recent study
describing a supercomplex of the BCR and Ragulator complexes on the surface of the
lysosome in a B cell lymphoma cell line (Phelan et al., 2018a). However, if the absence
of GIMAP5 had any major impact on mTORC1 or TCR signaling I would have
anticipated an impact on T cell activation or proliferation in GIMAP5-deficient patient
cells or the siRNA knockdown model.
Based on the BioID2 interaction data and previous data showing that Sphinx T
cells had increased mTORC1 activity (which I have also replicated) I hypothesized that
GIMAP5 was a negative regulator of the mTORC1 complex by influencing the Ragulator
complex. However, my data from multiple different model systems (Jurkat knockout
lines, siRNA knockdown in unstimulated/blasting T cells, GIMAP5-deficient patient
cells) clearly show no difference in mTORC1 activity in response to a variety of stimuli
(TCR stimulation, amino acid starvation/addback). Thus, I am forced to conclude that the
clinical benefit I observed with rapamycin treatment was most likely not due to the fact
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that GIMAP5 directly regulated mTORC1 and rather that inhibition of mTORC1 nonspecifically inhibited lymphoproliferation and autoimmunity. Furthermore, it would also
argue that the Ragulator complex may have roles beyond tethering mTORC1/Erk to the
surface of the lysosome which may be influenced by GIMAP5. Alternatively, it is unclear
from my data whether GIMAP5 is upstream or downstream of the Ragulator complex. It
is also possible that the activity of GIMAP5 is influenced by the Ragulator complex
rather than the inverse. This model would posit that the Ragulator complex may act as a
GAP or a GEF for GIMAP5 GTPase activity and would regulate some novel pathway
downstream of the Ragulator complex independently of mTORC1.
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CHAPTER 4: Human physiologic media reveals
extracellular calcium concentrations as critical for
T cell activation and effector function

________________________________________________________________________
Authors: Michael Leney-Greene, Jason Cantor, Helen C. Su, Michael J. Lenardo.
Michael Leney-Greene designed research, conducted experiments, performed analysis
and wrote this section. Jason Cantor, Helen C. Su and Michael J. Lenardo helped design
experiments and write the paper.
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I.

Summary

Lymphocytes are critical effectors of the immune system, playing major roles in the
susceptibility to infectious and autoimmune disease. In order to effectively treat these
diseases a better understanding of the in vivo function and conditions experienced by
immune cells is required. Many assays require the use of in vitro culture conditions
which are optimized for growth and thus are vastly different from the in vivo milieu. We
hypothesized that media modeled after the in vivo environment would better support
human T lymphocyte activation and survival in vitro. In this study, I showed that
physiologic media supports a much more robust response to antigen stimulation in
primary human T lymphocytes relative to RPMI. I demonstrated that this activation
defect is due to RPMI being profoundly hypocalcemic relative to the in vivo milieu and
show that addition of calcium chloride to RPMI can improve human T lymphocyte
activation. I propose that commonly used media formulations be modified to contain
physiological levels of ionic calcium to better model the in vivo environment.

II.

Results

HPLM is superior to RPMI in supporting naive human T cell activation
Lymphocytes in vivo are activated in a rich milieu containing high levels of amino
acids, lipids as well as various small organic metabolites. In contrast, typical in vitro
culture methods using RPMI only contain a skeleton of essential amino acids, vitamins,
glucose and salts all at non-physiological levels. Initially, I expected that HPLM may
reveal a defect in human GIMAP5-deficient T cells although ultimately this wasn’t the
case. However, independently of GIMAP5, I hypothesized that either small organic
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metabolites present in plasma but absent in RPMI or components common to both but at
different concentrations may influence lymphocyte activation. In order to test this I took
advantage of a synthetic media developed by Cantor et al. which contains physiological
levels of 40 different metabolites that are absent from RPMI (Cantor et al., 2017)(Table
3). I supplemented both RPMI and HPLM with dialyzed rather than complete FBS in
order to better control the levels of metabolites as well as ions in both preparations while
still maintaining protein growth factors required for cell survival.

Table 3: Detailed composition of RPMI, HPLM-Min and HPLM

I purified naïve T cells from healthy human donors and stimulated them in either
RPMI or HPLM using plate-bound anti-CD3/CD28 antibodies. I observed a striking
increase in levels of activation markers CD25 and CD69 in cells from five different
healthy donors cultured in HPLM compared to RPMI in both CD4+ and CD8+ naïve
human T cells (Figure 4.1A). Higher concentrations of anti-CD3/CD28 antibodies used to
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stimulate the cells could lead to nearly maximal response rates in both RPMI and HPLM
(i.e. >90% positive for both CD25 and CD69), though still with slightly higher activation
rates in HPLM. This demonstrates that cells stimulated in RPMI could be maximally
activated, while activation in HPLM lowers the stimulus threshold. The improved
activation of naïve T cells in HPLM was immediately apparent when studying the culture
via microscopy which revealed large clusters of activated T cells in the HPLM cultures
that were absent from cells cultured in RPMI (Figure 4.1B). This was accompanied by a
significant increase in cell size as measured by flow cytometry. Finally, with the lower
dose of TCR crosslinking antibody stimulation, I also observed robust proliferation of
cells in HPLM that was slower in cells stimulated in RPMI as measured by CTV dilution
(Fig. 4.1C).
Overall, my data suggests that some component of HPLM strongly augments
naïve human T cell activation and proliferation compared to conventional culture media.
I hypothesize that this is due to HPLM better modeling the in vivo milieu and providing a
superior environment for T cell activation.
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A) Measurement of T cell activation markers CD25 and CD69 on purified naïve
human T cells following stimulation with either 1 or 10g of plate-bound antiCD3/CD28 in HPLM or RPMI.
B) Bright-field microscopy images of naïve T cells stimulated with 1g of platebound anti-CD3/CD28 in either HPLM or RPMI.
C) CTV dilution plots of naïve T cells stimulated in either HPLM or RPMI.
D) Data shown in (A-C) represent 3-4 pooled experiments with different donors, with
B-C plotting the mean and standard deviation.
Figure 4.1A,B,C prepared by M.L.G.
Statistical significance was calculated via paired t-test, *p<0.05, **p<0.01, ***p<0.001.

The increased calcium concentration in HPLM augments T cell activation
I initially determined that HPLM greatly improved naïve human T cell activation
compared to RPMI. My next goal was to determine which component of HPLM was
responsible in order to both identify supplements that could improve T cell activation in
vitro and potentially discover new metabolic pathways that influenced T cell biology. To
do this, I compared the activation of naïve human T cells in either HPLM, HPLM-Min
(which lacks the 40 small metabolites added to HPLM but maintains the same
concentration of amino acids, glucose and ions) and RPMI. An overview of the
composition of these three media is given in Figure 4.2A while the complete formula is
given in table 3. I also included a condition which added all of the HPLM small
metabolites back to RPMI (RPMI-Metabolites). I then repeated the activation assays done
in Figure 4.1 using these different conditions.
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A) Diagram showing the relative composition of HPLM, HPLM-Min and RPMI.
Exact composition of each media is given in Supplemental Table 1.
B) Measurement of activation marker CD25 on CD4+ T cells comparing RPMI and
minimal-HPLM supplemented with various metabolite components unique to
HPLM.
C) Calcium flux following primary stimulation of isolated human CD8+ T
lymphocytes in either RPMI or HPLM. (continued on following page)
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D) Calcium flux following primary stimulation of isolated human CD8+ T
lymphocytes in RPMI supplemented with the indicated concentrations of calcium
chloride.
Figure 4.2A, B, C, D prepared by M.L.G.
Data shown in (B-D) represent 3-5 pooled experiments with different donors, with B-D
plotting the mean and standard deviation. Statistical significance was calculated via one
way ANOVA, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

To my surprise, I observed equivalent activation in the HPLM and HPLM-Min
conditions, and significantly decreased activation in the RPMI and RPMI-Metabolites
conditions (Figure 4.2B). These data suggest that the small metabolites in HPLM are
dispensable for early T cell activation and rather that the phenotype I observed was due to
differences in amino acid or ion concentrations in HPLM versus RPMI. One striking
difference was the largely increased level of calcium in HPLM relative to RPMI, which is
markedly hypocalcemic relative to the in vivo milieu (Table 3). Oddly, basal RPMI only
contains 0.432 mM of calcium which is severely hypocalcemic relative to typical
physiological levels of 2-2.5 mM (Goldstein, 1990). HPLM likely represents a
hypercalcemic condition as it contains 2.4mM of ionic calcium. While this is within the
physiological range of total serum calcium levels, it does not account for the fact that
50% of serum calcium is typically bound to albumin and thus potentially not bioavailable
for diffusion across membranes. As such, I included a condition of RPMI supplemented
with 2mM of calcium chloride to normalize it relative to HPLM (Figure 4.2B). The
addition of calcium completely rescued the early activation defect in RPMI relative to
HPLM.
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In order to further verify my findings that HPLM led to superior T cell activation
due to calcium levels I tested calcium flux following T Cell Receptor (TCR) stimulation
in either RPMI, calcium supplemented RPMI or HPLM. Most calcium flux protocols are
carried out in HBSS or Ringer’s solution; however, some other studies have shown
decreased calcium flux in RPMI (Prakriya et al., 2006; Gwack et al., 2008; Bertin et al.,
2014). I observed a striking decrease in calcium flux following activation in RPMI
supplemented with either dFBS or cFBS relative to either HPLM or RPMI supplemented
to equivalent calcium levels (Figure 4.2C). These data further support my hypothesis that
the defective activation shown in Figure 4.1 was due to a defect in calcium flux during
activation.
This raised the possibility that calcium levels in vivo could influence T cell
activation, and that hypocalcemic/hypercalcemic patients could be more prone to
immunodeficiency or autoimmunity, respectively. Furthermore, this provided strong
evidence that RPMI was a poor approximation of the in vivo condition and rather
represented a severely hypocalcemic environment. To test these ideas, I titrated calcium
levels in basal (FBS free) RPMI in 0.5 mM increments up to a maximum of 2.2 mM and
then measured calcium flux following TCR stimulation. I observed that basal RPMI gave
a poor calcium flux that could be improved with every concentration of calcium from
hypocalcemic (0.7 mM) through the physiological range and into the hypercalcemic
range (2.2mM). The concentrations tested yielded virtually identical magnitude and
kinetics of calcium fluxes (Figure 4.2D). This suggests that at physiological
concentrations of extracellular calcium the rate of increase of intracellular calcium is
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already at maximal and extracellular calcium concentrations likely do not affect the
sensitivity of T cells to activation in vivo. However, this finding again highlights that the
levels of calcium in RPMI are too low for full T cell activation when using dialyzed
serum. When using complete serum, this problem is compensated by calcium derived
from the serum. My data shows that only increasing the external calcium levels by
0.5mM would overcome the deficit in RPMI.
Effector cytokine production by CD8+ T cells is superior in HPLM
I hypothesized that HPLM would be an improvement over RPMI in modelling the
physiological environment that T lymphocytes encounter during an in vivo immune
response. Thus, while my initial experiments comparing RPMI and HPLM underlined the
hypocalcemic nature of RPMI, I sought to unravel the impact of small serum metabolites
on T cell activation and acquisition of effector functions in vitro. Thus, I designed a
series of experiments comparing T cells cultured in HPLM to HPLM-Min (See Table 3
for comparison). This would control for levels of amino acids, vitamins and small ions
while only the HPLM condition would contain the small metabolites. I also included cells
initially activated in RPMI and then cultured in IL-2 containing media for a further 14-21
days prior to restimulation and measurement of cytokine production.
I measured TNF and IFN production following restimulation of T cell blasts
with PMA and ionomycin. I did not observe any significant differences in cytokine
production between cells cultured in HPLM or HPLM-Min, indicating that the additional
metabolites added to HPLM do not majorly influence cytokine production under these
conditions (Figure 4.3A). However, as expected, I did observe a large decrease in both
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TNF and IFN production in T cells cultured in RPMI following restimulation. This
difference was consistent in cells restimulated with either PMA and ionomycin or antiCD3 antibodies crosslinked with protein A. This pattern was very reminiscent of the
result I observed with T cell activation, with HPLM and HPLM-Min being equivalent
and RPMI performing substantially worse. Again, the most likely interpretation is that the
small metabolites uniquely present in HPLM do not affect effector cytokine secretion,
while the different with RPMI is due to concentrations of either amino acids, glucose or
ions (most likely calcium).
This data did not differentiate between whether this difference in cytokine
production was due to the composition of the media during the initial stimulation, the
subsequent expansion phase or acutely during the restimulation phase. To test these
possibilities, I activated and expanded the cells in the media as in Figure 4.3A and then
immediately prior to restimulation moved them to fresh media. Thus, I observed robust
cytokine production in cells that were activated in HPLM or RPMI and then transferred
to HPLM or RPMI supplemented with 2 mM Ca2+. However, I observed equally poor
cytokine production in cells that were activated in HPLM or RPMI and transferred to
RPMI with no calcium supplement. Thus, I conclude that under these conditions the
concentration of calcium is critical acutely during restimulation, but dispensable during
the initial activation and expansion phases. This is consistent with previous findings
demonstrating that in murine T cells the concentration of calcium can influence cytokine
production (Zimmermann, Radbruch and Chang, 2015).
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A) Levels of cytokine production in primary human T lymphocytes following
restimulation after being expanded in the indicated media.
B) Two week old human T cell blasts that were activated and cultured in the
indicated media were transferred to fresh media of the indicated type. Shown are
levels of cytokine production following restimulation.
Figure 4.3A, B prepared by M.L.G.
Data shown represent 4-6 donors tested across three different experiments and each point
representing a distinct donor. Statistical significance was calculated via one way
ANOVA, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

CD19 CAR-T cell construct transduction efficiency is similar in HPLM and other medias
A large variety of recently developed clinical protocols require the in vitro culture
and expansion of large numbers human T cells (Newick et al., 2018). One of the major
correlates of the effectiveness of these treatments is the metabolic and differentiation
state of the T cell. For example, in Chimeric Antigen Receptor (CAR)-T cell therapy
patients with positive responses to therapy have been shown to have T cells skewed
towards a memory rather than effector phenotype (Fraietta et al., 2018).
Due to the improved activation of human T cells cultivated in HPLM relative to
RPMI I hypothesized that I may observe an improvement in transduction with
lentiviruses expressing CAR-T cell receptors. I sought to compare HPLM to strategies
typically used in clinical protocols which use two other synthetic medias: a mixture of
AIM V and RPMI (referred to as AIM V here) and X-VIVO 15. The latter has the added
advantage of being serum free, while HPLM/HPLM-min are supplemented with dialyzed
FBS and AIM V is supplemented with 5% human serum. I observed equivalent activation
in HPLM, HPLM-Min and AIM V media when stimulated with plate-bound antiCD3/CD28 antibodies as measured by CD25 (Figure 4.4A). However, I did observe a
116

significant reduction in T cell activation in X-VIVO 15 media relative to any of the other
conditions.

A) Levels of CD25 expression 24 hours after stimulation in primary naïve human T
cells cultured in the indicated media.
B) Fraction of primary human T cells positive for the CD19-CAR transgene 48 hours
after transduction in the indicated media.
Figure 4.4A, B prepared by M.L.G.
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Data shown represents 3 separate experiments of 2 donors with the mean and standard
deviation shown. Statistical significance was calculated via one way ANOVA, *p<0.05,
**p<0.01.

Transduction of T cells with lentiviruses typically depends strongly on how
robustly they are activated. Based on the data in Figure 4.4A I anticipated that HPLM,
HPLM-Min and AIM V media would have equivalent transduction efficiencies while XVIVO 15 would be lower. The results essentially tracked the activation data perfectly
with X-VIVO 15 media supporting a lower rate of transduction relative to HPLM and
AIM V (Figure 4.2B). Thus, HPLM performs as well or better than commonly used
culture media for the generation of CAR-expressing T cells.

III. Discussion
The development of cell culture techniques in the mid 20th century heralded an
enormous shift in life sciences research by offering much more rapid and reproducible
assay systems. However, these techniques have changed little in the intervening period as
my knowledge has grown and in particular media formulations developed in the 1950s
are still universally used today. Here I adapted a recent effort to modernize the field via
the development of a cell culture media modeled closely after the in vivo environment to
the study of primary human lymphocytes. I anticipated that this approach would both
potentially improve cell culture techniques for lymphocytes and also reveal insights into
the metabolism of T cell activation.
Calcium has long been known to be required for lymphocyte activation, with
more recent studies demonstrating the molecular machinery involved (Zhang et al., 2005;
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Prakriya et al., 2006). In fact, the molecular mechanisms underpinning this phenomenon
were accomplished in part through the identification and study of a novel Mendelian PID
(Feske et al., 2006). However, despite this fact, RPMI has been the primary culture media
used to study lymphocyte function for decades despite the fact that it contains
subphysiological levels of calcium. While some groups have observed increased in vitro
secretion of effector cytokines in IMDM (which has a a concentration of 1.5mM) or
calcium supplemented RPMI relative to basal RPMI in murine T cells ex vivo
(Zimmermann, Radbruch and Chang, 2015), I am the first to show such a drastic impact
on activation, proliferation and effector cytokine secretion in primary human T cells. It is
also likely that the use of FBS as a common supplement to cell culture augments the
calcium concentration of RPMI considerably, as I measured my current stock of FBS at
3.9 mM – raising the concentration to roughly 800 mM when added at a concentration of
10%. Based on my calcium flux data, this would appear to be sufficient to achieve
maximal calcium flux in my assay (Figure 4.2D). However, this still corresponds to a
strongly lymphopenic environment and it is quite possible that the cross-linking anti-CD3
antibody used in the calcium flux masks an underlying defect that would be present in
response to an in vivo antigen response. Furthermore, the calcium flux assay only
measures calcium changes for the first several minutes of a response, whereas in vivo the
process is much more dynamic and spread out over the course of hours/days.
Looking beyond calcium, a comparison of great interest to me was the HPLM versus
HPLM-min conditions. As these two media shared the same concentrations of amino
acids, glucose and ions they allowed a direct measurement of the impact of the plasma
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metabolites on T cell activation and proliferation. I hypothesized that human T cells
would behave differently in a media designed to more closely mimic the in vivo
environment. Curiously, comparing these two media revealed no differences in
CD25/CD69 expression, proliferation or cytokine production after stimulation. It is
nevertheless possible that there are underlying metabolic differences between the cells
grown in HPLM compared to HPLM-Min; however as they seem to have no functional
impact in this model system it seems unlikely that they are important regulators of T cell
biology. The same caveat applies to these experiments whereby the stimulus used to
active the T cells is very strong and artificial relative to a true antigen response and could
be masking a role for these serum metabolites.
Broadly speaking, my data underscores the artificiality of commonly used cell
culture conditions for T lymphocytes and identifies one component in particular which
can easily and rapidly be remedied by researchers in the field. This approach highlights
the value of studying human physiologic media and also further work to attempt to
improve the physiological relevance of in vitro techniques.
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CHAPTER 5 – Discussion
I.

Summary
Despite decades of study the function of the GIMAP family remains enigmatic.

GIMAP5 is the most extensively studied family member. Previous work has
demonstrated a drastic decrease in peripheral murine lymphocyte numbers following loss
of GIMAP5 protein. Various hypotheses including defective calcium flux, dysregulation
of Bcl-2 family members and aberrant GSK3 signaling have been proposed.
Furthermore, the biochemical study of this protein including the role (if any) of GTP
hydrolysis, interacting partners and specific metabolic/signaling processes influenced by
GIMAP5 remains nearly completely unexplored. Finally, the role of any of these proteins
in human biology remains nearly completely unstudied.
In this study I have described the first large scale human cohort of patients
suffering from a disease caused by loss-of-function mutations in GIMAP5. This recessive
Mendelian disease has 100% penetrance across four pedigrees and nine affected
individuals. Broadly speaking, the clinical features of the GIMAP5-deficient human
patients were remarkably similar to the phenotype of two independent mouse strains
carrying similar mutations (Ryan D Schulteis et al., 2008a; Barnes et al., 2010a). These
patients suffered from lymphopenia, thrombocytopenia, lymphadenopathy/splenomegaly,
NRH and bronchiectasis in addition to other pedigree specific autoimmune conditions. I
also developed the first in vitro loss-of-function CRISPR/siRNA models to acutely
deplete GIMAP5 in both murine and human T cells. I leveraged these models to reveal a
striking difference in T cell phenotype between mouse and man, as well as a previously
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unknown link between GIMAP5 and ceramide biology. I also established a retroviral
transduction model to rescue T cells from the sphinx mouse and used this to demonstrate
that regulation of GIMAP5 GTPase activity was required for proper function in addition
to definitively showing that the L223F patient mutation is non-functional. Lastly, I also
undertook an extensive characterization of the GIMAP5 interactome and showed three
main clusters of GIMAP5 interacting proteins. One cluster (the Ragulator complex) was
validated via two independent approaches.
Taken together, the body of work in this thesis sheds light on some of the major
mysteries surrounding GIMAP5 and the GIMAP family more broadly but also poses new
questions. Primarily, what is the explanation for the significant difference between the
mouse and human phenotypes in T cells in vitro given that their clinical features are so
similar? Furthermore, how does GIMAP5 regulate ceramide levels, and what is the
function of its interaction with the Ragulator complex?

II.

Clinical and functional phenotyping of GIMAP5deficient patients
My findings in the human model both extend previous results published in the

murine model as well as shed light on new phenotypes that had not been described.
GIMAP5-deficient human patients share many cardinal clinical features across the entire
cohort as well as with GIMAP5-deficient mice on a C57bl/6 background. B/T/NK cell
lymphopenia, mild anemia, thrombocytopenia and liver dysfunction were common to all
patients as well as the two murine models. However, in the human patients I also
observed some inter-pedigree variation likely caused by different genetic backgrounds as
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well as the harsher environment humans experience relative to laboratory. Furthermore, I
also observed an additional set of phenotypes in the human patients not present in the
murine model on a C57bl/6 background. For example, nearly all of the patients suffered
from recurrent lung infections and consequently bronchiectasis which was not apparent in
the SPF conditions experienced by the mice. In addition, studying the human model
revealed varied pedigree specific autoimmune conditions such as psoriasis (P3-1), uveitis
(P2-1), and autoantibody production (2-3, 2-4, 3-1). This raises the possibility that loss of
GIMAP5 predisposes to autoimmunity more generally and that other environmental and
genetic factors can contribute to the manifestation of these lower penetrance phenotypes.
We also analyzed some phenotypes shared with the murine model in more depth
in the human model than was previously done. Schulteis et al. show that in a knockout
murine model of GIMAP5 broad liver dysfunction occurs with histology showing large
areas of necrosis (Ryan D Schulteis et al., 2008c). I observed elevated liver enzymes in
the serum of the patients as well as one patient experiencing acute liver failure due to
nodular regenerative hyperplasia. Furthermore, some patients initially presented to
gastroenterologists rather than immunologists suggesting that the liver disease may be
more debilitating than the immunological issues in some cases. Histological findings
were very typical of NRH, with mild lymphocytic infiltrates and aberrant expression of
CD34 on the vasculature. Thus, GIMAP5 deficiency could represent the first monogenic
knockout murine model of NRH, as previous models relied on overexpression of both IL6 and the IL-6R on hepatocytes (Maione et al., 1998). Interestingly, Schulteis et al. claim
that crossing GIMAP5 to Rag2-/- deficient mice had no effect on the liver phenotype,
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suggesting that GIMAP5 plays a critical role in other cell types beyond lymphocytes
(Ryan D Schulteis et al., 2008a). This finding could be of great interest to the NRH field
as the study of GIMAP5 could reveal specific cell types and pathways involved in the
pathology of NRH which to date has remained very obscure. Conversely, this finding
could also point towards IL-6 playing a role in the liver pathology of GIMAP5-deficient
patients. This would suggest that therapies targeting the IL-6 axis may be more effective
at controlling liver disease in GIMAP5 patients than therapies aimed at controlling
autoreactive lymphocytes.
Unfortunately, my current study offers little understanding as to the etiology of all
clinical findings in the patient cohort. I hypothesize that many of the autoimmune
symptoms observed in these patients could be secondary to the lymphopenia, although
further work is required to test this.
We also carried out much more extensive profiling of PBMCs on these patients
than has previously been done in the murine model. Previous studies have shown a
decrease in naïve T cells (via CD44/CD62L expression). I observe a similar phenomenon
using roughly analogous human markers CD45RA and CCR7. I also carried out deep
phenotyping of patient PBMCs using an extensive CyTOF panel with 38 different
markers. These data reinforced my hypothesis that the major defects observed in
GIMAP5 deficiency were due to the lymphoid compartment as these patients had no
major phenotypic differences in any of the myeloid compartments. However, I did
observe perturbations consistent with extensive LIP – namely, a loss of naïve T cells, an
expansion of effector memory subsets and a drastic increase in the fraction of
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CD57+CD8+ T cells. Again, consistent with LIP I also observed extremely short
telomeres in patient T cells suggesting that significant homeostatic proliferation had
occurred after egress from the thymus. Curiously, the CyTOF phenotyping also revealed
differences in the B cell compartment of GIMAP5-deficient patients. This was
particularly surprising given my finding that human B cells do not express GIMAP5, in
contrast to murine B cells. This demonstrates that the mature B cells are being influenced
by the inflammatory/pro-autoimmunity environment generated by loss of GIMAP5 in
other cell types, or GIMAP5 is required at some earlier point in B cell development and
the rate of naïve B cell production is impaired. In terms of B cell function, nearly the
entire patient cohort shared B cell lymphopenia although the consequences of this were
much more varied with some individuals exhibiting hypergammaglobulinemia, others
hypogammaglobulinemia as well as some testing positively for autoantibodies. Overall,
my phenotyping data is strongly indicative of a disease characterized by normal myeloid
compartments but severe lymphopenia.
We hypothesized that this lymphopenia was the prime perturbation to the immune
system induced by loss of GIMAP5 and was central to my attempts to study the gene. My
current data does not allow me to differentiate between peripheral lymphopenia caused
by defective thymic output, trafficking defects resulting in sequestration in peripheral
lymphoid organs or a peripheral survival defect. Previous studies have published
conflicting claims with regards to T cell development in the murine model of GIMAP5
deficiency. One group has claimed that while the fraction of each thymic subpopulation is
unaffected, HSC function and survival in the bone marrow is impaired (Ryan D Schulteis
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et al., 2008a; Chen et al., 2011a). Another has claimed that thymic involution is
accelerated in the Sphinx mouse with the total number of thymus cells decreasing more
rapidly relative to controls (Chen et al., 2016). Moreover, it is clear that there is an ex
vivo survival defect of T cells isolated from GIMAP5-deficient mice which would
support a model with defective T cell survival in the periphery. More experiments
designed to differentiate between these possibilities are required to answer this question.
With regards to the human model even less data is available as I have been unable
to study thymic tissue. However, in contrast to the murine model, I have shown that
survival of GIMAP5-deficient T lymphocytes in vitro is normal. This would cast doubt
on the hypothesis that the lymphopenia is caused by defective peripheral survival,
although it is also possible that there is some element in vivo which I cannot replicate in
my in vitro culture system. While the lymphadenopathy observed in the GIMAP5deficient patients could indicate a trafficking disorder, this finding is discordant with the
murine model which have smaller lymph nodes with fewer cells. Measurement of naïve T
cell production by testing for T cell Receptor Excision Circles (TRECs) in the peripheral
T cells of humans and mice deficient for GIMAP5 would be extremely helpful in
differentiating between these possibilities.

III. GIMAP5 expression, structure and genetics
GIMAP5 has a GTPase domain with homology to other small GTPases. In
addition to this it also contains a C-terminal hydrophobic sequence which is thought to be
required for insertion into the lysosomal membrane. Unfortunately my attempts to test
this by mutating this sequence were stymied by the fact that deletion of this domain
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dramatically destabilized the protein. It is unclear whether this was due to an intrinsic
destabilization of the protein or stability of the protein is dependent on localization and/or
insertion into a membrane. Two of the alleles observed in the patient cohort (p.L223F and
p.N221S) were located in this domain. Thus, these mutations could lead to a loss of
protein due to destabilization or defective function of this C-terminal domain.
All affected individuals in my cohort carried either homozygous or compound
heterozygous mutations in GIMAP5. Individuals carrying these alleles in the
heterozygous state did not report any clinical complications, although it is possible that
my cohort is too small as the GIMAP locus has been linked to various autoimmune
conditions (Lee, Horie, Graham R Wallace, et al., 2013). As GIMAP5 is a GTPase, I was
surprised to see that many of the patient mutations were localized to sections of the
protein distal from the active site of the enzyme. Specifically, The P109L, N221S and
L223F alleles were all located either in the C-terminal hydrophobic regions of the protein
or in the GTPase domain but very distal from the active site. The I47T and L204P alleles
affected residues closer to the active site. However, this puzzle was resolved when I
measured levels of GIMAP5 in patient T cells via western and observed a dramatic
decrease in protein. Further work from my collaborators demonstrated that these alleles
intrinsically destabilized the protein even when synthesized and purified from bacteria.
Thus, it appears that the human patient mutations lead to a near complete loss-of-function
primarily due to destabilization of the protein rather than affecting rates of GTP
hydrolysis.
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Also of interest is the fact that some of these alleles are relatively common in the
general population. The Turkish patients in the cohort carried the I47T, P109L and
L223F alleles which had not previously been detected as of this writing. These could
represent alleles that are common in Turkey but underrepresented in available databases.
On the other hand, the Minor Allele Frequency (MAF) of the L204P mutation is on the
order of 0.1%, suggesting that there are a relatively high number of unions between
individuals heterozygous for this mutation. Indeed, another group has recently published
a study describing a single patient homozygous for the L204P mutation with clinical
features resembling my cohort (Patterson et al., 2018).
We also investigated the expression patterns of GIMAP5. Initially, I investigated
publicly available microarray data from a large variety of human tissues (Su et al., 2004).
This dataset showed significant expression in CD4+ and CD8+ T cells, some expression in
NK cells and monocytes and virtually no other tissues. I confirmed these findings at the
protein level via western blot from primary human tissues as well. However, I suspected
there were functionally significant non-lymphoid tissues which required GIMAP5 due to
the clinical phenotypes of GIMAP5-deficient patients. In particular, the bronchiectasis
and liver disease could both be due to GIMAP5 playing a role in non-lymphoid tissues.
The latter is also supported by the finding that GIMAP5-/-Rag2-/- mice still suffer from
liver disease. Thus, I also investigated GIMAP5 expression at the protein level from a
large variety of human tissues and saw robust expression in tissues with large populations
of T and NK cells such as the spleen and thymus. However, I also observed high levels of
GIMAP5 in other tissues such as lungs, ovary and prostate. It is unclear at this time
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whether this signal can be completely explained by resident lymphoid populations or not.
However, this finding prompted me to investigate publicly available single cell RNA-Seq
databases for GIMAP5 expression patterns, and observed robust GIMAP5 mRNA
expression in endothelial cells. I think it is likely that the liver phenotype in both my
GIMAP5-deficient mice and humans is in part or entirely caused by loss of GIMAP5 in
endothelial cells, although future studies in this area are required.

IV. GIMAP5 interactome data
The most critical lacunae in our knowledge of the GIMAP family is which
biochemical cellular processes it regulates. I sought to address this via the elucidation of
the GIMAP5 interactome. Previous work using overexpression systems in 293T or B cell
leukemia cell lines (which do not naturally express endogenous GIMAP5 and likely
many other lymphoid restricted binding partners) has posited that GIMAP5 directly
interacts with and regulates Bcl-2 family members on the surface of the mitochondria.
This finding was attractive due to the lymphopenia exhibited by GIMAP5-deficient
murine T cells as well as the decreased in vitro survival of GIMAP5-deficient murine
lymphocytes (Barnes et al., 2010a). However, more recent work by (Vivian W.Y. Wong
et al., 2010) as well as our group studying endogenous GIMAP5 in primary cells rather
than overexpression systems provides strong evidence that GIMAP5 is restricted to the
lysosome and is virtually absent from mitochondria where Bcl-2 family members
typically reside. This would suggest that the previous findings could be an artifact due to
the overexpression and encouraged me to explore other approaches to identify interacting
partners.
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Our BioID2 interactome represents the first robust dataset describing the
interactome of GIMAP5 in a T cell line. Interestingly, I did not observe any of the Bcl-2
family members that have previously been described to interact with GIMAP5. I also did
not observe GSK3, any genes related to calcium flux or FOXO family proteins all of
which are biochemical functions previously attributed to GIMAP5 (Ilangumaran et al.,
2009; Aksoylar et al., 2012; Patterson et al., 2018). However, I did observe a very robust
signal for the entire Ragulator complex (LAMTOR1-5, RagC, other Rag proteins were
present but not statistically significant) as well as multiple components of the TCR
signaling complex (CD2, CD3𝜀, CD3𝛿, CD4 and Lck). These findings do tie into one
previous publication suggesting that GIMAP5sph/sph T cells have increased Akt and
mTORC1 signaling (Chen et al., 2015). The TCR complex cluster, however, was
completely unexpected despite being among the most enriched proteins in the BioID2GIMAP5 condition. Specifically, I was initially unsure as to how a lysosomal protein
could be interacting with the TCR complex. However, a fascinating study recently
published describes an analogous situation in immortalized B cell lines. The authors
describe a novel complex of the BCR, MYD88 and the Ragulator complex on the surface
of the lysosome (Phelan et al., 2018b). Furthermore, this complex forms specifically in B
cell leukemia lines whose growth is sensitive to inhibitors of the BCR pathway. In the
case of GIMAP5, its role in the TCR/Ragulator complex remains unclear.
Lastly, I also observed a large cluster of proteins (Rab10, SNAP23, VAMP7,
Syntaxin1, etc.) which I broadly labeled as genes involved in cellular trafficking. From
this data alone it is unclear whether these are simply the genes involved in trafficking
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GIMAP5 to the lysosome/late endosome or whether GIMAP5 has a direct functional role
in their regulation. One possible model implied by these datasets is that GIMAP5
regulates the internalization and recycling/degradation of the TCR complex from the cell
surface.
Despite its strengths the BioID2 system still relies on overexpression of the bait
protein and could be prone to artifacts. This was addressed this via endogenous coimmunoprecipitations as well as PLA. The latter has the added bonus of showing that the
two proteins are temporally and spatially in contact in a cell and thus avoids artifacts
caused by lysing the cell and disrupting membranes and spatial localization of protein
complexes. Furthermore, these data greatly strengthen my confidence that GIMAP5 is
truly interacting with the Ragulator complex and more broadly suggests that my BioID2
dataset is robust.
One drawback of these approaches has been defining the precise protein(s) in
direct contact with GIMAP5. For example, it is extremely unlikely that GIMAP5 makes
direct contact with each protein of the regulator complex. Unfortunately, my attempts to
determine this were hindered by non-specific binding of GIMAP5 overexpressed in
293Ts as well as the fact that endogenous LAMTOR proteins form an obligate pentamer,
making it difficult to simultaneously overexpress the entire complex (data not shown).
Future approaches using Förster Resonance Energy Transfer (FRET) may be more
precise than the BioID2 technique and allow the determination of the direct binding
partner. Alternatively, crystallization of the Ragulator/GIMAP5 complex or purification
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of large quantities of each individual member in a bacterial expression system may
enable clarification of this point in the future.

V.

The functional role of GIMAP5 in lymphocytes
Due to my robust and reproducible data demonstrating that GIMAP5 is a T cell

specific member of the Ragulator complex, I invested a significant amount of effort
investigating downstream cellular processes. The most detailed studies to date have
shown the Ragulator complex to be required for mTORC1 recruitment to the lysosome
when sufficient amino acids are present, allowing for consequent activation by the
TSC1/2 complex (Bar-Peled and Sabatini, 2014). However, older studies have also
described these proteins as being scaffolds for Mek/Erk as well as being involved in
lysosomal trafficking to and from the perinuclear space (Pu et al., 2015; Pu, KerenKaplan and Bonifacino, 2017b). I and others have shown that T cells isolated from
GIMAP5sph/sph mice have increased cell size and mTORC1 signaling activity relative to
controls (Chen et al., 2015). This led me to hypothesize that GIMAP5 is a negative
regulator of mTORC1, most likely via its interaction with the Ragulator complex. My
collaborators and I also demonstrated that treatment of both mice and humans deficient
for GIMAP5 with mTORC1 inhibitors could lead to clinical benefit lending support to
this hypothesis. However, after extensively investigating multiple different models of
GIMAP5 deficiency in human cells (Jurkat CRISPR knockouts, GIMAP5-deficient
patient cells, GIMAP5 siRNA/CRISPR-RNP depletion strategies) I observed no
difference in a large number of mTORC1 readouts either at baseline, following TCR
stimulation, or amino acid starvation/addback. I measured proliferation, cell size,
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phosphorylation of targets such as S6, 4EBP1, Ulk1 and S6K. While the single-cell
Jurkat clones and individual patients/healthy donors showed some variability, more
controlled models such as the GIMAP5 siRNA knockdowns or CRISPR-RNPs showed
virtually no differences between cells lacking GIMAP5 and appropriate controls. Overall,
these data are very strong evidence GIMAP5 is not regulator of mTORC1 activity. While
it is possible that there are specific components of the in vivo milieu that are required for
this phenotype to become evident, I would argue it is much more likely that the increased
mTORC1 activity observed in the GIMAP5sph/sph mice is due to a broader ongoing
autoimmune reaction which can be alleviated with rapamycin treatment. Furthermore,
despite very similar clinical phenotypes, T lymphocytes isolated from human patients do
not exhibit increased mTORC1 activity directly ex vivo. I also observed a broad increase
p-Erk in lymph node cells from Sphinx mice suggesting that other pathways besides
mTORC1 are affected. I would propose instead that loss of GIMAP5 leads to cell death
independently of mTORC1, creating a lymphopenic environment where the remaining T
cells become activated by increased availability of self-peptide and cytokines. This
indirect effect can then be inhibited by rapamycin leading to abatement of some
symptoms in GIMAP5 deficiency. As mentioned previously, crossing GIMAP5-deficient
mice to Rag2-/- mice did not improve the liver phenotype. While the human patient who
was treated with rapamycin did experience a significant reduction in lymphadenopathy as
well as psoriasis following treatment, he continued to have elevated liver enzymes in his
blood suggesting that this is occurring via a separate mechanism.
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One of the most surprising results from this study has been the striking difference
in the in vitro phenotypes of murine versus human T cells deficient for GIMAP5. This is
most clearly illustrated by the fact that in my experiments knocking GIMAP5 out via
CRISPR-RNP electroporation in human T cells has no effect on survival or proliferation
following stimulation whereas the vast majority of murine T cells will die within 96
hours in the absence of GIMAP5. T cells isolated from GIMAP5-deficient patients or
generated via GIMAP5 siRNA may still retain sufficient protein for residual activity,
however, the CRISPR model should result in frameshift mutations leading to a complete
loss in protein providing very strong evidence that GIMAP5 is not required for survival
in human T cells. GIMAP3 is a pseudogene in humans, while GIMAP2 does not exist in
the mouse suggesting that perhaps another GIMAP family member can compensate for
the loss of GIMAP5 in human T cells. However, this seems very unlikely as firstly I have
shown that T cells from GIMAP5-deficient patients do not increase expression of other
GIMAP family members. Secondly, the fact that GIMAP5-deficient patients still suffer
from similar clinical features to the mice would argue that another gene cannot
compensate for GIMAP5 when it comes to in vivo phenotype. I hypothesize there are two
likely explanations for this finding. Firstly, the artificial in vitro environment used to
culture my human T cells could lack some critical factor that is present in vivo that would
alter the metabolism of the cells and lead to cell death. Similarly, my in vitro assays
typically use antibodies to cross-link CD3 and CD28 with high efficiency rather than the
much weaker self-peptide/TCR contacts and IL-7/IL-15 in vivo. Alternatively, it is
possible that some/most of the clinical features of GIMAP5 deficiency are T cell
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independent, or at least not caused by decreased survival. Studies in the murine model
would argue against this possibility as it has been shown that multiple manipulations of T
cells in GIMAP5sph/sph mice can rescue survival of the animal, implying an intrinsic
defect (Barnes et al., 2010a; Aksoylar et al., 2012; Patterson et al., 2018). Regardless,
this example has highlighted the importance of studying the human model as these
findings would have been completely overlooked if the field had been restricted to animal
models.

VI. Rapamycin as a treatment for GIMAP5 deficiency
GTPases are typically thought of as ‘molecular switches’ commonly thought to be
involved in signal transduction. Previous work which I have confirmed and extended has
shown increased mTORC1 signaling in T lymphocytes isolated from Sphinx mice (Chen
et al., 2015). Furthermore, multiple critical regulatory points of the mTORC1 pathway
have already been shown to regulate mTORC1 activity through modulation of GTPase
activity. Firstly, activation of the PI3K signaling pathway leads to activation of the
TSC1/2 complex, which in turn acts as a GEF for the small GTPase Rheb (Huang and
Manning, 2008). Rheb can then potentiate the activity of the mTOR kinase (Armijo et al.,
2016). Secondly, recent work has described heterodimers of the Rag GTPases recruiting
mTORC1 to the surface of the lysosome (which is thought to be required for its activity)
in response to the availability of amino acids (Bar-peled et al., 2012; Efeyan et al., 2013;
Bar-Peled and Sabatini, 2014). Thus, considering these previous results I hypothesized
that GIMAP5 provided a novel layer of mTORC1 regulation specific to the extreme
metabolic demands of lymphocyte activation. This was further supported by its
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localization to the surface of the lysosome and clinical phenotype which has significant
overlap with other Mendelian diseases and animal models leading to hyperactive
mTORC1. For example, T cell specific ablation of TSC1 in mice led to a very similar
phenotype to GIMAP5-deficient mice (Yang et al., 2011; Zhang et al., 2012). In the
human model, disorders of hyperactive PI3K and consequently increased mTORC1 also
share many features with GIMAP5 deficiency (Lucas et al., 2014).
Consistent with my hypothesis, I observed significant clinical improvement in one
patient as well as the Sphinx murine model of GIMAP5 deficiency. The
lymphadenopathy and splenomegaly were both drastically reduced and the psoriasis was
also largely resolved. However, serum liver enzymes remained elevated suggesting that
this aspect of the disease was caused by a different mechanism. Unfortunately, I did not
receive samples prior to commencement of the treatment which precluded an analysis of
the impact of rapamycin on the immune cell subpopulations. In the murine Sphinx model,
treatment with rapamycin was observed to reduce mTORC1 signaling and cell size as
expected, but also prevented the loss of naïve T cells and development of effector
memory T cell populations which I suspect are the root cause of many of the clinical
symptoms. Thus, the treatment appeared effective in at least one patient for certain
aspects of the diseaseas well as in the mouse model.
However, virtually all of my mechanistic data exploiting multiple models and
readouts showed no impact of the loss of GIMAP5 on mTORC1 signaling. Rapamycin is
also a general immunosuppressant and thus it is likely that the clinical benefit I observed
was due to an indirect effect of inhibiting mTORC1 signaling rather than a direct
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targeting of the pathway affected by GIMAP5 deficiency. Determination of the molecular
pathways regulated by GIMAP5 remains key to developing more effective therapies that
may address all of the clinical features of the patients. My data demonstrating increased
levels of ceramides in murine T cells acutely depleted of GIMAP5 provides a new
candidate pathway to target. Unfortunately while there are inhibitors of multiple enzymes
in this pathway and none of these are approved for clinical use and appear to be quite
toxic (Colvin, Cooley and Beaver, 1993). Furthermore, as of now my data remains in
vitro in nature and requires more work both in vitro and in in vivo murine models to test
potential efficacy. Overall, rapamycin or potentially bone marrow and/or liver
transplantation likely remain the best treatment options at this point.

VII. Proposing a new model of GIMAP5 function
As discussed above, many models of GIMAP5 function have been put forward
over the years. While I have been able to directly confirm many previous results from the
literature in the GIMAP5sph/sph model, none of them were consistent in the human model
or in vitro models of acute GIMAP5 depletion.
Curiously, GIMAP1 and (to a lesser extent) GIMAP6 deficient mice have very
similar phenotypes to GIMAP5sph/sph or knockout mice (Saunders, Louise M.C. Webb, et
al., 2010; Pascall et al., 2013, 2018; Webb et al., 2016). The other GIMAP family
members are less clear as human GIMAP2 does not have a direct murine homologue,
GIMAP7 knockout mice have not been generated, and GIMAP8 deficient mice have
virtually no phenotype (Krücken et al., 2004; Webb et al., 2014). Despite having similar
phenotypes at the organismal level, the subcellular localizations of these proteins are very
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different. GIMAP1 localizes to the Golgi, GIMAP2 and 7 are thought to heterodimerize
on the surface of lipid droplets, GIMAP5 to the surface of the lysosome and GIMAP6 is
thought to be cytosolic but recruited to autophagosomes when autophagy is induced
(Nitta and Takahama, 2007; Vivian W.Y. Wong et al., 2010).
The similarity in phenotypes combined with the different localizations of the
GIMAP family proteins suggests that these are all essential, non-redundant genes at
different steps in the same pathway. Thus, I propose a new model of GIMAP family
function in regulating lipid metabolism and/or transport. Experimentally, this is supported
by my high-throughput experiments showing dramatic alterations in lipid metabolism in
GIMAP5-deficient murine lymphocytes. Furthermore, each GIMAP family member
localizes to an organelle important for lipid metabolism. For example, the heterodimer of
GIMAP2/7 localizes to the surface of lipid droplet presumably via the hydrophobic Cterminal domain of GIMAP2. Lipid droplets serve as cellular reservoirs of lipids and
cholesterol. Thus, GIMAP2/7 could regulate mobilization/storage of lipids from lipid
droplets. Most lipids are synthesized in the ER and then transported through the Golgi to
their destinations throughout the cell. I speculate that GIMAP1 may be involved in this
process. Further experiments to test this model requires metabolic profiling of
lymphocytes deficient in GIMAP1, 2, GIMAP6 and GIMAP7 as well as the generation of
mice deficient for GIMAP7.
One other question raised by this model is why lymphocytes would require
specific machinery for lipid metabolism that is absent from other cell types. Multiple
genetic Lysosomal Storage Diseases (LSDs) that disrupt lipid metabolism have been
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identified and studied, however, these individuals have not been reported to suffer from
immunological abnormalities. One method of diagnosis involves detecting lipid bodies in
lymphocytes isolated from PBMCs directly via light microscopy (Kanzaki, 2011). These
lipid bodies are not evident in mice or patients lacking GIMAP5, indicating a metabolic
defect of a different nature. I hypothesize that the extraordinary metabolic demands of T
cell activation and rapid cell division in the face of pathogen attack requires additional
levels of regulation, some of which could be provided by members of the GIMAP family.

VIII. HPLM as a novel media for the culture of human T
lymphocytes
In vitro cell culture techniques have greatly accelerated biological research and
provide much more easily accessible and high throughput methods. However, despite this
most media used for cell culture protocols has remained virtually unchanged for decades.
Improvements to cell culture media or the development of media more closely modeling
the in vivo environment would be easy to adopt by many research groups and have a large
benefit to the field at large.
Cantor et al. have recently developed a media designed to more closely mimic
human plasma, termed HPLM. However, to date only one study on HPLM has been
published and no attempt was made to test the function and growth rate of lymphocytes
in HPLM. I hypothesized that HPLM would better support the growth of human T cells
in cell culture. My data did in fact show much greater activation of naïve human T cells
in HPLM relative to RPMI. I showed this was due to the physiological levels of calcium
in HPLM, while RPMI is severely hypocalcemic relative to the in vivo environment. Of
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note, these experiments were conducted in HPLM/RPMI supplemented with dialyzed
FBS in order to preserve the composition of each media while still adding the required
growth factors. The dialyzed FBS should be stripped of all ions and small organic
molecules. I measured the calcium concentration in complete FBS to be nearly 4 mM,
thus under common culture conditions with a supplement of 10% FBS the amount of
calcium in RPMI is roughly doubled. Based on my calcium flux data, it would appear
that while this concentration would still be severely hypocalcemic (~0.8mM) at least
under those conditions functionally that appears to be sufficient. It remains unclear if
culturing cells in 0.8mM rather than physiological concentrations of calcium affects other
aspects of T cell biology or not.
Other groups have observed similar results in different conditions. For example,
Zimmermann et al. in 2015 first induced colitis in mice via T cell transfer (Zimmermann,
Radbruch and Chang, 2015). They then isolated lamina propria T cells and restimulated
them acutely in vitro in either IMDM, RPMI or RPMI supplemented with 1mM CaCl2.
Under these conditions, they observed slightly decreased secretion of effector cytokines
IL-10, IFN, IL-17, TNF and IL-22. I observed a much more robust difference between
my RPMI and HPLM/RPMI + Ca2+ conditions. This is likely due to the fact that I
activated and expanded my cells prior to restimulation, ensuring that the vast majority
were strongly activated and primed to secrete cytokines following restimulation as
opposed to measuring this directly ex vivo. I also extend these results by showing that
under the hypocalcemic conditions of RPMI both the initial calcium flux into the cell
following activation is deficient as well as early activation events including CD25 and
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CD69. Other groups have also observed decreased calcium flux in basal RPMI relative to
other media (Prakriya et al., 2006; Gwack et al., 2008; Bertin et al., 2014).
While my work does not provide convincing evidence that the small metabolites
present in HPLM have a significant impact on T cell function or biology, I nevertheless
did show improved activation in HPLM due to higher levels of calcium relative to RPMI.
Either the use of HPLM or the addition of supplemental calcium to RPMI has the
potential to improve the efficiency and physiological relevance of in vitro T cell assays.

IX. Conclusion
These findings have led me to propose a new model of GIMAP5 function: that
GIMAP5 is a novel, T cell specific member of the Ragulator complex on the surface of
the lysosome (Figure 5.1). Based on my interactomics data it also appears to either form a
larger supercomplex consisting of various members of the TCR complex, the Ragulator
complex as well as endosomal trafficking proteins or is able to sequentially associate
with these groups of proteins. From this point the loss of GIMAP5 leads to a
dysregulation of ceramide biology, resulting in an excess accumulation of ceramides and
cell death.
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A) Figure showing a model of GIMAP5 activity incorporating the novel interactions
between GIMAP5 and the TCR/Ragulator complexes. The absence of GIMAP5
leads to ceramide accumulation, cell death and consequently lymphopenia
induced proliferation and autoimmunity which can be relieved by Rapamycin
treatment.

There are still major conceptual questions that remain with regards to the biology
of GIMAP5. Firstly, while I both define the interactome and cellular pathways that
GIMAP5 regulates in murine T cells, a molecular mechanism connecting the Ragulator
complex/TCR/GIMAP5 and ceramide biology is lacking. Further studies into the link
between the Ragulator/TCR complex and ceramide biology, perhaps by lipidomics
studies of Ragulator-deficient T cells, are required. The second major unanswered
question is the nature of the mouse-human difference in terms of the in vitro phenotype
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of GIMAP5-deficient T lymphocytes. Whether the human cells required specific
conditions or stimuli in order to exhibit defective survival, T cells are not the cell type
causing the in vivo condition or some other possibility remains to be seen.
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Materials and Methods
Immunoblotting
Protein lysates were isolated from cell pellets via a 20 minute incubation in lysis buffer
(1% NP-40, 150 mM sodium chloride, 50mM Tris-HCl, pH 7.4 plus Roche c0mplete
protease inhibitor cocktail and then clarified via centrifugation at 14,000 to 16,000 x g at
4C for 20 minutes. Total protein levels were measured by BCA assay (Pierce) prior to
reduction with 5% beta-mercaptoethanol and SDS Loading Solution (Quality Biological)
at 95C for 15 minutes. Equal amounts of protein were electrophoresed on either 4-12%
Bis-Tris or 10% Bis-Tris gels (NuPAGE, Life Technologies) and wet-transferred to
nitrocellulose membranes. In the case of human total tissue western blots, equivalent
amounts of protein from 19 different human tissues were run on a gel (Zyagen) and then
processed in a similar fashion. These were then blocked in 5% non-fat milk in 0.05%
TBST and probed with primary antibodies to GIMAP1, GIMAP4, GIMAP5, GIMAP6
and GIMAP7 (generous gifts from Dr. Geoffrey Butcher); GIMAP2 and GIMAP8
(produced by GenScript); IkB (662402, Biolegend), -Actin (ab20272)(purchased from
Abcam); LAMTOR1 (C11orf59, #8975), LAMTOR4 (C7orf59, #13140), RagA (#4357),
RagC (#3360), mammalian Target Of Rapamycin (mTOR, #2983), Rheb (#13879),
LAMP1 (#15665), Raptor (#2280), phospho-4E Binding Protein 1S65 (p4EBP1, #9451),
phospho-S6 ribosomal proteinS240/244 (pS6, #5364), phospho-p70 S6 kinaseThr389
(pS6K, 9234) (all purchased from Cell Signaling Technology). Binding of primary
antibodies was then measured via HRP-tagged antibodies specific for the relevant species
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and visualized by chemiluminescent substrate (Luminata Classico/Forte western HRP
substrate or Thermo Fisher SuperSignal West Femto Maximum Sensitivity Substrate).
Co-Immunoprecipitations
3x107 cycling primary human T cell blasts were incubated with cRPMI containing 0.5
Units/ml (U/ml) of IL-2 overnight and restimulated with HIT3 (BioLegend, 10 ug/ml)
and 10 μg/ml F(ab')2 Fragment Goat Anti-Mouse IgG (Jackson ImmunoResearch) or 100
U/ml of IL-2 for the indicated timecourses. Alternatively, T cell blasts were starved of
amino acids via incubation in amino acid free RPMI (US Biological, R9010-01)
containing dialyzed FBS (Thermo Fisher, A3382001) for one hour. They were then
restimulated for the indicated times with complete RPMI (cRPMI). ACell lysates were
precleared with unconjugated Dynabeads Protein G (Thermo Fisher Scientific) for 30
minutes with rotation at 4°C. Primary antibodies were then added to the precleared
lysates and incubated with rotation overnight at 4°C. Dynabeads Protein G were added
and incubated for an additional 1 hour at 4°C. Immunoprecipitates were washed four
times with lysis buffer. Immunoprecipitated proteins were eluted from the dynabeads via
5 minutes at 95°C in SDS sample loading buffer resolved by electrophoresis and
analyzed by immunoblotting.
In Vivo Rapamycin treatments
Rapamycin (LC labs) was dissolved in DMSO to generate a concentrated stock solution.
This was then further diluted in PBS for in vivo use. 7-9 week old age and sex matched
mice were injected intraperitoneally with 2mg/kg of rapamycin daily for two weeks prior
to isolation of tissues for further experimentation.
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Cytof
This assay was performed with the Human Immune Monitoring Center at Stanford
University as previously described (Leipold and Maecker, 2015). Frozen PBMCs from
patients or healthy controls were thawed, washed twice, resuspended in CyFACS buffer
(PBS supplemented with 2% BSA, 2 mM EDTA, and 0.1% sodium azide), and viable
cells were counted by Vicell. 1.5x106 viable cells were stained for 60 minutes on ice with
50l of the antibody-polymer conjugate cocktail described in Table S4. Sources for
antibodies are listed in Table S4 while the polymer and metal isotopes were purchased
from DVS Sciences. Following staining, the cells were washed twice in FACS buffer
before resuspension in 100l PBS buffer containing 2 g/ml Live-Dead (DOTAmaleimide (Macrocyclics) containing natural-abundance indium). The cells were washed
twice with PBS before fixation with 100l of 2% PFA in PBS and placed at 4C
overnight. The next day, the cells were pelleted and washed by resuspension in fresh
PBS. The cells were washed twice in MilliQ water before resuspension in 700l of
MilliQ water before injection into the CyTOF (DVS Sciences). Data analysis was
performed using FlowJo v9.3 (CyTOF settings) by gating on intact cells based on the
iridium isotopes from the intercalator, then on singlets by Ir-191 vs cell length, then on
live cells (Indium-LiveDead minus population). Further analysis on these populations
was then carried out using SPADE v. 3.9 using the following definitions:
T cells: CD3+ CD19- CD33CD4+ T cells: CD4+ CD8- TCRCD8+ T cells: CD8+ CD4- TCRTCR T cells: CD3+ TCR+
Naïve T cells: CD45RA+ CCR7+
TEMs: CD45RA- CCR7146

TCMs: CD45RA- CCR7+
TEMRAs: CD45RA+ CCR7NK cells: CD56+ HLA-DR- CD3- CD19- CD33B cells: CD19+ CD20+ CD3- CD33-

Flow Cytometry
For human experiments, patient or control PBMCs were washed once in PBS and stained
with 50l of Zombie Aqua (Biolegend) viability dye for 20 minutes on ice. After
washing once with FACS buffer, cells were stained in 50l of FACS buffer containing
diluted antibodies for 30 minutes on ice. Cells were then washed three times in FACS
buffer and fixed before acquisition on either a LSR II or LSRFortessa (BD Biosciences).
Murine cells isolated from either spleen or lymph nodes were stained and analyzed in a
similar manner. Data was analyzed using FlowJo v. 9.9.5.
Telomere analysis
Frozen PBMCs from patient P1.3 and P1.4 were shipped to Repeat Diagnostics for
measurement of telomere length via Flow-FISH. A fluorescently labeled nucleic acid
probe was hybridized with the TTAGGG repeats in telomeres. Signal strength was then
plotted relative to telomere lengths for healthy control subjects in order to calculate the
percentile for each patient.
Confocal/STED microscopy
Cycling T lymphocytes were either treated with Mitotracker were incubated for 30 min at
37oC with 6.25 nM of Mitotracker Red CMX-ROS in complete RPMI with 100 U/mL
IL-2. For confocal imaging, cells were plated onto poly-lysine coated coverslips for five
minutes before addition of an equal volume of 8% paraformaldehyde for 30 min at room
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temperature. After washing the coverslips twice with PBS, the samples were
permeabilized for 15 min using 0.1% Triton X-100, washed, and then blocked with 5%
BSA for at least 45 minutes. Samples were then incubated with primary antibodies
diluted in PBS with 0.05% Tween-20 and 5% goat serum for two hours. After washing
twice, the samples were then treated with secondary antibodies and Hoescht 33342 for 30
min at room temperature in the dark. Following two washes with PBS, then coverslips
were mounted with Prolong Gold onto slides and left to dry overnight. Confocal images
were acquired on a Leica SP5 X-WLL microscope and for STED, images were acquired
using a Leica SP8 STED microscope. Analysis was performed using Imaris software.
Proximity Ligation Assay
Primary human T cell blasts were washed once in PBS and then fixed in 4%
paraformaldehyde for 30 minutes at room temperature. Cells were then permeabilized
with 0.1% Triton X-100 for 5 minutes at room temperature, washed twice with PBS and
resuspended in 1ml of Duolink blocking solution for 1 hour. Cells were washed twice
with PBS and resuspended in 50l of the specified primary antibody solutions overnight
with shaking at 4C. The following morning, cells were washed twice in Duolink Buffer
A, then incubated in secondary antibody for 1 hour at 37C. Samples were sequentially
washed twice, incubated with ligase for 30 minutes at 37C, washed twice and incubated
with Duolink In Situ Detection Reagents Green (Sigma Aldrich) at 37C for 2 hours.
Cells were then washed twice and either analyzed by flow cytometry or mounted on glass
slides in Prolong Antifade with DAPI (Life technologies, P36971) for acquisition with a
Leica SP5 X-WLL microscope.
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Cell Culture & T cell expansion
In the case of patient cells, freshly isolated or frozen PBMCs were stimulated at
5x106/mL in cRPMI with 2 ug/mL of PHA-L (lectin from red kidney bean (Phaseolus
vulgaris), Sigma-Aldrich L2769), in the presence of 1 ug/mL anti-CD28 (Biolegend) and
1 ng/mL recombinant IL7 (Biolegend, Cat) for 48 hours. The cells were washed twice
with cRPMI and resuspended in media at 1 x 106/mL with 100 IU/mL Recombinant
Human IL2 (rhIL2), and cultured for up to 3 weeks with fresh rhIL2 and medium
supplemented every 2 days. HUVECs were cultured using L200 growth medium
supplemented with low serum growth supplement (Thermo Fisher).
Exome and Whole Genome Sequencing Analysis.
Genomic DNA was isolated from PBMCs of proband, parents and healthy relatives from
each pedigree. Exome sequencing were generated using SureSelect Human All Exon
50Mb Kit (Agilent Technologies) coupled with Illumina HiSeq sequencing system
(Illumina). Whole Genome Sequencing (WGS) were generated based on Standard
Coverage Human WGS from Broad Institutes. For individual samples, WES produced
~50-100X sequence coverage for targeted regions and WGS produced 60X coverage for
proband and 30X coverage for family members. DNA sequence data was aligned to the
reference human genome (build 19) using Burrows-Wheeler Aligner (BWA) with default
parameters and variants were called using the Genome Analysis ToolKit (GATK) (Li and
Durbin, 2009). Variants were then annotated by functional impacts on encoded proteins
and prioritized based on potential disease causing genetic model. Variants with minor
allele frequency < 0.1% in the dbSNP (version 137), 1000 Genomes (1,094 subjects of
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various ethnicities; May 2011 data release), Exome Sequencing Project (ESP, 4,300
European and 2,203 African-American subjects; last accessed August 2016), ExAC
databases (61,000 subjects of various ethnicities; March 2016 data release) or Yale
internal database (2,500 European subjects) were filtered. Autosomal-recessive
inheritance was investigated and genes with rare homozygous or compound heterozygous
variants were prioritized.
Sanger Sequencing of Genomic DNA
Direct bidirectional Sanger sequencing of GIMAP5 mutation, p.I47T, from genomic
DNA of two affected patients (P1-1 and P1-2) and their parents was performed following
PCR amplification using forward primer: 5’-AAGATAACTTGTCTGCAACACCA-3’,
and reverse primer: 5’-GTAGCAGTCCCCGATGTTCT-3’. Nomenclature of the
GIMAP5 variants is based on NCBI reference sequence NM_080916.2.
Orthologues and Other Human GIMAPs
Full-length orthologues of GIMAP5 protein sequences from several species and related
human GIMAP-family members (GIMAP1, 2, 4, 6, 7 and 8) were obtained from
GenBank. Protein sequences were aligned using the Clustal Omega algorithm. For
microarray data measuring GIMAP5 expression in human tissue, data was exported from
(Su et al., 2004).
T cell activation and proliferation assays
Primary human T cells from either GIMAP5-deficient patients or healthy donors were
isolated from PBMCs. Following any manipulations (such as siRNA/CRISPR-RNP
mediated depletion – see other sections) cells were then labeled with CellTrace Violet
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(CTV) (Thermo Fischer Scientific). Briefly, a 5mM stock of CTV in DMSO was diluted
1000 fold in PBS to generate a 5M working stock. T cells were then resuspended in the
working stock and incubated for 20 minutes at 37C, then washed once in RPMI. Cells
were then stimulated with either CD2/3/28 magnetic beads (Miltenyi) or a dose response
of plate-bound CD3/CD28 for 3-5 days. Cells were then stained for various surface
markers as described elsewhere and CTV dilution was analyzed via flow cytometry.
To measure early T cell activation events, unlabeled primary human T cells/total
PBMCs were activated either by plate-bound CD3/28, CD2/3/28 activation beads or
soluble CD3/CD28. Cells were analyzed by flow cytometry either 24 hours (CD69
expression) or 72 hours (CD25 expression) following stimulation.
BioID2
pCI-BioID2-GIMAP5 was constructed by InFusion cloning technology according to the
manufactural instructions (Clontech). A synthesized gBlock DNA that composed of a
Kozak sequence, the BirA biotin ligase (BioID2), a 9x poly-glycine linker, and human
GIMAP5 coding sequences into the pCI-neo backbone (Promega). The empty vector only
contains the biotin ligase (BioID2) coding sequence and the 9x polyG linker. GIMAP5deficient Jurkat cells were transfected with the two linearized BioID2 via BTX. The
transfected cells were transferred to RPMI and stable transfectants were selected by
limiting dilution against 800 ug/mL of G418 for over three weeks.

Jurkat clones were cultured in stable isotope labeling amino acid culture (SILAC) RPMI1640 media (ThermoFisher). The low, medium, and heavy isotope supplementation and
preparation were detailed previously (Phelan et al., 2018b), with low molecular weight
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isotope medium used for culturing a Jurkat clone expressing BioID2 alone and separately
with medium and heavy isotopes for BioID2-GIMAP5. The SILAC cultures were
expanded for 2 weeks before 50 uM D-biotin (Invitrogen) was added 20 hours prior to
harvesting a total of 100 million cells from each culture. The cells were harvested,
washed once with PBS and then all cultures were pooled into one tube and washed twice
more with PBS. Cell pellets were lysed with 30 uL/million of lysis buffer (50 mM Tris.Cl
pH7.5, 145 mM NaCl, 1% NP40, 0.5% deoxycholate, 0.05% SDS, 10% glycerol, 1 x
EDTA-free protease inhibitor cocktail (Roche)), at 4 C for 30 minutes. The lysate was
isolated by 10,000 x g centrifuging 10 minutes at 4 C. Biotinylated proteins in the
remaining lysate were isolated by via a two hour incubation with 400 uL of lysis-bufferwashed Dynabeads MyOne Streptavidin C1 (Invitrogen 65002) at 4ºC. After washes, the
beads were resuspended in LDS sample buffer plus reducing agent (NuPAGE), and
boiled for 5 min before PAGE electrophoresis separation and cutting of the gel into 20
slices, which were processed as previously described (Oellerich et al., 2019). After
tryptic digestion samples were separated by a UltiMate 3000 RSLCnano HPLC system
coupled to a Q Exactive HF mass spectrometer. Data analysis was done using the
MaxQuant software.
siRNA mediated depletion of GIMAP5
T cells were isolated from PBMCs of healthy donors and either stimulated and expanded
in IL-2 for 6-10 days or processed immediately. 10-30x106 cells were used per condition.
Cells were centrifuged, then resuspended in 9ul of P3 electroporation buffer (Lonza) plus
1ul of 20M siRNA specific for GIMAP5 or a scrambled negative control. Cells were
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then electroporated with the EO-115 program using the Lonza 96 well shuttle system.
160l of warm RPMI (plus 100U/ml of IL-2 for the T cell blasts) was immediately added
and the cells were then transferred to 6ml of RPMI (plus 100U/ml IL-2 for T cell blasts).
Significant depletion of GIMAP5 was not detected until at least 72 hours post
electroporation.
CRISPR-RNP mediated depletion of GIMAP5
CRISPR-RNP mediated knockout of both primary human and murine T cells were done
as previously described (Seki and Rutz, 2018). Briefly, in the human model, T cells were
isolated from PBMCs of healthy donors and immediately used while in the murine model
T cells were activated with ConA or plate-bound anti-CD3/CD28 plus IL-2 for 6-9 days
prior to use. 10-30x106 cells were used per cuvette with the volumes scaled accordingly.
2-3 pre-designed crRNAs (IDT) per gene were conjugated to ATTO550 labeled
tracrRNA at a 1:1 ratio to form gRNAs. The resulting gRNAs were added to purified
Cas9 enzyme (QB3 Macrolab – Berkeley) at a 3:1 molar ratio and conjugated at room
temperature for 10 minutes, with 180pmol of Cas9 enzyme used per 10 million cells.
Cells were centrifuged and resuspended in 20l of P2 (human) or P4 (murine)
electroporation buffer (Lonza) per 10 million cells. 15ul of gRNA-Cas9 conjugates were
then added to 20l of cells and incubated for 2 minutes before electroporating using the
amaxa 4D nucleofector and the EH100 program (human) or the CM137 program
(murine). 1ml of warm RPMI was immediately added to the cells and then they were
transferred to 6ml of RPMI (plus 100U/ml of IL-2 for the pre-activated murine cells). In
the human cells significant depletion of GIMAP5 was observed after 48-72 hours, while
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in the pre-activated murine T cells significant depletion could already be observed at 24
hours with the peak being around 48 hours post-electroporation.
RNA-Seq
Primary human T cells were purified from PBMCs of healthy human donors using a
magnetic human pan T cell isolation kit (Miltenyi) and GIMAP5 was depleted as
described in the siRNA knockdown section. After 72 hours, the unstimulated T cells were
stimulated with CD2/3/28 beads (Miltenyi) for 0, 4, 12 or 24 hours before RNA was
isolated via TRIzol (Invitrogen) with some aliquots of cells from the unstimulated
timepoint being used to validate knockdown efficiency. RNA-Seq and data analysis was
then performed by Merck via proprietary internal pipeline.
qPCR
RNA was isolated from T cells previously electroporated with either siRNAs specific for
GIMAP5 or negative controls using standard TRIzol (Invitrogen) extraction procedures.
cDNA was then generated using the Firststrand cDNA synthesis kit (Roche). All RTPCR was performed using a 7500 Real Time PCR System (ABI). The expression of
genes of interest were first normalized to GAPDH expression levels and then expressed
using the 2-Ct method.
Apoptosis Assays
PBMCs from either GIMAP5-deficient patients or healthy donors were stimulated with
anti-CD2/3/28 beads as described above and expanded in 100U/ml of IL-2 for 15-20
days. Apoptosis was then induced in cycling T cells via a variety of methods. Firstly,
cells were treated with a dose response of 1-100 ng/ml of anti-Fas crosslinking antibody
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(clone CH11) or 0.1-10,000 ng/ml anti-CD3 (Hit3) for 24 hours. Alternatively, cells
were washed twice and transferred to RPMI supplemented with FBS but devoid of IL-2
and viability was tracked over 5 days. In both assays the fraction of viable cells was
defined as AnnexinV-LiveDead-.
Autophagy Assays
Autophagic flux was measured in cycling T cells from either patients deficient for
GIMAP5 or T cells from healthy donors rendered deficient for GIMAP5 via CRISPRRNP electroporation. Cells were split and either treated with 50nm of Bafilomycin A1
(Sigma) or incubated in RPMI. Cells were then stained for surface proteins. Intracellular
LC3-II levels were measured according to the Flowcellect kit instructions (EMD
Millipore). The autophagic flux was defined via the Mean Fluorescence Intensity (MFI)
of LC3-II staining via the following formula: (MFIBaf – MFIbasal)/MFIbasal as previously
described (Klionsky et al., 2008).
Plasmids and retroviral transduction
Various GIMAP5 cDNAs were cloned into the MSGV1 retroviral plasmid vector
(Genscript). These plasmids were transfected via Turbofect (Thermo Fisher Scientific)
into Platinum-E cells (Cell Biolabs, Inc.). Supernatants were collected for viral
transductions on day 2, sterile filtered and stored at 4C.
Murine CD4+ T cells from GIMAP5sph/sph mice were enriched from lymph nodes using a
MojoSort CD4+ T cell isolation kit (Biolegend). Cells were then stimulated at a
concentration of 2x106 cells/ml with 3g/ml of Concanavalin A in RPMI for 24 hours.
Cells were washed, resuspended in viral supernatant plus 5g/ml of Polybrene plus
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100U/ml of IL-2 and spun at 2000rpm for 60-120 minutes at 35C. 24 hours later an
equivalent amount of RPMI containing 100U/ml of IL-2 was added to the culture to
dilute the viral supernatant twofold. 24 hours following this, the viral supernatant was
washed out completely and the transduced cells were resuspended in RPMI containing
100U/ml of IL-2. Viability and the fraction of transduced cells were then monitored every
three days for the following two weeks.
mTORC1 Activation assays
Following siRNA mediated depletion of GIMAP5 in either unstimulated or pre-activated
human T cells (see siRNA knockdown section) cells were (re)stimulated through the
TCR. T cells were (re)activated with 10g/ml of HIT3 and 10g/ml of F(ab’)2 fragment
(Jackson Imunoresearch) for the indicated timepoints. Protein lysates were generated and
analyzed for various downstream mTORC1 targets as described in the immunoblotting
section.
Alternatively, T cells depleted of GIMAP5 via siRNA were incubated in amino acid free
RPMI plus 10% dialyzed FBS for two hours. Samples were taken prior to amino acid
starvation or at the end of two hours, while a final batch of cells were resuspended in
amino acid replete RPMI containing 10% FBS for another hour. Protein lysates were then
generated and analyzed for levels of various phosphorylated proteins downstream of
mTORC1 as described in the immunoblotting section.
Statistical Analyses
Data were analyzed using Graphpad Prism 7.0. Depending on experimental design
statistical significance was tested via either two-tailed unpaired or paired Student’s t test.
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P-values  0.05 were considered significant (*p<0.05; **p<0.01; ***p<0.001;
****p<0.0001), p > 0.05 non-significant (n.s.). Flow cytometry data was analyzed via
Flowjo 9.9.5 (Treestar). No statistical methods were used to pre-determine sample size.
Details on the test used can be found in the respective figure legends.
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